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Abstract 
Metabolic disturbances associated with central obesity and insulin resistance might underlie 
the higher rates of diabetes and coronary heart disease in South Asians compared with 
Europeans. A cross sectional study of 135 healthy South Asians and Europeans, aged 40- 
55 years, was performed to test whether lower insulin sensitivity in South Asians is explained 
by ethnic differences in body fat pattern and to establish if there are ethnic differences in 
postprandial triglyceride and intramyocellular lipid (IMCL) content that are associated with 
insulin sensitivity. 
Visceral fat area (VFA), measured by CT scan, was higher in South Asians than in 
Europeans in analyses adjusted for age, sex and body mass index (p=0.001). VFA was 
strongly associated with insulin sensitivity index (ISI), measured by the short insulin 
tolerance test, in both groups independently of total % body fat (measured by DEXA scan). 
In age and sex adjusted analyses ISI was 0.71 % min-' lower in South Asians (95% CI -1.18 
to -0.25, p=0.003). Adjustment for body fat pattern and triglyceride (fasting and 8 hour 
postprandial) reduced the ethnic difference in ISI to - 0.41 % min-' (95% Cl -0.86 to 0.03, 
p=0.066). In both groups 8 hour postprandial triglyceride was highly correlated with ISI and 
VFA and the relationship of ISI to VFA was eliminated by adjusting for triglyceride. In a sub- 
study, mean IMCL content (measured by magnetic resonance spectroscopy) was higher in 
South Asians (p=0.046). In Europeans IMCL was correlated positively with % body fat, 
waist/hip ratio, VFA and negatively with ISI. In South Asians IMCL was not significantly 
related to ISI or obesity. 
We conclude that body fat pattern and IMCL cannot account for ethnic difference in insulin 
sensitivity. Alterations of lipid metabolism, possibly in the postprandial period, are likely to 
underlie the association of central obesity with insulin resistance. 
Keywords 
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Overall plan of the thesis 
The rates of insulin resistance, diabetes mellitus and coronary heart disease are known to be 
higher in people originating from India, Pakistan and Bangladesh (South Asians) than in 
people of European descent. This project was designed to test a set of related hypotheses 
about the mechanisms relating obesity (generalised obesity and central obesity) to insulin 
resistance and increased coronary heart disease (CHD) risk in South Asians. It is hoped 
that the results will guide further research on the aetiology and control of both diabetes and 
CHD. 
This thesis is arranged in four parts. The first part deals with the background and rationale 
to this area of research and is presented in chapters 1,2,3 and 4. These deal specifically 
with the epidemiology of coronary heart disease in South Asians and prevalence of the 
insulin resistance syndrome in this group in chapter one; with the proposed role for 
postprandial lipids in chapter two; and with the potential role for skeletal muscle cell 
triglyceride stores in insulin resistance in chapter three. The aims of the study are described 
in chapter four. 
The second part describes the methods employed to achieve the aims and objectives of this 
study (chapter 5). In the third part the results are presented along with relevant discussion 
(chapters 6 to 9). The final part of the thesis is dedicated to overall discussion, conclusions 
and suggestions for future research (chapters 10 and 11). 
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CHAPTER 1: Epidemiology of Coronary Heart Disease in 
South Asians Overseas 
1.1. Use of the term "South Asian" 
Different terms have been used to describe the people originating from the Indian 
subcontinent, which includes the countries of India, Pakistan, Bangladesh and Sri Lanka. 
Some of these have included "Asian", as is in common use in the U. K., but which in the 
United States has been used more commonly for people originating from the Far East; and 
"Indian Asians" or "Asian Indians" as has been used in the published literature in the past 
on both sides of the Atlantic to distinguish these people from Pacific Indians and Native 
American Indians. Throughout this dissertation the term "South Asian" is used to denote 
origin from any part of the Indian subcontinent. 
However, the people originating from countries as diverse as those that form part of the 
subcontinent are not homogeneous, and it is fair to ask the question whether they can all be 
studied together when considering their risk for coronary heart disease or diabetes. 
1.1.1. Heterogeneity of the people constituting "South Asians" 
Within India it has been claimed that there might be genetic differences in the people of 
north India (Aryan descent) and south India (Dravidian descent). However this has not 
been supported by genetic studies'. Within each of the parts of the Indian subcontinent 
there is great heterogeneity in the population: there are people of diverse cultural, religious 
and linguistic backgrounds such as Hindu Gujaratis, Punjabi Sikhs, Muslim Bangladeshis 
and Muslim Pakistanis, Tamil South Indians and Sri Lankans, many of whom are 
Hindu, 
but many converted to Christianity, and to Buddhism, with widely differing dietary and 
lifestyle habits. Moreover, South Asians have historically emigrated since 1834 to various 
parts of the world as indentured labourers2'3, forming sizeable communities 
in Mauritius, 
the West Indies, Natal, the Straits Settlements, Fiji and East Africa. The indentured labour 
system was banned in 1917 but a steady migration of professionals, traders, agricultural 
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and manual workers and their families has continued ever since. Migration, on peoples' 
own initiative, to the U. K. from the Indian subcontinent increased after 1960 and reached a 
peak around 1966-674. There has also been a steady stream of migration to North 
America. It is estimated that there are some 11 million South Asians living outside of the 
subcontinent. 
1.2. High risk for coronary heart disease among South Asians 
It has long been observed in several parts of the world that mortality and morbidity from 
coronary heart disease (CHD) are higher in people of South Asian descents. This is 
reflected in the higher relative risks for CHD among South Asians when compared with 
other ethnic groups. For example, when compared with populations known to be at low 
risk for CHD, such as the Chinese6, Melanesians' and Africans', the age standardised 
CHD death rates calculated from national mortality data have ranged between 3 to 4 times 
higher among immigrant South Asian men than in other groups settled in the same country. 
Even when compared with populations known to be at high risk for CHD, such as 
Europeans9 and South Africans10, the relative risk for CHD mortality in South Asians was 
higher by a magnitude of around 50%. 
The high coronary mortality is seen in the heterogeneous subgroups of people within the 
South Asian population - thus Gujarati Hindus, Punjabi Sikhs and Muslims from Pakistan 
and Bangladesh all share the high CHD mortality"'12 Although minor variations in heart 
disease risk factor profiles between Indian sub-communities have been demonstrated13, the 
overwhelming evidence points to all cultural groups in the Indian subcontinent sharing an 
increased risk of CHD morbidity and mortality. Thus it is reasonable when investigating 
CHD risk to consider individuals from different parts of the Indian subcontinent 
collectively, even though they may originate from a wide range of cultural backgrounds. 
There are two important observations about the high rates of CHD in South Asians. 
Firstly, the high rates of CHD are common to South Asian populations residing around the 
world. This raises the point that any environmental factor that might explain the high rates 
of CHD in South Asians must be common to all the main ethnic groups of the Indian 
subcontinent, to both sexes, and persist several generations after migration. Secondly, the 
higher relative risk for CHD and type 2 diabetes in South Asians does not wear off with 
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increasing generations since migration, i. e., it continues to diverge from the rates in other 
ethnic groups in the same country. For example, in Singapore, a rapid transition to 
affluence has been shared by all three of the main ethnic groups residing there (Chinese, 
Malays and Indians), but the prevalence of diabetes is much higher in Indians than in 
Chinese". From studies of CHD in other migrant populations (such as the Japanese in the 
U. S. A. ) it has emerged that CHD rates in those settled overseas the longest and in their 
descendants converge to those in the host population15. This has formed the basis of the 
view that between-population differences in CHD rates are environmentally rather than 
genetically determined. However given the contrasting situation in South Asians where 
higher risk persists several (five or six) generations post-migrations, a genetic explanation 
is more likely to apply than an environmental one. 
The relative risk of coronary disease in South Asian men is highest at early ages: between 
1979 and 1983, CHD mortality in men aged less than 40 years born in South Asia was 
more than twice the U. K. national average16. In patients undergoing coronary angiography 
the anatomical distribution of disease does not differ between South Asians and Europeans, 
but the extent and severity of lesions are greater in South Asians", 'g. Case fatality six 
months after acute myocardial infarction was reported to be twice as high in South Asians 
compared with Europeans', but a large part of this excess hazard was attributable to non- 
insulin dependent diabetes (NIDDM): adjustment for NIDDM reduced the hazard ratio 
from 2.02 to 1.26'9. 
Despite a reduction in CHD mortality in all Western European countries between 1970 and 
1985, over the same period there was a6% and 13 % increase in CHD mortality for South 
Asian men and women respectively' 1,16°2o By 1991, however, there was a decline in CHD 
mortality compared with 1970-72, among those born in the Indian sub-continent (20% for 
men and 7% for women)9. However, this decline was of a smaller magnitude than those 
born in England and Wales (29% for men and 17% for women)9. 
The consistency of the high risk of CHD among South Asian people in several studies from 
around the world, affecting both sexes and with early onset, particularly in men, has 
driven research to try to identify the risk factors that contribute to this excess risk. The 
speculation has been that there might be a common underlying explanation for the high 
CHD risk. 
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1.2.1. Coronary heart disease in the Indian Subcontinent 
There are no current population based national data on CHD incidence, prevalence or 
mortality in the Indian subcontinent, although studies from some towns in India exist. The 
largest of these was a population study in Delhi in 1985-86, of 13,723 men and women21. 
Prevalence of ECG changes was 7% in men and 4.3% in women aged 45-64 years. 
However the overall prevalence of Minnesota-coded major Q waves was 3.6 %22. A survey 
of 725 adults aged over 30 years in the city of Varanasi showed a 6.5 % prevalence of 
CHD (based on WHO chest pain questionnaire and ECG changes)23. The prevalence of 
CHD in urban settings in India is reported to be higher than that among inhabitants of rural 
areas and is approximately equivalent to that among South Asians who have settled outside 
the subcontinent22'24-26 
1.2.2. Coronary risk factors in South Asians 
A thorough description of the prevalence of conventional risk factors such as levels of 
smoking, blood pressure and serum cholesterol in South Asians has been given before by 
McKeigue and colleagues', ". A brief summary is given here. Compared to the U. K. 
national average of about 30%, the prevalence of smoking in men of Gujarati Hindu and 
Indian or Pakistani Muslim origin is generally comparable, higher among Bangladeshi 
Muslims, and much lower (about 4%) in Punjabi Sikhs, whose religion prohibits them 
from smoking. Smoking rates are very low in all groups of South Asian women except 
Bangladeshis. No South Asian community studied in the U. K. has higher average plasma 
cholesterol levels in middle age than the national average of about 6.0 mmol/l. It has been 
found that compared with Europeans, average blood pressure levels are higher in Punjabi 
Hindus and Sikhs, similar in Gujarati Hindus and Pakistani Muslims, and lower in 
Bangladeshis. However, although conventional risk factors such as smoking, hypertension 
and hypercholesterolaemia remain highly important risk factors for CHD within each 
ethnic group of Europeans as well as South Asians, they fail to account for the excess of 
CHD rates in South Asians when compared to Europeans22,28,29. 
Non insulin dependent diabetes mellitus is present in about 20 % of South Asian men and 
women aged over 40 years in the U. K., compared with about 5% of Europeans29. In a 
case control study the proportion of all myocardial infarctions which were attributable to 
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NIDDM - the aetiologic fraction - was found to be 21 % in South Asians versus 3% in 
Europeans30. However, most South Asian patients with CHD are not diabetic3' and 
glucose intolerance cannot alone explain more than a small proportion of the coronary risk 
in South Asians32. Levels of haemostatic factors such as fibrinogen were similar to or 
lower in South Asians than those in Europeans33,3a and factor VIIc was lower in 
Bangladeshi than European men28. Thus haemostatic factors also do not account for the 
excess CHD risk in South Asians. 
An adverse diet among South Asians has been implicated in promoting CHD. However in 
studies that assessed diet similar proportion of total energy intake was derived from fat in 
both European and South Asian groups, and the polyunsaturated/saturated fat ratio was 
higher in South Asians33°35.36 Psychosocial factors possibly contributing to CHD were 
investigated in a cross sectional study of Punjabi origin South Asians with the general 
population in Glasgow37. A much larger proportion of South Asians reported worse socio- 
economic circumstances as well as stress factors such as longer working hours, low 
income, crowded housing, liability to attack and perceived lack of social support. The 
authors of the study proposed that stress and socio-economic deprivation, along with the 
high prevalence of diabetes was likely to explain the excess risk of CHD in South Asians. 
However the study was based on a small number of 173 South Asians, and no attempt was 
made at studying specifically the relationship between coronary risk factors and socio- 
economic status or CHD and socio-economic status. Additionally the participants 
expressed little dissatisfaction about these conditions. No clear-cut role of these stresses in 
promoting CHD has been found in South Asians, but it is plausible that they play some 
contributory role. 
Based on the failure of the above risk factors to account for the excess CHD in South 
Asians, and on the results of cross-sectional surveys in east London28 and Southall, west 
London29, McKeigue et al have suggested that a pattern of physiological disturbances 
related to central obesity and insulin resistance underlies the high coronary risk and 
diabetes prevalence in South Asians. 
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1.3. The insulin resistance syndrome 
1.3.1. Background 
In 1975 in their seminal paper Miller and Miller38 proposed that a reduction in plasma 
HDL-cholesterol concentration may accelerate the development of atherosclerosis and 
hence CHD, by impairing the clearance of cholesterol from the arterial wall. This was 
later also confirmed by findings from the Framingham study in 197739. Around the same 
time a predictive role for triglycerides was also shown in prospective studies40. High 
levels of fasting triglyceride and low levels of plasma HDL-cholesterol have been found 
fairly consistently in South Asians overseas compared with other groups. This was 
specifically reported in South Asians in Trinidad compared with people of African origin" 
and in the U. S. A. compared with European descent Americans42. In Fiji higher plasma 
triglyceride levels were shown compared to Melanesians43, and in East London mean 
HDL-cholesterol was 0.3 mmol/1 lower and plasma triglycerides after a glucose load were 
50% higher among Bangladeshis than in Europeans28. In fact in the latter study McKeigue 
et al identified a pattern of interrelated metabolic disturbances among South Asians of 
Bangladeshi descent: glucose intolerance, low plasma HDL-cholesterol, and high 
concentrations of insulin and triglyceride after a glucose load. In other populations these 
aa disturbances are associated with insulin resistance, as 
1.3.2. Definition of the insulin resistance syndrome 
The insulin resistance syndrome (also known as the `metabolic syndrome' or `Syndrome X' 
first defined by Reaven) has been defined as a cluster of related factors that include 
resistance to insulin-stimulated glucose uptake, glucose intolerance, hyperinsulinaemia, 
increased levels of VLDL triglycerides, decreased levels of HDL-cholesterol and 
hypertension". Insulin resistance is also associated with central obesity -a pattern of 
obesity in which a high proportion of body fat is deposited intra-abdominally. 
The mechanisms underlying the associations of features of the insulin resistance syndrome 
are poorly understood. Resistance to insulin-stimulated glucose uptake is probably 
responsible for the glucose intolerance, hyperinsulinaemia, and hypertension. Failure of 
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insulin to suppress release of non-esterified fatty acids (NEFA) from adipose tissue 
(particularly increased intra-abdominal adipose tissue of central obesity) may cause 
hypertriglyceridaemia46, low plasma concentrations of HDL-cholesterol, and changes in the 
composition and size of particles in the LDL fraction47. 
1.3.3. The relation of coronary risk to insulin resistance in South Asians 
McKeigue and colleagues proposed in 1988 that a tendency for this insulin resistance 
syndrome to develop was generally present in South Asians overseas, and that this 
tendency might underlie the high rates of CHD and type 2 diabetes5'28. They later 
confirmed these findings in further studies of South Asians living in north-west London, 
where they also found a tendency towards central obesity associated with all the above 
features22°29. Waist-hip ratio (as an index of central obesity) was higher in South Asian 
than European men although the average body mass index was no higher in South Asian 
men than in European men29. In the Southall study22 adjusting for central obesity, glucose 
intolerance and hyperinsulinaemia reduced the odds ratio for major Q waves on ECG from 
2.4 (when adjusted for age, smoking and cholesterol) to 1.5, explaining two thirds of the 
excess CHD morbidity in South Asian men. 
1.3.3.1. Support for the insulin resistance hypothesis in South Asians 
Several lines of evidence support the insulin resistance hypothesis as the explanation for 
the high CHD risk in South Asians. Socio-economic status, smoking, plasma cholesterol, 
blood pressure, haemostatic factors and fatty acid composition of plasma lipids differ 
markedly between the various South Asian groups who share the high CHD risk28,29,33,35It 
is also important to highlight that in some South Asian groups who share high CHD risk, 
some of the risk factors associated with insulin resistance are not more unfavourably 
distributed than in Europeans. For instance, in comparison with Europeans, South Asian 
Muslims do not have higher systolic and diastolic blood pressures, Sikhs do not have lower 
HDL cholesterol, and Gujarati Hindus do not have higher fasting triglyceride levels. As 
high CHD risk is common to all these groups, it follows that the increased CHD risk in 
South Asians cannot be mediated mainly through raised blood pressure, low HDL- 
cholesterol or raised fasting triglyceride. However, common to all South Asian groups at 
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high risk of CHD are central obesity, hyperinsulinaemia, high diabetes prevalence and 
28 
. raised 
triglyceride level after a glucose load'29 
The narrowing of the sex difference in CHD mortality that occurs in South Asians after the 
age of 40 years parallels the changes in body fat pattern and lipoprotein pattern that occur 
in women around the time of the menopause. The attenuation of the sex difference in 
coronary risk in older South Asians is also explained by the insulin resistance syndrome, 
since the insulin resistance syndrome is associated with several risk factors which are 
normally less prevalent in women than in men. These include central obesity, raised 
plasma triglyceride, and lower HDL-cholesterol. A similar loss of women's immunity to 
CHD occurs in NIDDM48. 
Several other groups have also confirmed these findings of higher WHR, higher levels of 
fasting triglyceride and lower levels of HDL-cholesterol combined with higher prevalence 
of glucose intolerance among South Asians. These cross sectionala9, so and case control 
studies31°s' have supported the hypothesis that features of the insulin resistance syndrome 
promote CHD risk in South Asians. 
Studies among young South Asian adults also suggest early onset of features of insulin 
resistance. Young (mean age 21 years) male offspring of South Asian patients with 
coronary disease were found to have significantly higher fasting insulin levels and waist- 
hip ratios than age matched male offspring of European patients52. Additionally, young 
relatives of South Asian patients with NIDDM compared with age matched subjects 
without such a family history were demonstrated to have significantly higher fasting insulin 
levels and poorer insulin sensitivity measured by the short insulin tolerance test53. It thus 
appears that South Asian people have a tendency to features of the insulin resistance 
syndrome from an early age. The insulin resistance hypothesis provides a unifying 
explanation for the high rates of both diabetes and CHD in South Asians. 
1.3.4. Origins of insulin resistance: genes or environment? 
1.3.4.1. Genetic hypothesis 
The pathophysiology and aetiology of insulin resistance and development of type 2 diabetes 
is not clearly understood. Neel first proposed a "thrifty genotype" hypothesis in 196254 to 
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explain the between population variation in the prevalence of diabetes which have been 
observed this century. He proposed that during the early stages of human evolution a 
series of genes were selected that gave a survival advantage to individuals who underwent 
cyclic changes in food availability, as would be associated with the hunter-gatherer or early 
agriculturist lifestyle. Expression of these genes would result in a "quick insulin trigger" 
(large bursts in insulin secretion) in response to hyperglycaemia, thus leading to reduced 
urinary caloric loss and the efficient storage of dietary calories as fat. This would provide 
an energy store (from breakdown of fat in adipocytes to release NEFA) to be used in times 
when food was more scarce and hence would be beneficial when there was a cyclical 
availability of food. He also proposed that such a setting would become detrimental to 
health in conditions of more plentiful food supply, as the quick insulin trigger would 
become over-stimulated, leading to beta-cell decompensation and diabetes. 
This hypothesis came under question when it was reported that the high rates of diabetes 
(and glucose intolerance) previously recorded in the Pacific island of Nauru were 
decreasing, despite the recent transition from undernutrition to relative affluence" 
1.3.4.2. Environmental hypothesis 
Exactly 30 years after Neel's hypothesis, Hales and Barker suggested a "thrifty phenotype" 
hypothesis56 as an alternative to the thrifty genotype hypothesis. Their hypothesis proposes 
that the high rates of diabetes result from undernutrition in fetal and infant life, followed 
by relative over nutrition later, suggesting an environmental rather than genetic basis for 
the disease. They postulated that this hypothesis better explains the changes seen in 
Nauru. Based on the associations seen between low birth weight and subsequent 
development of CHD, hypertension and type 2 diabetes (or glucose intolerance), they have 
proposed that the peri-conception and pregnancy period has influences on foetal growth 
(such as foetal undernutrition) which "programme" the susceptibility to development of 
these disorders in later life57-59. They showed in particular that factors associated with low 
birth weight and with high adult BMI contribute independently to an individual's glucose 
tolerance. 
There has been support for this hypothesis from other groups. Recent evidence suggests 
particularly increased risk among small babies of women with high body mass index60. A 
study of twins in Denmark" found that in both monozygotic and dizygotic twins discordant 
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for type 2 diabetes, the birth weights of the diabetic twins were significantly lower than 
those of the non-diabetic twins. This supported the role of a non-genetic (environmental) 
intrauterine component, such as intrauterine environment, for the development of diabetes 
later in life. One study has found results conflicting with this hypothesis. This study62 
compared 174 Russian adults exposed in utero to malnutrition during the 1941-42 siege of 
Leningrad, with controls born before the siege or outside Leningrad. Fasting and 2h 
glucose were not significantly higher in the group exposed to malnutrition in utero than in 
controls. However, it is uncertain whether malnutrition in this population was restricted to 
those classified as exposed. The Dutch famine study63, in contrast, reports a higher mean 
2h glucose in those exposed to famine during mid gestation or late gestation than in those 
not exposed, and this effect was independent of BMI. This famine of 1944-45 was sharply 
delimited and provides a good setting for testing the hypothesis that impaired nutrition in 
foetal life may cause increased risk of diabetes in adult life. 
The "Barker" hypothesis has been extended to other populations at high risk for diabetes, 
including South Asians, Native Americans and Mexican-Americans. In a study of 1179 
Pima Indians there was a U-shaped relationship between birth weight and prevalence of 
diabetes64. Prevalence of diabetes was raised only in those with birth weight less than 2.5 
kg or more than 4.5 kg. In a study in the south Indian city of Mysore the prevalence of 
diabetes was positively related to ponderal index (weight/ length') at birth65 (in contrast to 
the inverse associations seen in European populations). The authors suggested that the 
effects of gestational diabetes on size at birth and beta-cell function in adult life might 
account for this association. In a study of 4 year old children in India there was an inverse 
association between low birthweight (weight less than 2.4kg) and 30 minute post-load 
glucose and insulin levels in 201 routine deliveries66. However no association was seen in 
low birthweight children looked after in a special care baby unit. Whincup and 
colleagues67 have studied these relationships in children aged 10-11 years from 10 towns in 
the U. K., including children of South Asian origin. They found that in all children 
childhood obesity was a stronger determinant of insulin level and insulin resistance than 
size at birth (either ponderal index or birthweight). It appears that in populations at high 
risk for diabetes the inverse relationship between glucose intolerance and size at birth is 
less clear, and the relationship may be U shaped or reversed. This could be attributable to 
the effects of glucose intolerance during pregnancy. 
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1.3.4.3. Which hypothesis explains the ethnic differences in prevalence of insulin 
resistance and diabetes? 
There arises a question as to whether impaired foetal growth can account for ethnic 
differences in prevalence of diabetes. In other words is the thrifty phenotype hypothesis 
important only in explaining the high prevalence of diabetes within populations or does it 
explain variation between populations as well? Although reduced foetal growth may be 
part of the explanation for high prevalence of diabetes in the high risk populations, the 
evidence that genetic factors underlie the ethnic differences in diabetes risk remains 
compelling. Evidence from migrant (see sections 1.1.1 and 1.2) and admixture studies 
suggests that differences in diabetes risk between high risk ethnic groups such as Pacific 
islanders and low-risk ethnic groups such as Europeans are attributable to genetic factors. 
In Nauruans inverse associations of diabetes with genetic markers of European admixture 
have been reported68. Admixture in Nauru resulted mainly from unions between Nauruan 
women and European men; thus the effect was to introduce European genes but not 
European maternal environment. It is possible that ethnic differences in the risk of 
diabetes could be a consequence of ethnic differences in foetal growth which have a genetic 
basis. 
There is yet another hypothesis called the "foetal insulin hypothesis" as an alternative 
explanation of the association of low birth weight with diabetes and vascular disease" 
This hypothesis has been proposed in 1999 by Hattersley and Tooke, and it proposes that 
the association between low birthweight and adult insulin resistance is principally 
genetically determined. Central to this hypothesis is the concept that insulin-mediated 
foetal growth will be affected by foetal genetic factors that regulate either foetal insulin 
secretion or the sensitivity of foetal tissues to the effects of insulin. However this 
hypothesis is not entirely consistent with the findings of the Danish twins study61 or the 
Dutch famine study63. Of practical importance is the point that if ethnic differences in 
disease risk have a genetic basis it is possible to map the genes underlying these differences 
by studying populations where there has been recent admixture70. 
Epidemiology of CHD in S. Asians 1-26 
1.3.5. The basis of the metabolic defect in insulin resistance 
Although insulin resistance is strongly associated with central obesity in South Asians as in 
other ethnic groups, it is not known whether the primary defect is central obesity, 
resistance to insulin action, or some other defect. Many studies have demonstrated that 
excessive accumulation of fat in the abdominal region is strongly associated with metabolic 
alterations such as disturbed plasma lipoprotein profile 7-71, hyperinsulinaemia, insulin 
resistance and glucose intolerance 74-76. In the cross-sectional study in Southall, adjusting 
for waist-hip ratio (WHR) explained only about half of the ethnic difference in insulin 
levels29. However, WHR is not an accurate measure of the proportion of body fat sited 
intra-abdominally: the correlation with CT scan measures is only about 0.55". To 
establish whether the ethnic difference in insulin resistance can be explained by central 
adiposity, we need to measure visceral fat distribution directly by CT scan. 
If adiposity is important then there should not be a difference in insulin resistance between 
lean people of South Asian and European origin. In other conditions associated with 
insulin resistance, susceptibility to insulin resistance depends on the levels of adiposity. 
Thus overweight women with polycystic ovary syndrome (PCOS) are more insulin 
resistant than weight-matched controls, but when lean women with PCOS are compared 
with lean controls there is no difference in insulin sensitivity's. In a study in Swedish men, 
the association between thinness at birth and raised post-load insulin levels was present 
only in men who were overweight79. South Asian infants born in the U. K. are thinner at 
birth than native British infants, and it is possible that the tendency to insulin resistance in 
South Asian adults is similarly dependent on the degree of obesity. It is important to test 
whether in South Asians the slope of the regression line for the relation between central 
obesity and insulin resistance is parallel to that for Europeans, or the lines cross over with 
varying adiposity. 
1.4. Mediation of increased coronary risk 
It is not established which component of insulin resistance promotes CHD. It is possible 
that hyperinsulinaemia and insulin resistance increase the risk for CHD indirectly through 
their effects on cardiovascular risk factors, such as raised triglyceride and lowered 
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HDT. -cholesterol levels. It is also possible that hyperinsulinaemia and insulin resistance 
have direct effects on the coronary artery wall and thereby promote atherosclerosis80 
As discussed earlier (section 1.3.3.1) the effect of insulin resistance on the excess CHD 
risk in South Asians cannot be mediated mainly through blood pressure or HDL cholesterol 
since these risk factors are not unfavourably distributed in all the groups of South Asian 
settlers in the U. K. who share high CHD risk28,29. Other disturbances associated with 
central obesity and insulin resistance include elevated plasminogen activator inhibitor 
(PAI-1)81, elevated IDL and predominance of small dense LDL82'83, the last of which has 
been particularly speculated to be associated with the increased atherogenic risk in South 
Asians. However, one study84 concluded that compared to European-descent men, South 
Asian men in Texas had larger LDL particles and a lower prevalence of small dense LDL 
in the presence of normolipidaemia. In contrast a recent study of 92 men in London has 
found a preponderance of lower LDL size among South Asians compared to Europeans 
and Afro-CaribbeansS5 . 
Raised triglyceride levels are seen both in obesity and insulin resistance. Coronary heart 
disease in South Asians is more strongly associated with raised plasma triglyceride levels 
than with any other metabolic measurement, but ethnic differences in fasting triglyceride 
levels are too small to account statistically for the excess prevalence of CHD in South 
Asian compared with European men22. It is possible that postprandial rather than fasting 
triglyceride levels could account for the excess risk of CHD in South Asians. There are no 
published studies that have measured postprandial lipid metabolism in South Asians. The 
potential role of postprandial lipids in insulin resistance and coronary heart disease is 
explored in chapter 2. 
The mechanism of how insulin resistance comes about is also not known. One possibility 
is that it comes about as a result of increased stores of triglyceride in skeletal muscle cells. 
The evidence for this is presented in chapter 3. 
1.4.1. The controversy about the role of insulin and insulin resistance in 
CHD 
The hypothesis that insulin resistance or hyperinsulinaemia is causally related to the risk of 
CHD is still controversial. An extensive review of the evidence from prospective studies 
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for and against the association between baseline insulin level and future risk of CHD has 
been presented by Laakso86. Many reject the insulin hypothesis87-89. Jarrett87 has noted that 
raised fasting and post-load insulin levels not only fail to predict CHD consistently when 
other risk factors are taken into account, but sometimes fail to predict even in univariate 
analyses. However, even if insulin fails to be a risk factor in univariate analysis, it does 
not necessarily imply that hyperinsulinaemia cannot contribute to accelerated atherogenesis 
or thrombogenesis. It is still possible that the effects of insulin are mediated through its 
impact on other cardiovascular risk factors. The insulin resistance hypothesis does not 
assume that insulin only directly promotes atherogenesis. Thus it is possible that the 
associations between hyperinsulinaemia and CHD are mediated through disturbances of 
lipoprotein metabolism such as raised plasma triglycerides, low HDL-cholesterol and small 
dense LDL. 
Nevertheless it has been observed that raised fasting or post-load insulin levels are far less 
consistently predictive of cardiovascular disease than would be expected if the insulin 
resistance hypothesis is correct. To explain this McKeigue and Davey9° have argued that 
this is largely attributable to failure to control for the effects of undernutrition and weight 
loss resulting from poor health. Poor nutritional status is a strong predictor of mortality in 
the elderly, and smoking is a powerful confounder of this relationship. The strength of the 
co-morbidity effects is demonstrated by the observation that men who died of CHD were 
leaner than those who survived in some of the studies such as the Rancho Bernardo 
cohort91, the Gothenburg Study92, and in the Multiple Risk Factor Intervention Trial93 
Thus it is plausible that failure to control for confounding by co-morbidity is responsible 
for the lack of association between raised insulin levels and cardiovascular disease in 
several cohort studies. 
McKeigue and Davey9° have proposed that the key question for public health is not 
whether raised insulin levels are an independent risk factor for CHD, but whether 
measures to alleviate the syndrome of metabolic disturbances associated with insulin 
resistance and central obesity will reduce the risk of CHD. 
In summary, the reasons for the relative excess of NIDDM and CHD in South Asians 
remain unclear but features associated with the insulin resistance syndrome remain a strong 
candidate for providing a unifying explanation. Thus preventative strategies to reduce the 
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risk of coronary heart disease and diabetes in South Asian communities may have different 
emphases to those designed for European groups. For instance the most important 
intervention in South Asians may constitute alleviation of insulin resistance. There remain 
many gaps in our knowledge about the relationship between body fat distribution 
(especially central obesity), insulin resistance and lipid metabolism. This study was 
designed to investigate some of these. 
1.5. Measurement of insulin resistance 
In contrast to clinical syndromes of insulin resistance which are rare and typified by 
striking clinical features such as acanthosis nigricans and ovarian hyperandrogenism in 
women, the insulin resistance and its related metabolic disturbances that most people get, 
and has been thus far referred to, develops insidiously and without symptoms. Dose- 
response studies point against an insulin receptor binding defect in the majority of people 
with insulin resistance, but suggest instead changes in post receptor signalling or 
intracellular response. Glucose metabolism and storage have been the focus of 
investigations into alterations in intracellular metabolism. Indirect calorimetry and isotopic 
studies have demonstrated reduced glucose oxidation94 and diminished insulin-stimulated 
glycogen synthesis95 in insulin resistant subjects at lower and higher insulin concentrations, 
respectively. 
Insulin is important in the regulation of substrate metabolism. Insulin regulates glucose 
metabolism (causes glycogen synthesis, and prevents gluconeogenesis) as well as fat 
metabolism (anti-lipolytic effect; suppresses production of NEFA from adipocytes) and 
protein metabolism. Most studies quantitate insulin action in terms of its glucose 
regulatory effects. This is due in large part to the technical ease of measurement of 
glucose concentration. 
Traditionally in epidemiological studies insulin resistance has been "approximated" by the 
surrogate measure of plasma insulin level, often in response to an oral glucose 
load. This 
provides an indirect measure of insulin action, but alterations in insulin secretion and/or 
clearance can alter insulin concentrations in the absence of any change 
in insulin action. 
The correlations of fasting and post-glucose insulin levels with insulin sensitivity evaluated 
by the euglycaemic clamp technique range at most from 0.6 to 0.796. Thus measurement 
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of plasma insulin level alone is inadequate in a study such as the current one, the primary 
objective of which is to compare insulin sensitivity in South Asians and Europeans, and to 
study its relationship specifically with obesity. We wanted to measure insulin sensitivity 
more accurately, and more reflective of the dynamic situation in vivo. The choice of 
methods available to do this is summarised below. 
1.5.1. Clamp techniques 
The euglycaemic hyperinsulinaemic clamp technique97 is currently regarded as the "gold 
standard" for measuring insulin sensitivity in vivo, against which other methods are 
compared98-102. It involves artificial elevation of plasma insulin using an infusion of 
exogenous insulin over a period of 3 to 6 hours. Plasma glucose is kept at a physiological 
level by infusing glucose at a rate adjusted to the prevailing insulin concentration. Samples 
are taken from an arterialised hand vein for the duration of the study. The rate of glucose 
infusion represents insulin-mediated glucose disposal assuming that the steady state insulin 
level is sufficient to suppress hepatic glucose production. This assumption can be tested by 
infusing labelled glucose and measuring the ratio of labelled to unlabelled (endogenously 
produced) glucose in the plasma. 
A hyperglycaemic hyperinsulinaemic clamp can be used to measure acute and steady-state 
glucose-stimulated insulin secretion, in addition to insulin-mediated glucose disposal. 
Overall the clamp techniques relate net blood glucose elimination rate to the plasma insulin 
concentration. 
However, clamp techniques are complex, prolonged, invasive and expensive, and not 
suitable for large numbers of subjects. In absolute terms the clamp may considerably 
overestimate insulin sensitivity by the presence of sustained hyperinsulinaemia and the 
increasing rate of glucose infusion required to maintain euglycaemia. This creates a non- 
physiological state, because in normal physiology there is never such sustained 
hyperinsulinaemia. Thus while clamp-derived measures provide an adequate reference, 
their use in epidemiological studies should be viewed with caution. 
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1.5.2. Intravenous glucose tolerance test and minimal modelling 
Minimal model analysis of glucose and insulin concentration profiles during an intravenous 
glucose tolerance test (IVGTT) avoids the procedural difficulties of the clamp. Minimal 
model analysis uses mathematical analysis of the non-steady state glucose and insulin 
concentrations during an IVGTT to provide a measure of the constant that best relates 
change in glucose disposal rate to change in plasma insulin concentration. An IVGTT 
involves a bolus injection of glucose into an antecubital vein, and frequent sampling from 
the contralateral arm. The modelling technique was originally described by Bergman in 
197999. The index of insulin sensitivity derived during minimal modelling represents the 
ability of insulin to enhance total net glucose disappearance from the extracellular fluid (by 
suppressing glucose production as well as by increasing its utilisation). 
The complexity of this method lies in the computer modelling rather than in the metabolic 
test itself. The test is moderately invasive and time-consuming (3 hours) but does not 
require sophisticated equipment. One disadvantage is that intravenous administration of 
glucose bypasses gastrointestinally stimulated secretion of insulin via substances such as 
cholecystokinin-pancreozymin (CCK-PZ), and so the peak insulin secreted is less than that 
in response to an oral challenge. Additionally, although a physiological insulin dynamic is 
employed (in comparison with the clamp), the technique depends on there being a 
sufficient insulin response (i. e. beta cell response). 
1.5.3. Insulin suppression test 
In this test endogenous insulin secretion is suppressed with somatostatin (or with 
intravenous propranolol and adrenaline), coupled with a fixed constant glucose and insulin 
infusion'o, 'o4 Steady-state plasma glucose (SSPG) represents an index (the higher the 
glucose, the greater the magnitude of insulin resistance). Although relatively simple to 
perform, it assesses the ability of both insulin and glucose to facilitate glucose uptake. 
Interpretation may be confounded by the effect of the agents used to inhibit insulin 
secretion on insulin action and by differences in urinary glucose excretion since plasma 
glucose may exceed the renal threshold in some but not all subjects during study. 
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1.5.4. Short insulin tolerance test 
The measurement of glucose disappearance from plasma after intravenous insulin injection 
is the basis of the insulin tolerance test, which has been used widely to estimate in vivo 
insulin action105'°a There are however two main criticisms of the insulin tolerance test: (a) 
insulin induced fall in glucose results in a counter-regulatory hormonal response (which 
includes secretion of glucagon, catecholamines, growth hormone and cortisol), which in 
turn slows the glucose disappearance rate from plasma106'107,109, and (b) insulin injection 
may induce hypoglycaemia which is both unpleasant and potentially dangerous. 
Both these problems can be overcome by modification of the test. Firstly the blood 
glucose decline can be measured over the initial 15 minutes, before the onset of the 
counter-regulatory response which usually sets in about 20 minutes after insulin 
injection10-1z Secondly, to avoid symptomatic hypoglycaemia in healthy subjects, a 
reduced dose of insulin bolus (0.05 units per kg) can be used102, "3 This is a modification 
of the insulin dose of 0.1 units per kg body weight which has been validated against the 
euglycaemic hyperinsulinaemic clamp in normal, obese and diabetic individuals100" 
With these modifications the low dose short insulin tolerance test (SITT) is derived. In this 
test, glucose levels are measured every 2 minutes from an arterialised hand vein after the 
injection of a bolus of short acting insulin, and the test terminated at 15 minutes with 
intravenous glucose. The rate of disappearance of glucose (KITT) is calculated as 0.693/t'h 
the glucose half life (tv2) being derived from the slope of the plasma glucose concentration 
curve from 3 to 15 minutes101. This K TT is equivalent to multiplying the slope (of the 
decline in log transformed blood glucose concentration from 3 to 15 minutes) by a -100 
factor13 The glucose decline occurring in the first 15 minutes after insulin administration 
is the function of insulin-stimulated glucose uptake by tissues, as well as insulin-inhibited 
glucose output by the liver. 
The advantages of the SITT include simplicity, safety and brevity. Even at the lower dose 
of insulin (0.05 u/kg) the intra-individual reproducibility has been shown to be good 
(coefficient of variation 6.9 ± 2.6 % 102), with close correlation of the SITT derived insulin 
'02 
sensitivity with that derived from euglycaemic clamp studies (r = 0.81, p<0.005) 
The choice of the SITT for the current study is defended in section 5.10.1. 
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1.6. Other proposed risk factors for CH D 
A whole host of potential risk factors for CHD have been proposed over the past few 
years. Evidence for the possible role of some of these risk factors in explaining the higher 
CHD risk in South Asians is beginning to emerge. 
Elevated level of lipoprotein(a) [Lp(a)] has been reported to be an independent risk factor 
for CHD114,115 Lp(a) is an LDL-like substance containing a highly carbohydrate-rich 
protein, apo(a), with striking homology with plasminogen, a key protein of the coagulation 
process. Higher Lp(a) levels have been reported in South Asians compared with 
Europeans 16'"' and compared with Malay and Chinese residents of Singapore"8. The 
extent to which Lp(a) could account for the ethnic differences in CHD mortality has not as 
yet been examined. 
Evidence for the association between concentrations of total plasma homocysteine and 
vascular disease has recently been reviewed19 It has been suggested that raised 
homocysteine levels in South Asians may contribute to their excess CHD risk12o 
It has been suggested that the occurrence of a procoagulant and proinflammatory state in 
the vasculature may be associated with increased coronary risk. A recent review presents 
the evidence for how triglyceride rich lipoproteins may promote atherosclerotic vascular 
disease by adverse effects on platelet function, coagulation and vascular inflammation12' . 
There is also a growing body of evidence that C-reactive protein, a marker of 
inflammation, is associated with CHD122. No studies of an ethnic comparison of C-reactive 
protein have been reported in the literature. 
Some studies have reported associations between CHD and persistent bacterial infection 
with Chlamydia pneumoniae and Helicobacter pylori123, '24, although there is still 
uncertainty about how far these associations can be accounted for by residual confounding 
by factors such as smoking and socio-economic status'23-125. Whether these chronic 
infections may be associated with the higher CHD risk in South Asians is as yet unknown. 
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CHAPTER 2: Postprandial lipids 
2.1. The association of postprandial lipids with CHD 
2.1.1. Relation between fasting triglyceride concentration and CHD 
A high fasting plasma triglyceride concentration has long been implicated as a risk factor 
for coronary heart disease (CHD). The first case-control study of this association showed 
elevated fasting triglyceride levels among CHD cases compared with controls12'. The 
earliest prospective study demonstrated an increased incidence of CHD among men with 
elevated triglyceride levels at baseline, compared with men with lower levels127. However 
even in this early study it was speculated that the triglyceride association may not be 
independent of other plasma lipid levels. In the decades of research since then the 
independent role of triglycerides remained controversial as a number of studies found that 
while fasting triglyceride was univariately associated with CHD, this association did not 
remain statistically significant after controlling for other lipid risk factors, especially 
HDL-cholesterol128. Part of the reason for this cancellation of effect of triglyceride may 
have been due to the fact that there is a strong inverse association between triglyceride and 
HDL-cholesterol levels, resulting in multi-colinearity in multivariate statistical models. 
However, Hokanson and Austin performed a meta-analysis of population based prospective 
studies of the relation between fasting triglyceride level and CHD129. They showed that 
based on combined data from 17 studies, even after adjustment for HDL-cholesterol there 
was an independent association between fasting triglyceride and CHD incidence in men 
[RR 1.14,95% CI 1.05 to 1.28] and women [RR 1.37,95% Cl 1.13 to 1.66]. These 
relative risks were calculated and standardised with respect to a1 mmol/l increase in 
triglyceride concentration. 
It has been previously shown that plasma triglyceride levels were strongly associated with 
prevalent myocardial infarction in South Asians, but the ethnic differences (South Asian 
vs. European) in all fasting lipid fractions, including triglyceride, were small and 
inconsistent22. Two decades ago Zilversmit hypothesised that postprandial triglyceride-rich 
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lipoproteins (chylomicron remnants) may be important in atherogenesis130. Since then 
there have been several studies of the relation between postprandial triglyceride levels and 
the risk for CHD. 
2.1.2. Relation between postprandial triglyceride concentration and CH D 
In a case-control study of 101 men, Patsch et a113' showed that postprandial 
hypertriglyceridaemia was associated with coronary stenosis defined angiographically. In 
this study single postprandial triglyceride levels at 6 and 8 hours after the meal were highly 
discriminatory (p <0.001) between cases and controls, even after adjusting for the effect of 
fasting triglyceride level. The triglyceride levels at 6 and 8 hour time points exhibited a 
greater difference between cases and control subjects than did the global magnitude of 
postprandial lipaemia. 
Supplementation of the test meal with vitamin A and subsequent measurement of retinyl 
palmitate (retinyl ester) in plasma provides a reliable marker of chylomicron and 
chylomicron remnant metabolism, and is a more sensitive index of the nature of the 
particles that contain triglyceride than the measurement of triglyceride level alone132-'35. In 
a smaller study of 40 normolipidaemic cases and controls, Groot et a1136 showed that 
patients with angiographic coronary artery disease showed a marked delay in the clearance 
of postprandial retinyl esters as well as in the normalisation of plasma triglyceride 
concentrations between 6 to 12 after the test meal compared with controls. The authors 
argued that this delayed clearance was due to a slower rate of chylomicron remnant 
removal. 
In a further case-control study of 170 normolipidaemic people Weintraub et al137 
demonstrated that the area below the chylomicron remnant retinyl palmitate curve was 
significantly increased in the coronary artery disease (CAD) group (mean 23.4 µmol/l. h, 
SD 15.0) as compared with controls (mean 15.3 µmol/l. h, SD 8.9), p<0.001. This was 
following a fat meal of 50g fat per square metre of body surface. The association of 
postprandial response with CAD was highly significant before (p=0.0001) and after 
(p=0.001) adjusting for differences in basal triglycerides. The authors argued that the 
higher level of chylomicron remnants in normolipidaemic patients with CAD may explain 
their susceptibility to atherosclerosis. Further, Simpson et a1138 showed that the magnitude 
of postprandial lipaemia is higher in CAD patients, irrespective of whether 
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hypercholesterolaernic or not. Fenofibrate was able to decrease lipidaemia in cases and 
controls, but did not abolish the differences between these groups. 
Additional evidence for an association of postprandial lipaemia with atherosclerotic risk is 
provided by the offspring study of Uiterwall et a1139. Although 80 sons of men with severe 
CAD and 55 sons of control individuals had similar post absorptive concentrations of 
plasma triglycerides, postprandial responses to a liquid challenge meal providing 77.5 g fat 
per m2 of body surface area differed significantly. The early rise in serum triglyceride 
concentrations and the maximum concentrations reached at 4-6 hours after the meal were 
comparable in the two groups. However, triglyceride concentrations remained 
significantly higher 8h (+27%), 10h (+33%) and 12h (+17%) after the meal in the sons 
of patients, suggesting delayed clearance compared with the sons of control individuals. 
There is convincing evidence for the role of postprandial triglyceride rich lipoproteins 
(TGRL) in CHD risk among people of European descent1 ', '4' Whether ethnic differences 
in postprandial triglyceride level could account for different rates of CHD in Europeans 
and South Asians is not known. No one has reported on postprandial triglyceride levels in 
a comparative study of South Asians and Europeans, and the role of postprandial lipids in 
insulin resistance or risk for CHD has not been examined among South Asians. We 
hypothesise that South Asians are likely to have elevated levels of postprandial lipids 
compared with Europeans, and that ethnic differences in postprandial triglyceride level will 
accompany the ethnic differences in central obesity, plasma lipids and insulin resistance. 
We wanted to test whether ethnic differences in insulin sensitivity could be accounted for 
by body fat distribution (including measurement of visceral fat area directly by CT scan). 
Meal tolerance tests are difficult and laborious to perform on large numbers of subjects as 
they involve giving a fatty meal in the fasting state, followed by a further 12 hour period of 
fasting, and several measurements of lipids at hourly intervals in this period. One study, 
however, demonstrated that postprandial measurements were more reproducible than 
fasting triglyceride determinations, and that reliable postprandial measurements can be 
implemented in epidemiologic studies by using a modified fat tolerance test142. In this 
study it was shown that the correlation between postprandial triglyceride levels (for a 
single postprandial triglyceride concentration measured at 9 hours after a fatty meal), over 
a wide range of levels at two visits was strong (r=0.87). In addition, the reliability 
coefficient (percentage of total variation in analyte which is attributable to between 
participant variation) was 85% for the postprandial triglyceride, compared with 
64% for 
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the fasting triglyceride level14'. It has also been proposed by Patsch 13 ' and Weintraub 137 
that a single 8 hour postprandial triglyceride level can discriminate well between cases of 
CAD on angiography and matched controls. 
2.2. Relation between postprandial triglyceride concentration 
and insulin resistance 
By the 1970's the highly significant associations between fasting triglyceride, insulin 
resistance and hyperinsulinaemia were defined143 However, very little information has 
been available about the relationship between insulin resistance and postprandial lipaemia. 
The potential importance of this association is due to two reported research findings. 
Firstly, as discussed above it has been proposed that postprandial lipaemia might play a 
part in the pathogenesis of CHD. Secondly, it has been proposed that resistance to glucose 
disposal and/or compensatory hyperinsulinaemia may also increase the risk of CHD44 
Few studies have now addressed this issue. 
Reaven's group14' showed in a study of 37 non-diabetic individuals that insulin resistance 
[measured by the steady state plasma glucose (SSPG) in an insulin suppression test] was 
associated with plasma total postprandial triglyceride concentration (r=0.66, p<0.001) 
and retinyl palmitate (r = 0.51, p<0.01) . The association was also strong for postprandial 
triglyceride concentration and retinyl palmitate in both Sf (Svedberg flotation) > 400 
(chylomicrons) and Sf 20 to 400 (chylomicron remnants and VLDL) fractions. They 
concluded that insulin resistance plays an important role in regulating the postprandial 
concentration of TGRL, including those of intestinal origin. However a limitation of this 
study is that no adjustment was made for the fasting triglyceride level, which is known to 
be a strong predictor of the postprandial triglyceride response. Thus we don't know if 
postprandial triglyceride concentration was an independent associate of insulin resistance. 
In contrast Byrne et a1145 failed to find an association between features of the insulin 
resistance syndrome and postprandial triglyceride concentration in a study of 57 men. 
Also Weintraub et al133 did not find a significant association between fasting insulin and the 
postprandial triglyceride response in a study of 15 subjects. However, another group 
found an association between fasting insulin level and postprandial triglyceride in a study 
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of 113 young (mean age 26 years), healthy, normal weight men146. They found that fasting 
and postprandial triglyceride peak values showed a bimodal frequency distribution, with a 
low fasting and a high fasting triglyceride group, and "normal" responders and "high" 
responders to the fat-load. Fasting insulin levels were significantly higher in high 
responders than in normal responders, whereas they did not differ between the low and 
high fasting triglyceride group. In a recent study in men, Couillard et a1147 showed that 
visceral obesity is associated with an impaired postprandial triglyceride clearance, and that 
visceral obesity may contribute to fasting and postprandial hypertriglyceridaemia by 
altering NEFA metabolism in the postprandial state. They reported that features of the 
insulin resistance syndrome, namely fasting hypertriglyceridaemia, hyperinsulinaemia and 
low HDL-cholesterol concentrations as well as increased visceral adipose tissue 
accumulation were all significant correlates of an impaired postprandial TGRL clearance. 
A recent cross-sectional study of 26 men has shown that healthy first degree relatives of 
patients with type 2 diabetes are insulin resistant and have 50% higher 6-hour incremental 
area under the curve compared with a control group"' 
Although studies of relation between postprandial lipaemia and insulin resistance are few, 
there exist studies of the relation between postprandial lipaemia and diabetes. Postprandial 
lipaemia is increased in NIDDM, together with a defective removal of remnant 
particles 149,150 It is not clear what the underlying mechanism is for postprandial lipaemia 
in NIDDM, but it seems that there might be a defect in the removal of remnant particles. 
Curtin et al's' showed that NIDDM patients had an altered pattern of apoB-48 in response 
to an oral fat load. ApoB-48 is the structural protein of chylomicrons and is a more 
specific marker for remnant particles than is retinyl palmitate. It has been shown that 
elevated postprandial lipaemia is mainly due to an increase in apoB-100 (structural protein 
of endogenous, or hepatic derived VLDL-triglyceride) containing particles and only a 
minor part represents the apoB-48 particles140 A competition between apoB-48 and 
apoB-100 particles for removal could explain the accumulation of apoB-100 containing 
particles in the postprandial state, particularly if VLDL-apoB-100 production is increased, 
as occurs in NIDDM. 
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2.2.1. Mechanism underlying the relation between insulin resistance and 
postprandial I ipaemia 
It has been long debated which comes first in the sequence of events: hyperinsulinaemia, 
insulin resistance or dyslipoproteinaemia. Evidence from prospective studies is sparse, but 
tends to support the concept that insulin resistance and compensatory hyperinsulinaemia 
precedes the development of hypertriglyceridaemia and an atherogenic lipoprotein 
phenotype152,153 Another study has shown that families with endogenous 
hypertriglyceridaemia are at an increased risk of developing glucose intolerance and 
NIDDM during a 10 year follow-up period154 However, no prospective data are available 
for postprandial triglyceride. 
On the other side of the argument, there is a growing body of opinion that lipid 
disturbances come first, leading to development of insulin resistance and NIDDM. The 
evidence for a key role of continuously elevated levels of NEFA in the pathogenesis of 
insulin resistance and NIDDM has been reviewed in an excellent review by Boden155. It is 
proposed that NEFA provide an important link between obesity (particularly central 
obesity) and insulin resistance. However Frayn156 proposes that it is a bit simplistic to 
think of any one change as 'primary'. Rather the many associations of insulin resistance 
are so interrelated that disturbance to any one may bring about the whole pattern of 
metabolic disturbance. 
The mechanism by which insulin resistance is related to postprandial lipaemia is not clearly 
understood. The normal effect of insulin is most pronounced in the postprandial period 
and is mediated both through inhibition of the intracellular hormone-sensitive lipase and 
through an increase in the re-esterification of fatty acids within adipose tissue 117 . The 
reduced delivery of NEFA to the liver, coupled with the direct suppressive effect of 
insulin, leads to postprandial diminution of hepatic VLDL-triglyceride secretion under 
normal circumstances. Insulin also stimulates the activity of peripheral LPL, aiding the 
removal of TGRL from the circulation. In insulin resistance increased flux of NEFA to 
the liver secondary to a failure of insulin to suppress NEFA release from adipose tissue is 
an important factor leading to the elevation of circulating TGRL46' 
158,159 Thus hepatic 
VLDL-triglyceride secretion may continue in the postprandial period, with enlargement of 
the circulating triglyceride pool. Furthermore, the insulin activation of adipose tissue LPL 
is blunted in the insulin resistance syndrome, which impedes the clearance of VLDL 
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particles and lowers HDL-cholesterol levels156 It has been argued by Frayn160 that 
inappropriate release of NEFA in the postprandial period is likely both to reduce the 
sensitivity of glucose metabolism to insulin and to accentuate postprandial lipaemia. 
It has been shown that increased visceral obesity is related to insulin resistance74-76. It has 
also been shown that visceral obesity is related to postprandial lipaemia'a'"161,16z Thus 
visceral obesity is an obvious link between insulin resistance and postprandial lipaemia. 
2.3. Mechanism of association between postprandial Iipaemia 
and CH D risk 
Postprandial lipaemia could affect the atherosclerotic process directly through the 
postprandial lipoproteins, or indirectly through its effects on other lipoproteins such as 
LDL and HDL cholesterol. Other mechanisms may be involved , such as induction of 
platelet function that may favour thrombosis"'. 
2.3.1. Direct mechanisms 
The hypothesis first put forward by Zilversmit13° focused on the atherogenic potential of 
chylomicron remnants of exogenous (dietary) origin. However, the "triglyceride 
intolerance hypothesis" formulated by Miesenböck and Patsch13"'64 suggests that 
hypertriglyceridaemia is potentially atherogenic through cholesterol transferred from 
cholesterol-rich lipoproteins such as HDL and LDL to triglyceride-rich lipoproteins 
(VLDL), which owing to their enrichment with cholesteryl esters (CE), cannot be 
degraded properly and end up in the vessel wall. When the integrated level of TGRL's in 
the postprandial state is high, cholesteryl ester transfer protein (CETP) - mediated transfer 
of CE from HDL and LDL to TGRL's in exchange for triglycerides is extensive. Hence 
HDL-cholesterol levels decrease, LDL particle size is reduced, and CE-rich remnants of 
TGRL's are formed. Each of these consequences of postprandial triglyceride metabolism 
is potentially atherogenic. Rapp et a! 165 isolated intact TGRL from human atherosclerotic 
plaque tissue. These lipoproteins resembled the TGRL encountered in plasma, except for a 
slightly larger particle size and enrichment in apolipoprotein E. Thus this study 
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demonstrated clearly that the TGRL are deposited in the atherosclerotic plaque. However 
the authors did not emphasise that plasma contained apolipoprotein B-48, whereas the 
plaques did not. From this it could be interpreted that chylomicron remnants are not 
directly implicated in atherogenesis. Instead, their metabolism might induce atherogenic 
alterations in the properties of other cholesterol containing lipoproteins. In an extensive 
review of the relation between triglyceride and CHD, Karpe and Hamsten166 speculate that 
the metabolism of postprandial TGRL represents a repeated daily atherogenic influence on 
other lipoprotein species in the plasma, rather than inducing atherosclerosis per se. 
2.3.1.1. Direct effects on the vascular endothelium 
It has been suggested that postprandial lipaemia could directly affect the vascular 
endothelium. Sattar167 has reviewed the accumulating evidence which suggests that TGRL 
may be directly damaging to the endothelium. It is suggested that TGRL can cross the 
endothelial barrier and enter the arterial wall, and bring about endothelial damage possibly 
through oxidative mechanisms. Impaired endothelial function is considered a marker of 
atherogenesis. Recent technology has allowed the study of flow-mediated dilatation 
(FMD) of the brachial artery by ultrasound as a marker of endothelial function. Thus 
reduced FMD is considered a marker of endothelial dysfunction. 
One study showed a significant reduction in FMD in the brachial artery following a single 
high-fat meal in 10 normocholesterolaemic volunteers 168. The same group also found that 
pre-treatment with vitamin C and vitamin E blocked this effect, supporting the hypothesis 
that oxidative stress is a link between postprandial TGRL and endothelial damage169 
Another group10 measured FMD after inducing a transient hypertriglyceridaemia by 
infusion of a lipid containing solution (Intralipid®). They found that FMD decreased from 
7% to 1.6% in response to the intralipid infusion, showing that transient triglyceridaemia 
decreases vascular reactivity. It is plausible that repeated elevations of postprandial 
triglyceride could have more permanent effects on the endothelium. 
2.3.2. Indirect mechanisms 
Postprandial lipaemia could be atherogenic in an indirect way by modifying other 
lipoproteins important in atherosclerosis such as LDL and HDL. The magnitude of 
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lipaemia is positively associated with the plasma levels of apoB"', possibly reflecting a 
tendency for an individual with poor fat tolerance to overproduce apoB containing 
lipoproteins. A mechanism leading to loss of HDL2 as a result of pronounced postprandial 
lipaemia has been demonstrated' 2. The levels of HDL2 exhibit a negative association with 
CHD at least as powerful as all other known risk factors. Postprandial lipaemia could 
affect LDL in regard to its atherogenecity. LDL was the first lipoprotein species with a 
demonstrated role in atherosclerosis 13. Modified LDL are taken up by macrophages and 
endothelial cells, leading to the formation of foam cells, one of the first steps in 
atherosclerosis1'. Individuals with triglyceride intolerance and the triglyceride intolerance 
syndrome usually exhibit a preponderance of smaller denser LDL15; also, during 
postprandial lipaemia, LDL are more oxidisable and can lead to CE accumulation in 
macrophages16. Thus postprandial lipaemia can exert its atherogenic potential through its 
effect on LDL. 
In conclusion postprandial lipaemia affects all three major lipoprotein classes, i. e. TGRL 
become enriched in CE, LDL size is reduced, and HDL cholesterol levels are lowered, 
leading to foam cell formation and atherosclerosis. Magnitude and duration of 
postprandial lipaemia determine how much cholesterol is diverted from LDL and 
HDL into 
TGRL through which it causes atherosclerosis. 
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CHAPTER 3: I ntramyocel lu lar lipid content and insulin 
resistance 
3.1. Muscle triglyceride stores as a possible mediator of relation 
of obesity to impaired insulin action 
3.1.1. The mechanism 
Although numerous experimental studies in humans and animals have demonstrated that 
weight gain increases insulin resistance while weight loss ameliorates it, the mechanism of 
the association between obesity (including central obesity) and insulin resistance is poorly 
understood. Most insulin-mediated glucose disposal takes place in skeletal muscle"', "', 
and in insulin resistant individuals there is an impairment in the ability of muscle to take up 
glucose and store it as glycogen1', 180 This is associated with impaired glycogen synthase 
activity in muscle18', but the cause of this defect is not clear. 
One possible physiological mechanism for insulin resistance is the glucose-fatty acid cycle, 
in which glucose and non-esterified fatty acids (NEFA) compete for utilisation by 
muscle182°'s3 The key points of this cycle are as follows: the increased availability of 
NEFA in blood produces an increase in intra-muscular acetyl-CoA and citrate content; 
acetyl-CoA inhibits pyruvate dehydrogenase, and this in turn reduces glucose oxidation; 
citrate inhibits phosphofructokinase 1 and thus glycolysis itself, eventually resulting in the 
impairment of glucose uptake. However, this hypothesis has come into question because 
many groups"'-ßs6 have not been able to reproduce the findings in rat skeletal muscle that 
Randle et al demonstrated in rat heart muscle. While the suppressive effect of NEFA on 
carbohydrate oxidation has been generally confirmed by others, it remains controversial 
whether NEFA also inhibits insulin-stimulated glucose uptake 
(i. e., causes peripheral 
insulin resistance). However, in an extensive review Boden"' argues that the reason many 
studies failed to find inhibition of glucose uptake 
by NEFA is because this inhibition 
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develops late (after 4h of fat infusion), and insufficient time of fat plus insulin infusion has 
been given in these studies (about 2h). 
There have been several attempts to pursue the hypothesis that insulin-stimulated glucose 
uptake is blocked by elevated NEFA levels in plasma1'. Although such an effect can be 
demonstrated experimentally' 87, several lines of evidence indicate that elevated plasma 
NEFA levels are unlikely to be an important determinant of insulin resistance in the 
population. In normoglycaemic individuals steady-state measurements of resistance to 
insulin-mediated glucose uptake do not correlate with the plasma NEFA response to a 
meal188. Although South Asians are on average more insulin-resistant than Europeans, 
fasting and post-challenge NEFA levels are no higher in South Asians than in 
Europeans15s 
In their original hypothesis, however, Randle and Hales did not suggest that insulin 
resistance in non-insulin dependent diabetes resulted only from elevated plasma NEFA 
levels. They proposed that glucose uptake was inhibited also by NEFA derived from 
breakdown of triglyceride stores within muscle cells182. Thus there are two potential ways 
in which NEFA may promote insulin resistance. Firstly it is possible that there is substrate 
competition between glucose and muscle-cell derived NEFA, which could cause insulin 
resistance. Another possibility is that NEFA induce insulin resistance by a direct 
impairment of glucose transport. 
There is now a growing body of evidence for the latter possibility. Boden et a1189 have 
shown that increasing concentration of NEFA decreases glucose uptake in a dose- 
dependent fashion. The decrease is caused (i) mainly by a reduction in glycogen synthesis 
(either due to impairment of glycogen synthase activity, or due to a reduction in glucose 
transport/phosphorylation), and (ii) to a lesser extent by a reduction in carbohydrate 
oxidation. Roden et al have further shown that NEFA induce insulin resistance by initial 
inhibition of skeletal muscle glucose transport/phosphorylation19o, 
'9' which is then followed 
by a 50% reduction in both the rate of muscle glycogen synthesis and glucose oxidation190. 
Roden et al conclude that in contrast to the mechanism of substrate competition between 
NEFA and glucose as a cause of insulin resistance, elevation of plasma 
NEFA causes 
insulin resistance by inhibition of glucose transport and/or phosphorylation, with a 
subsequent decrease in rates of glucose oxidation and muscle glycogen synthesis190. 
More 
support for this mechanism of inhibition of glucose transport activity 
by elevated NEFA 
has come more recently from Shulman's group192. They 
found that rates of whole-body 
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glucose uptake, glucose oxidation and muscle glycogen synthesis were 50-60% lower 
following a lipid infusion (compared to a glycerol infusion), and were associated with a 
90% decrease in the increment in intramuscular glucose-6-phosphate concentration, 
implying diminished glucose transport or phosphorylation activity. To distinguish between 
these two possibilities, intracellular glucose concentration was measured and found to be 
significantly lower in the lipid infusion studies, implying that glucose transport is the rate- 
controlling step. 
3.1.2. Evidence for the role of intramyocellular lipid in insulin resistance 
Recent evidence from animal studies supports the idea that triglyceride stores in skeletal 
muscle are an important determinant of insulin resistance. Correlations of around -0.90 
were reported between insulin-stimulated glucose uptake and triglyceride levels in the 
hindquarter muscles of rats by Storlien et a1193. In comparison, the correlation between 
muscle triglyceride levels and plasma triglyceride was only 0.44. High fat diets increase 
muscle triglyceride levels in rats and also induce insulin resistance; the drug benfluorex 
blocks both these effects 194 
Evidence for the role of intramyocellular lipid (IMCL) in insulin resistance in humans is 
slowly accumulating. In a study of patients undergoing minor surgery, mean triglyceride 
levels in muscle biopsies taken from the rectus abdominis muscle were six times higher in 
patients with non-insulin dependent diabetes than in controls"'. It has been shown that 
IMCL content in muscle biopsies is an important source of energy within the muscle196 and 
that increased IMCL content is associated with impaired insulin-stimulated glucose uptake 
in type I diabetes mellitus197. Lithell et a1198 have shown that the energy supply to the 
muscles during heavy physical work (such as long distance skiing) is partly derived from 
intracellularly stored lipid. Their group, and others199 have shown that slow twitch fibres 
(or type I fibres) have a larger content of triglyceride than fast twitch fibres (or type II 
fibres). Lithell et a1198 showed that during heavy exercise triglyceride stores in slow twitch 
fibres are decreased. 
Intramyocellular lipid content measured in gastrocnemius muscle biopsy in a study of 
normoglycaemic women was negatively associated with glycogen synthase activation, 
demonstrating that increased muscle triglyceride stores are associated with decreased 
insulin-stimulated glycogen synthase activity200. In addition IMCL content was positively 
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associated with features of the insulin resistance syndrome (including waist to hip ratio and 
fasting NEFA)200. However in this study there was no association between insulin 
sensitivity measured directly by the short insulin tolerance test and IMCL content. No 
mention was made of the level of physical activity of the 27 participants. The authors of 
this study argued that one of the reasons for the lack of association between insulin 
sensitivity and IMCL content could be due to a poor correlation between the biopsy lipid 
content and the overall skeletal muscle lipid content in the subjects (which would determine 
insulin sensitivity). They cite in favour of this argument the fact that the triglyceride 
content of skeletal muscle is extremely variable both within any one muscle and between 
different muscles201. It is probably related to the fact that gastrocnemius muscle does not 
contain as high a density of type I or slow twitch fibres as other muscles, especially the 
soleus. 
Another study measured IMCL content in biopsy specimens of the vastus lateralis muscle 
of 38 non-diabetic Pima Indian men and quantified insulin sensitivity by the euglycaemic 
clamp202. Percent body fat was measured by under water weighing. A negative 
relationship was found between IMCL and insulin sensitivity (r=-0.53, p<0.001). Insulin 
resistance was significantly related to IMCL content independently of all measures of 
obesity (percent body fat, waist to thigh ratio and BMI). 
3.2. Non-invasive measurement of intramyocellular lipid 
Until recently the studies of this relationship were limited due to the invasive nature of 
muscle biopsy to measure IMCL. However a group of physicists in Tubingen, Germany 
reported in 1993 that muscle cell triglyceride stores can be detected in vivo by nuclear 
magnetic resonance (NMR) spectroscopy203. Using double spin echo localisation 
technique, they were able to identify proton NMR signals in human soleus muscle from 
two different compartments containing fatty acids or triglycerides of similar composition. 
One of these compartments corresponds to triglyceride within adipocytes and the other to 
triglyceride within muscle cells. Other groups have also found the same204 and validated 
the technique20S. One group in London has also used this technique and performed 
reproducibility studies206. They reported that the intra-examination coefficient of variation 
for proton NMR spectroscopy measurements of IMCL in the soleus muscle was 
4% and 
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the inter-examination coefficient of variation for repeated determinations in three different 
examinations was 11 %20'. This is much lower than the 24% coefficient of variability in 
repeated biopsies of human skeletal muscle207. As described above (section 3.1.2) the 
intracellular lipid content of biopsy specimens is determined to a large extent by fibre type 
198 (slow twitch or fast twitch), which in turn is dependent upon the choice of muscle type 
for study. Use of NMR spectroscopy of soleus muscle takes away this limitation, as 
reflected in the lower coefficients of variation for repeat measurements. 
Since this non invasive technique of NMR spectroscopy for the quantification of IMCL has 
become available, few studies of relation of IMCL content and insulin resistance have been 
reported. One recently reported by Krssak et a1208 in 23 healthy people showed an inverse 
correlation between IMCL content and insulin sensitivity measured by the euglycaemic 
hyperinsulinaemic clamp (r= -0.69, p=0.002). They also found that IMCL was not 
related to BMI, fasting triglyceride, NEFA, glucose or insulin. In a series of small studies 
McGarry's group have also reported increased IMCL content in association with insulin 
resistance 209-21. Two very recent studies have reported increased IMCL content in non- 
diabetic offspring of type 2 diabetic parents212,213. The number of studies in Europeans is 
limited, and performed in small numbers of subjects, and no such studies have been 
performed in South Asians. 
In summary: the hypothesis that IMCL content is an important determinant of insulin 
resistance is attractive because it can provide an explanation for the experimental 
dissociation of the effects of changes in energy balance and obesity on insulin resistance. 
In humans a hyperinsulinaemic response to glucose challenge can be induced by 
hyperalimentation or reversed by calorie-restricted diets within a few days, before there 
has been any appreciable change in total body fat stores214'215 It may even be possible to 
account for the relation of insulin resistance with central obesity, since NEFA derived 
from adipocytes drained by the portal vein would drive hepatic synthesis of very-low- 
density lipoprotein (VLDL) triglyceride particles46 which deliver triglyceride to peripheral 
tissues. 
Based on the above evidence we wanted to test three closely related hypotheses: 
1. That insulin resistance is associated with high IMCL content; 
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2. That IMCL content is higher in South Asians than in Europeans; 
3. That high IMCL content is associated with central obesity 
If our main (first) hypothesis is confirmed, in future studies one can hope to define 
behavioural and pharmacological interventions that reduce muscle cell triglyceride stores 
and reverse insulin resistance. 
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CHAPTER 4: Hypotheses, Aims and Objectives 
It is now clear that the high prevalence of diabetes mellitus in South Asian people is one 
manifestation of a pattern of metabolic disturbances related to central obesity and insulin 
resistance in this group. It is not clear whether central obesity is the primary defect in this 
syndrome, or whether some other more fundamental disturbance underlies resistance to 
insulin action, central obesity and lipid disturbances in South Asians. Although CHD risk 
in South Asians is strongly associated with raised plasma triglyceride levels, the 
differences between South Asians and Europeans in fasting plasma lipid levels are too 
small to account for the excess coronary risk in South Asians compared with Europeans. 
There remain many gaps in our knowledge about ethnic differences in the relationship 
between body fat distribution (especially central obesity), insulin resistance and lipid 
metabolism. This study was designed to investigate some of these closely related issues. 
Our specific hypotheses, objectives and aims were as follows: 
4.1. Hypotheses: 
1. That central obesity is the primary disturbance underlying the resistance to insulin 
action and disturbances of lipid metabolism in South Asians 
2. That central obesity will account for the ethnic difference in insulin resistance 
3. That disturbances of postprandial lipids, rather than fasting lipids, may mediate the 
excess coronary risk in South Asians compared with Europeans, and that elevated 
postprandial triglyceride is part of the cluster of CHD risk factors associated with the 
insulin resistance syndrome 
4. That the relation between insulin-mediated glucose uptake and central obesity 
is 
mediated through triglyceride stores in skeletal muscle 
To test these hypotheses specific objectives and aims were defined as 
follows: 
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4.2. Objectives 
1. To test whether differences in body fat distribution can account statistically for the 
difference in insulin sensitivity between South Asians and Europeans 
2. To test whether there are differences in postprandial lipid handling between South 
Asians and Europeans sufficient to account for the excess coronary risk in South 
Asians 
3. To test whether muscle cell triglyceride stores can account for the relationship of 
insulin resistance to central obesity and ethnicity 
4.3. Aims 
1. To determine whether the tendency to insulin resistance in South Asians compared with 
Europeans is present at all levels of adiposity, or only at high levels of adiposity [i. e. 
are the regression lines for the association between insulin sensitivity and obesity 
parallel, or do they cross over with varying adiposity] 
2. To test whether the ethnic difference in insulin resistance can be explained by central 
adiposity (when measured accurately by CT scan) 
3. To test whether elevated postprandial triglyceride levels are associated with insulin 
sensitivity and obesity, and whether the ethnic difference in insulin sensitivity (and 
hence in the risk for CHD) can be accounted for by postprandial triglyceride level 
4. To test whether excess triglyceride stores in skeletal muscle (measured non-invasively 
by nuclear magnetic resonance spectroscopy) can account for the relationships of 
ethnicity and central adiposity to insulin resistance 
5. To test whether bio-electrical impedance analysis is a valid and reproducible 
epidemiological field method to measure total percent body fat in South 
Asians 
Although not part of the original a priori hypotheses and objectives of this study, the 
opportunity to measure ethnic differences in plasma concentrations of a marker of 
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inflammation, C-reactive protein, became available towards the end of the study. The 
rationale for doing this, and the results and the relevant discussion relating to this are 
presented in chapter 9. 
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CHAPTER 5: Subjects and Methods 
5.1. Study design and setting 
The most appropriate study design to achieve the objectives of this study (section 4.2) was 
a cross sectional study of European and South Asian men and women. We wanted to study 
individuals who were young enough to not have already developed chronic illnesses of 
interest (CHD and diabetes), and thus an age group of 40 to 55 year old people was 
chosen. We also wanted to study people over a wide range of body size; thus we decided 
to include people with body mass index (BMI) ranging from 17 to 34 kg/m2. 
The London Borough of Ealing was chosen as the setting for the study for two main 
reasons: (i) good contact already exists with general practitioners in the area, with 
successful collaboration in previous studies", ", (ii) the Borough has the second largest 
ethnic minority population of the outer London boroughs, one in three of its residents 
being born outside the United Kingdom21'. In the 1991 Census, over 52,000 or 19% of the 
population of Ealing defined themselves as Indian, Pakistani, or Bangladeshi. This reflects 
immigration predominantly of Sikhs from the Indian state of Punjab, and to a lesser extent, 
of Gujarati Hindus and Pakistani Muslims, which occurred largely in the late 1960s and 
1970s. 
5.2. Sample size 
The sample size was calculated on the basis that we wanted to be able to detect a difference 
of 0.3 %/min/kgm 2 in the slope of the relationship of insulin sensitivity to body mass index 
(BMI) between South Asians and Europeans. Having 42 people of each ethnic group 
would have 90% power to detect such a difference at the 5% significance level. This 
difference in slope would mean that if at a BMI of 20 kg/m2 there is no ethnic difference in 
insulin sensitivity, then at a BMI of 25 kg/m2 there would be a mean ethnic difference in 
insulin sensitivity of 1.5% min-'. This difference would be equivalent to the difference in 
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insulin sensitivity between non-diabetic and diabetic Europeans. However the target 
sample size was increased to 60 people of each ethnicity, to allow for (i) analyses 
separately by sex group if necessary, (ii) other objectives of the study (such as the 
postprandial lipid comparisons), (iii) tests for interactions and (iv) drop-outs from the 
study. 
5.3. Ethical approval and consent for study 
Ethical approval for the study was obtained from the local ethical committees of the 
London School of Hygiene & Tropical Medicine and Ealing Hospital NHS Trust. 
Additional ethical approval was obtained for the nuclear magnetic resonance spectroscopy 
(see 5.5.7 below) from the ethical committees of the London School of Hygiene & 
Tropical Medicine and the Hammersmith Hospital. Written informed consent was 
obtained from all participants for the whole study at the first visit. Further written 
informed consent was obtained at each of the separate visits for the short insulin tolerance 
test and the fat tolerance test. 
5.4. Subject recruitment 
We wrote to partners at six general practices in the Southall and Greenford areas of the 
Borough of Ealing. We sent them a full copy of the study protocol and explained the 
planned nature of research. We asked for their participation in the study and for their 
consent to download copies of their practice lists held by the Ealing and Hammersmith 
Health Authority and to contact eligible patients. Four of the practices gave written 
consent to participate. This enabled the release from the Ealing and Hammersmith Health 
Authority of names, sex, dates of birth, NHS numbers and addresses of all patients 
registered with those 4 practices. From this a list was made only of people qualifying on 
age criteria of between 40 to 55 years old. Permission was then gained to go through each 
of these names individually on the practice database (computerised 
in 3 practices, but done 
manually from GP records in 1 practice), to delete from the 
list any subjects who had any 
of the exclusion criteria, which are summarised below 
Subjects and methods 
With the help of the practice 
5-55 
manager addresses and other details were amended as appropriate. Those whom the 
practice manager could identify as being of other than South Asian or European ethnicity 
were excluded at this stage. If the practice records had a note of the patient's BMI, those 
falling outside the range of 17 to 34 kg/m2 were also excluded. 
5.4.1. Exclusion criteria for the study 
Age: Age outside the range 40 to 55 years 
Illness: People were excluded if there was a history of diabetes mellitus, ischaemic heart 
disease, epilepsy, gall bladder or liver disease, chronic severe illness, or any weight losing 
conditions including cancer or malabsorption. People with known psychiatric illness, 
alcohol abuse or drug abuse were also excluded. Any patients with known HIV positive 
status or Hepatitis B positive status were also excluded. 
Body mass index (BMI): Persons with BMI outside the range of 17 to 34 kg/m2 were 
excluded. This information on BMI was available from GP records in some patients, but 
was calculated from the height and weight information provided in the short questionnaire 
that was sent to all potential participants. 
Drugs: People on any drugs influencing insulin resistance or glucose metabolism were 
excluded from the study; these included beta-blockers, ACE-inhibitors, thiazide diuretics 
and loop diuretics. Women who were on hormone replacement therapy or the oral 
contraceptive pill were excluded because of potential influence on lipids in the fat tolerance 
test. Lipid lowering drugs also constituted an exclusion criterion. 
Pregnancy: Women were asked to state clearly if there was any chance of them being 
pregnant. If there was, or if they were breast-feeding, they were excluded from the study. 
Ethnicity: Any persons who were of any other ethnicity except of South Asian origin or 
European origin were excluded from the study. 
Other: People who declared that they were planning to move out of the area within the 
next year were also excluded, as it would be difficult to trace them, and also attendance 
may have become difficult for five separate visits, if they had moved outside the study 
area. 
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From June 1996, three waves of mailshots were performed. Roughly equal numbers of 
South Asians and Europeans were approached. Each eligible person was sent an invitation 
letter with a covering letter signed by their General Practitioner recommending the 
research project, an information sheet, and a brief reply questionnaire. The questionnaire 
was designed to collect basic information such as telephone number, current height and 
weight to calculate BMI, medical diagnoses and drug history to establish eligibility. Those 
who responded with a completed questionnaire were then sent a second, more detailed 
information sheet, to enable potential participants to decide whether they wanted to commit 
themselves to what was going to be quite an involved study, requiring at least 5 separate 
visits to the hospital. A breakdown of the response rates, eligibility and withdrawal after 
the second information sheet is as follows: 
Total number mailed 1638 
Total responded 351 (21.5%) 
Ineligible 89 
Withdrew 52 (after reading 2nd information sheet) 
Eligible 210 
In reserve 67 (as enough numbers consented to participate) 
Attended for screening 143 
5.5. The protocol for study visits 
To complete all the tests to achieve the study objectives 
it was necessary for each 
participant to attend for five separate visits. The tests and measurements at 
these visits 
were as follows. 
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5.5.1. Visit one for screening health check 
Prior to this visit a letter of appointment was sent to each participant detailing the need for 
overnight fasting for 12 hours, and to bring with them a completed self-administered 
questionnaire. On arrival at Ealing Hospital each person was welcomed, and the health 
check explained in detail, in English, Hindi or Punjabi, as appropriate. Consent was 
taken, fasting status confirmed, and then each person started on the same sequence of 
screening investigations as follows. 
Blood pressure was measured twice with an automated sphygmomanometer (OMRON, 
U. K. ) after resting for five minutes in a chair. 
The participant was then sent to the "anthropometry station" where he/she was given a 
gown, and asked to remove clothes down to underwear. Height was measured by a 
stadiometer and weight on an electronic weighing scales (Soehnle). BMI was calculated as 
weight in kg divided by the square of the height in metres. Measurement of waist (at the 
midway point between iliac crest and lower end of rib cage) and hip (across the greater 
trochanters) circumferences were performed using a spring-loaded measuring tape. 
After dressing, the participant then had measurement of bio-electrical impedance 
(Bodystat- single frequency BIA) to give a measure of percent body fat. For this an 
electrode each was placed on the right foot and wrist as per manufacturer's instructions and 
a tiny 800 µamp current passed. The participant's height and weight were entered into the 
machine. A reading for impedance and percent body fat was obtained. 
Lastly the subject went to the phlebotomy station where a fasting venous sample was taken 
for triglyceride, glucose and insulin assays, and then a 75g oral glucose load given in the 
form of Lucozade (donated by Smith Kline Beecham), consumed steadily over 5 minutes to 
perform the standard oral glucose tolerance test (OGTT)21. At this point we reviewed the 
self-completed questionnaire with the participant to complete any unanswered questions or 
to seek clarification. Participants were then given a slip of paper detailing the time at 
which they should return for their 2-hour sample after emphasising the need to continue 
fasting and refrain from smoking. After the completion of the OGTT the participants were 
offered breakfast. 
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5.5.1.1. Referral to general practitioners 
On the basis of results from screening, participants were referred to their general 
practitioners for further management if any of the following were identified: 
i) systolic blood pressure greater than 140 mmHg 
ii) diastolic blood pressure greater than 90 mmHg 
iii) serum fasting triglycerides greater than 2.3 mmol/1 
iv) impaired glucose tolerance (two-hour glucose > 7.8 but less than 11.1 mmol/l) 
v) diabetes mellitus (two-hour glucose > 11.1 mmol/1) 
Those with fasting triglyceride level > 3.5 mmol/l were excluded from the rest of the 
study as performing the fat tolerance test could potentially result in acute pancreatitis in 
such individuals. Those with newly diagnosed diabetes were also excluded, but those with 
impaired glucose tolerance were requested to continue with the study. 
5.5.1.2. Frequency matching on BMI 
Once the information on BMI was available after the screening visit, only those 
participants who had BMI between 17 and 34 kg/m2 were invited to continue with the rest 
of the study. We wanted to study people over a wide range of BMI so that the relation 
between obesity and insulin resistance could be assessed over a wide range. Efforts were 
made to achieve equal numbers of participants (in each of the 4 sex and ethnic groups) in 
categories of BMI < 23.0,23.0 to 25.9,26.0 to 28.9 and > 29.0. 
5.5.2. Visit two for DEXA scan 
The DEXA scans were performed according to standardised protocols at the Medical 
Physics Department of the Northwick Park Hospital. They were performed by the same 
operator on each occasion (Consultant Medical Physicist, Mr U. Bhonsle). The operator 
was not blinded to the sex or ethnicity of the participants, but the degree of automation of 
the scanning procedure makes operator bias unlikely. Measurements were made with a 
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total body scanner, Hologic QDR 4500 W (Waltham, Massachusetts, USA), and regional 
distribution measured using both a default option and manually determined regions. The 
machine uses a dual energy (100kVp & 140kVp) x-ray fan beam and the subject receives an 
entrance exposure of about 1 mR, (= 8.6 p. Gy). Each whole body scan takes about 5 
minutes. The subject lies supine, with their arms by their side. The whole body image is 
divided into 10 regions of interest (ROI): head, left and right arms, left and right legs, 
pelvis, lumbar spine, thoracic spine and left and right ribs. Using the ROI, fat, lean tissue 
and bone regions are determined, and their values calculated. By comparing these values 
to the spine phantom (provided by the manufacturer) a fat/lean tissue ratio is found. The 
masses of fat, lean tissue and bone are then calculated. 
The main measurement of interest to this study was the total percent body fat, so that the 
measurement of the same by BIA (as a field method) could be validated in South Asians, 
which has not been done before. A by-product of the scan, of interest to the participants, 
was measurement of bone mineral density (BMD) to screen for risk of osteoporosis. 
Participants and their general practitioners were informed of presence of osteopaenia or 
osteoporosis in the lumbar and hip regions (according to standard guidelines by the WHO), 
so that appropriate action could be taken. 
5.5.3. Visit three for CT scan 
All participants were sent a detailed letter to explain what was involved in this visit, 
including the dose of radiation they would be exposed to. To determine the visceral 
adipose tissue area, a single-slice CT scan of the abdomen at the level of L4-L5 was taken. 
The standard protocol for CT was followed at the Radiology Department of Ealing 
Hospital. Abdominal fat was measured by a single slice (10 mm thickness) CT scan at the 
level of L4-L5 using a Toshiba X-speed scanner, with exposure time 2.7 seconds and 
exposure factors 160 mA and 120 kV. Participants were scanned in a supine position with 
arms stretched above their heads. Total fat area (TFA) of the abdomen was calculated by 
delineating the surface of the scan with a graph pen and computing the area in the 
attenuation range of -190 to -30 HU. The visceral fat area (VFA) was measured 
by 
drawing a line within the muscle wall surrounding the abdominal cavity218. Subcutaneous 
fat area (SFA) was calculated as the difference between TFA and VFA. 
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A scannogram was first performed in each person to determine the exact positioning of the 
x-ray beam. All scans were performed by two designated CT radiographers. 
Both the visits for scanning (DEXA and CT scan) were performed on weekends in between 
the visits for metabolic measurements. 
5.5.4. Visit four for the short insulin tolerance test (SITT) 
The subjects were asked to attend after a 12 hour overnight fast. They were asked to 
abstain from alcohol and smoking during the fasting period 
A cannula was inserted retrogradely into a dorsal right hand vein for venous access for test 
samples, and a winged butterfly inserted in the ipsilateral antecubital vein for 
administration of insulin and intravenous glucose. The hand was placed in a warm water 
bath (Grant Beckerman) maintained at 43°C to "arterialise" the venous blood. Arterialised 
blood was taken because of the previous finding that no significant correlation between the 
euglycaemic insulin clamp and SITT measured insulin sensitivity indices was found with 
venous blood sampling, while a close correlation was found when arterialised blood was 
used10°. It has been shown that a heated superficial hand vein can adequately "replace" the 
artery for the measurement of total body glucose kinetics21'. Twenty minutes later a 
baseline `arterialised' blood sample was taken for the zero minute sample. Immediately 
following that a bolus of human actrapid insulin was administered intravenously into the 
antecubital vein at a dose of 0.05 units/kg body weight. Blood samples were then taken at 
3,5,7,9,11,13, and 15 minutes for measurement of blood glucose, and at 5 minutes for 
insulin measurement. The test was terminated at 15 minutes with 25 ml of 50% dextrose 
intravenously into the antecubital vein and the blood glucose checked again using a 
glucometer (Boehringer Mannheim). If glucose level was below 4.5 mmol/l oral Lucozade 
was offered, biscuits given and a further bolus of intravenous glucose given if necessary 
until the glucose level rose above 4.5 mmol/l. All participants were additionally given a 
full breakfast before leaving the hospital building. 
None of the participants suffered a frank (biochemically confirmed) hypoglycaemic attack. 
In general there were no problems with the test, except in one lady who had a swollen arm 
as a result of inadvertent extravasation of the dextrose solution into the tissues. 
She 
recovered fully. Some participants complained of a strong sense of tingling and 
discomfort 
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in the shoulder region during the administration of the dextrose solution at the termination 
of the test, but this passed away in every case, within 30 minutes of the injection, with no 
sequelae. 
5.5.5. Visit five for the fat tolerance test 
The fat tolerance test was performed using the method of Patsch171'220. Participants 
attended after an overnight fast of 12 hours. On arrival the protocol for the fat tolerance 
test was explained in detail and any questions answered. A fasting sample of blood was 
taken for baseline measurement of lipids. Then the participants drank the test meal over 5 
to 15 minutes. The test meal consisted of a cream- based liquid containing 65 gram of fat 
per square meter of body surface area. The meal was made by the registrant prior to each 
visit, according to the following recipe: 350 ml of heavy whipping cream (39.5 % fat), 20 g 
of chocolate flavoured Nesquik®, 15 g of granulated sugar, and 12 g of instant non-fat dry 
skimmed milk, made up per 2 square meters of body surface area. To this was added 
100,000 IU of vitamin A drops (Roche, U. K. ), the rationale for which is described in 
section 2.1.2. This recipe provided 1400 kcal per 2 square meters of which 83% were 
derived from fat (138g), 14% from carbohydrate (48g) and 3% from protein (9.5g). The 
volume of the test meal was reduced in proportion to the participant's body surface area 
(using the formula: volume = 175 ml x body surface area). 
The participants were then asked to consume only plain water or up to 2 cups of plain 
(sugarless, black) tea or coffee, refrain from any food, smoking and any vigorous exercise 
until their return for the postprandial sample. For most participants this was a single 
sample at 8 hours, but in those who consented and were able to attend twice (n=35), two 
postprandial samples were collected at 6 hours and 8 hours. All participants were then 
offered a meal in the hospital canteen. 
The test meal was tolerated well. A few participants reported feeling nauseated but only 
one person vomited after the meal. (Some people actually enjoyed the drink and asked for 
the recipe! ). No one reported gastrointestinal discomfort or symptoms of malabsorption. 
The details of the lipid analyses and the laboratory protocol for these are given below in 
section 5.8. 
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5.5.6. Total number participating after the screening visit 
Of the 143 people who attended for the screening health check (visit 1) a number of people 
were not eligible and some withdrew from the study. The reasons for these were as 
follows: 
Ineligibility: A total of 11 people were ineligible (TG > 3.5 mmol/l in 4 European men, 
BMI < 17 in 1 European man, HRT use in 1 European woman, newly diagnosed diabetes 
on OGTT in 1 South Asian woman, diagnosis of cancer in 1 European man and 
"inappropriate" ethnicity - n=3). 
Withdrawals: A total of 12 people withdrew from the study (3 - no reason given; 3- 
moved away; 2- lack of time; 2- road traffic accident; 2- felt tests too invasive). 
5.5.6.1. Numbers completing each part of study 
The number who participated in each of the subsequent visits is shown in Table 1 below. 
Table 1: Number of people attending for various stages of the study by sex and 
ethnic groups. 
European South Asian 
Men Women Men Women Total 
DEXA scan 31 30 27 31 119 
CT scan 30 31 30 29 120 
SITT 29 28 27 30 114 
FTT 28 29 28 28 113 
5.5.7. Visit six for nuclear magnetic resonance spectroscopy 
This part of the study was performed in a sub-sample of 40 men only. 
This method for measuring triglyceride stores in skeletal muscle became available during 
the course of the study (the technique was being developed and validated at the start of the 
study). 20 men of each ethnic group were randomly chosen from among the men who had 
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completed the rest of the study to have this measurement. Those men who had any metal 
implants from any source, including previous surgery were excluded, as this technique 
uses strong magnetic fields. Standard protocol for MRI scan in use at the Robert Steiner 
MRI Unit at the Hammersmith Hospital was applied. Briefly, the participant was asked to 
lie on a narrow couch, having removed all metal objects including jewellery, watch and 
rings. The region of interest was the left lower leg - in particular a region of the soleus 
muscle that contains no visible septa or adipose tissue. Subjects were positioned supine, 
with their left leg immobilised in a 30 cm diameter quadrature bird cage coil. The couch 
was then moved into the MRI scanner, with the head of the participant remaining outside 
the scanner whenever possible. The scanning was done over a period of 20 minutes. 
Magnetic resonance spectroscopy data were acquired on a 1.5T Picker prototype system. 
Transverse T1 weighted MR images (TR 300, TE 30 ms) were acquired to determine the 
placement of the 'H-MRS voxels, with a slice thickness of 10 mm, a 14 cm field of view 
and 128x256 data matrix. Spectra were obtained using a double spin echo- PRESS (Point 
RESolved Spectroscopy) sequence206 with TE/TR =135/ 1500 ms and an 8 cm3 voxel. 
Spectra were acquired with both the creatine signal and the water signal as an internal 
standard. 
Spectra were analysed as previously described206. Briefly, the muscle spectra were 
analysed by VARPRO, an iterative non-linear least square fitting method operating in the 
time domain. The water peak was quantified by using one exponentially decaying sinusoid 
(corresponding to one Lorentzian line in the frequency domain), while total creatine (TCr 
= PCr + free Cr) and choline (Cho) resonances were modelled as two single Gaussian 
decaying sinusoids with equal damping factors. The (-CH2-)n and -CH3 resonances from 
intracellular and extracellular triglycerides were deconvoluted and modelled as one 
Gaussian decaying sinusoid each. Peak areas for each signal were obtained and lipid 
resonances were quantitated with reference to internal water or to total creatine after 
correcting for Ti and T2. The spectrum generates 4 lipid peaks [corresponding to -CH3 
and -CH2 moieties in myocytes and adipocytes] - as shown in Figure 1. There is a 
difference in resonance frequencies of about 0.2 ppm (Larmor frequency difference 
12-13 Hz at 1.5 T) between adipocyte (1.6 ppm) and intramyocellular (1.4 ppm) TG 
methylene proton signals. Spectral analysis then resolves the lipid peaks to give a single 
measurement of the myocellular triglyceride content (in mmol/kg dry weight), using 
creatine as an internal standard. This technique has been validated against muscle biopsy, 
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and reproducibility studies at the Hammersmith Hospital have shown intra and inter- 
examination coefficient of variation of 4 and 13 % respectively (8 subjects examined 3 
separate times)2o6 
ET(-CH2-)n 
i, fIý.. 
3210 
chemical shift / ppm 
Cho: Choline containing compounds; TCr: total creatine; (-CH2-)n and -CH3 resonances of 
extramuscular (ET) and intramuscular (IT) triglyceride; ppm: parts per million 
Figure 1: Typical magnetic resonance spectra of the soleus muscle 
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5.6. Questionnaire data 
A self-administered questionnaire, sent by post, was filled out by all participants prior to 
attending for the first visit for the study. It included questions on personal medical history, 
family history, drug history, smoking and alcohol consumption, occupation, diet and 
exercise. At the first (screening) visit we reviewed the self-completed questionnaire with 
the participant to complete any unanswered questions or to seek clarification. If 
communication in English was a problem, clarification was provided in Hindi or Punjabi. 
All questionnaires were fully completed. 
Occupational social class was coded as manual or non-manual based on the Registrar 
General's Classification. Data on physical activity and smoking were coded as follows: 
5.6.1. Physical activity 
i. The subjects stated if they participated in any regular sport (% active) 
ii. How far they walked daily (< % mile [1], % to 1 mile [2], 1-3 miles [3], or 
>3 miles [4] ). From this was derived a walking score as follows: upto I mile/day 
[1], 1-3 miles/day [2] or >3 miles/day [3] 
iii. The number of hours per week spent in watching television (< 8h [1], 9-15 h [2] or 
> 15 h [3]) 
iv. The subjects self-rated the amount of exercise they took on a regular basis The latter 
was recoded to an activity score as follows: much less active [1], somewhat less 
active [2], about as active [3], somewhat more active [4], or much more active [5], 
compared to others their age 
5.6.2. Smoking 
Questions on smoking elicited a response to whether the participant was a current smoker, 
an ex-smoker or a never smoker. The category of ever smoker included ex-smokers and 
current smokers. 
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5.7. Sample collection, preparation and transport to the 
laboratory 
The protocols for sample preparation at the specimen collection site at Ealing Hospital 
were as follows: 
5.7.1. Screening visit 
At 0 hours: Take 20 ml blood from participant into syringe, and divide it as follows: 
" 10 ml into Lithium Heparinised tube, place on ice, mix, spin within 30 minutes (3000 
rpm, 10-15 minutes). Then store (at -20°C) 1.0 ml aliquots of plasma in Eppendorf 
tubes for glucose and insulin assays (and a spare sample for backup). 
"5 ml into EDTA tube, place on ice, mix, spin within 30 minutes (3000 rpm, 10-15 
minutes). Then store a 1.0 ml aliquot at -20°C for a backup sample. Leave cells and 1 
mm above the buffy coat: save this in the EDTA tube itself (at -70°C) as "BUFFY 
COAT" for future DNA analysis. 
"5 ml into Plain tube, keep at room temp for 30 -45 minutes until clot forms, spin (3000 
rpm, 10-15 minutes), spin again if supernatant not clean looking. Then store (at -20°C) 
1.0 ml aliquots in Eppendorf tubes for fasting triglyceride and NEFA assays (and a 
spare sample for backup). 
At 2 hours (post glucose load) : Take 16 ml blood from patient into a syringe and divide 
as follows: 
" 10 ml into Lithium Heparinised tube, place on ice, mix, spin within 30 minutes (3000 
rpm, 10-15 minutes). Then store (at -20°C) 1.0 ml aliquots of plasma in Eppendorf 
tubes for glucose and insulin assays (and a spare sample for backup). 
"6 ml into Plain tube, keep at room temp for 30 -45 minutes, spin (3000 rpm, 10-15 
minutes), spin again if supernatant not clean looking 
serum for NEFA and a spare one for backup at -20°C. 
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5.7.2. Visit for the short insulin tolerance test 
During this test 4 ml samples of blood were drawn from the arterialised hand vein at -6,0, 
3,5,7,9,11,13 and 15 minutes and placed into Lithium Heparinised tubes. The same 
protocol was followed for sample preparation and storage as above for glucose levels at all 
time points, and for insulin levels at -6 and 5 minutes. 
5.7.3. Visit for the fat tolerance test 
" At 0 hr (fasting): 40-45 ml blood was drawn and placed into 4 EDTA (10 ml) tubes and 
1 Sodium - Citrate (5 ml) tube. 
" At 8 hr (postprandial): 35-40 ml blood was drawn and placed into 4 EDTA tubes. 
The tubes were immediately placed on ice and spun in a centrifuge as soon as possible at 
3000 rpm for 15 minutes. The supernatant was then divided into aliquots for storage or 
transport to the laboratory as summarised in Table 2. 
Table 2: Summary of protocol for handling of samples 
EDTA Aliquot size/type/n Label/timing transport Storage/analysis 
1x 6ml (0h) FRESH LIPID Oh ice/dry ice -70°C or analyse in 
batches (for VLDL) 
2x 6m1 (8h) FRESH LIPID 8h ice 1. chylo spin* 
2. freeze for VLDL 
2xI ml (0h) LIPID 1&2, Oh ice/dry ice analyse (total & HDL 
cholesterol, TG, NEFA) 
2xI ml (8h) LIPID 1&2,8h ice/dry ice analyse (TG, NEFA) 
0.5 ml x2 preservative ApoB48 &100 (Oh, 8h) ice/dry ice freeze -20/70°C 
1 ml (wrapped in foil) RP 8h ice/dry ice freeze -20/70°C 
RP = retinyl palmitate, TG = triglyceride, VLDL = very low density lipoprotein, NEFA = non- 
esterified fatty acids. 
* The 8-hour (postprandial) "fresh lipid" sample was subjected to ultracentrifugation on receipt at 
the laboratory to separate into chylomicron and non-chylomicron fractions. The protocol for this 
is summarised in section 5.8.6. 
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Extra EDTA plasma aliquots (0.5 - 1.0 ml) were frozen at -70°C for future analyses for 
CETP, leptin, C-reactive protein, anti-oxidants, and LDL-subfractions. Two further spare 
aliquots were also stored. Three aliquots of sodium-citrate plasma were also stored (at 
-70°C) for future analyses for coagulation factors including PAI-1. 
5.8. Laboratory analyses 
All laboratory analyses were performed at the Wynn Division of Metabolic Medicine 
(Wellington Road, St. John's Wood, London, NW8). The laboratory's own Standard 
Operating Procedures with good quality control were used. However there was no 
previously established procedure at the Wynn Laboratory for the separation of the 
chylomicron and non-chylomicron fractions of plasma. Hence there was no established 
quality control for this particular procedure. Technical problems associated with this 
procedure are explained in section 5.8.6. Details of the laboratory methods were as 
follows. 
5.8.1. Glucose 
Glucose was measured on samples collected in lithium-heparinised tubes. The plasma 
aliquots were transported to the laboratory on dry ice in batches. Prior to analysis the 
plasma samples were thawed and centrifuged in the lab. Using kits supplied by Boehringer 
Mannheim the glucose assay was performed using a Cobas Mira discrete analyser (Roche, 
Switzerland). Glucose was converted to gluconate and hydrogen peroxide by glucose 
oxidase. Peroxidase then catalysed the reaction between hydrogen peroxide and 
4-aminophenazone to form a chromogen which was measured colorimetrically. The 
resulting absorbance was proportional to the initial glucose concentration. Internal quality 
was assessed using control sera and assayed chemistry controls supplied 
by Medical 
Analysis Systems, US and Randox Laboratories, (Co. Antrim, Ireland) respectively. 
External quality control was assessed using the Randox Laboratories system. 
Within- and 
between-assay coefficients of variation were <1% and < 2.5 % respectively. 
Subjects and methods 
5-69 
5.8.2. Insulin 
Plasma insulin concentration was determined by a microplate-based chemiluminometric 
assay specific for plasma insulin (supplied by Molecular Light Technology Research 
Limited, Cardiff, U. K. ). Samples were kept at -20°C at Ealing Hospital and transferred in 
batches, on dry ice, to the laboratory, where they were stored at -70°C. Insulin 
concentration was measured in one batch once all the samples had been stored. The 
samples kept at -70°C were thawed at room temperature before centrifuging at 3000 rpm 
for 10 minutes. The assay demonstrated negligible (below 2%) molar cross-reactivity with 
intact proinsulin, split 32-33 proinsulin and des 31,32 proinsulin. No detectable cross- 
reactivity was observed with C-peptide at levels up to 18ng/mL. Between assay coefficient 
of variation was less than 7% (range 13-110 micro Units/ml). 
5.8.3. Total cholesterol 
This was measured with colorimetric assay using a MIRA analyser on fresh samples of 
EDTA plasma. The enzymatic reagent ("CHOL" from Boehringer Mannheim) cleaves 
cholesteryl esters to release free cholesterol, then sets up a colour-producing reaction with 
the free cholesterol. Standardisation was performed using Precinorm-L (human based 
material supplied lyophilised and stored at 2-6°C) obtained from Boehringer Mannheim. 
Internal quality control was performed using the HDL plus series (1,2 and 3) obtained 
from Biostat. External quality control was assessed using the Randox Laboratories system 
(as above). Between-assay coefficient of variation was <2%. 
5.8.4. HDL-cholesterol 
HDL-cholesterol measurement was performed on fresh plasma samples stored at 4°C 
within 48 hours of being taken. HDL was separated from chylomicrons, VLDL, IDL and 
LDL by spinning for an hour with a manganese chloride and heparin solution. Under 
these conditions, the apolipoprotein B present in other lipoproteins (but not HDL 
cholesterol) forms complexes with mucopolysaccharides. The complexes sedimented to 
form a pellet, and HDL-cholesterol was measured in the supernatant using colorimetric 
assay and a Cobas Mira analyser. Internal quality control was performed using the HDL 
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plus series (Biostat). The between-assay coefficient of variation was <5%; that within 
assays <1%. External quality control was assessed using the Randox Laboratories system 
(Crumlin, Co. Antrim, Ireland). 
5.8.5. Triglycerides 
Triglyceride levels were measured using a colorimetric assay in fresh whole plasma 
samples kept at 4°C and transported to the lab on ice within 48 hours of collection. 
Triglycerides were cleaved with Triglycerides N (WAKO, Alpha Laboratories, Eastleigh, 
U. K. ) to release glycerol and free fatty acids. The ensuing colour-producing reaction 
between glycerol and reagent was measured with a Cobas Mira analyser. Thus in effect it 
is total glycerol that is measured in this assay, rather than triglyceride. Plasma glycerol 
levels depend on the rate of lipolysis by hormone-sensitive lipase in fat cells and by 
lipoprotein lipase at the vessel wall........ If there are differences in lipolytic activity or in 
the half life of glycerol between the two ethnic groups, this could affect interpretation of 
the triglyceride concentration. Internal quality control was assessed using the HDL plus 
series (Biostat). Within-assay CV was <1% and between-assay CV <4%. External 
quality control was assessed using the Randox Laboratories system as above. Triglyceride 
in the non-chylomicron fraction was also measured as above, while triglyceride in the 
chylomicron fraction was derived from subtraction of non-chylomicron TG from whole 
plasma TG. The procedure for chylomicron separation was as follows. 
5.8.6. Chylomicron separation 
Ultracentrifugation was performed to separate the chylomicron and non-chylomicron 
fractions of the 8 hour (postprandial) plasma. Aliquots from each of these two fractions 
were then stored for future analysis of ApoB-48, ApoB-100 and retinyl palmitate. 
Four ml plasma was pipetted into swing-out rotor (SW40 Ti) ultracentrifuge tubes 
(Polyallomer 14x95 mm centrifuge tubes obtained from Beckman). This was overlaid with 
1.006 g/ml density KBr solution up to 1 cm from the top. This solution was made by 
adding 8.436g solid KBr (Merck, product number 10195) to 1.0 litre of distilled 
de-ionised 
water. Overlaying was best done using a fine-tip Pastette (Alpha LW4060) and 
letting the 
salt solution ooze out at the level of the meniscus, no higher and no lower. 
This process is 
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best visualised if a dark object is placed behind the tube. The tubes were balanced and 
placed into accurate positions on the rotor, and then spun at 18,000 rpm for 20 minutes at 
4°C. 
The supernatant, which forms the chylomicron fraction, (top 2.5 ml of the density layer) 
was taken off , mixed, and aliquotted as follows. 0.5 ml aliquots, mixed with 
preservative, were stored at -20°C for future analysis of ApoB-48 and ApoB-100 in the 
chylomicron fraction of plasma. A 1.0 ml sample was stored wrapped in foil at -70°C for 
future analysis of retinyl palmitate in the chylomicron fraction of plasma. One 0.5 ml 
aliquot was kept as a spare 8h sample of the chylomicron fraction (at -70°C). 
The infranatant was made up to 10 ml with density solution 1.006 g/ml in plain 10 ml 
tubes (white cap). This formed the non-chylomicron fraction of plasma and was mixed and 
aliquotted in an identical way as for the chylomicron fraction above. In addition 
triglyceride level was measured in a 0.5 ml aliquot of the non-chylomicron fraction of 
plasma. 
Quality control was established using blood from 4 healthy members of the laboratory staff 
4 hours after a high fat meal at an Indian Restaurant. Forty mls of blood from each 
volunteer was collected into EDTA tubes and spun at 3000 rpm in a Mistral centrifuge for 
15 minutes. Five ultracentrifugal spins were set up every day with 2 pooled plasma 
samples in each spin for three consecutive days. Chylomicrons were separated as per the 
procedure above and total triglyceride and non-chylomicron triglyceride concentration was 
measured on each of the samples. Chylomicron triglyceride level was obtained by 
subtracting the non-chylomicron triglyceride concentration from the total triglyceride 
concentration. The coefficients of variation for between assay were 1.03% for total 
triglyceride, 2.2% for non-chylomicron triglyceride and 1.8% for chylomicron triglyceride 
concentration. 
There was an unforeseen problem with the chylomicron separation procedure in the 
laboratory. The Biochemist who had devised a written protocol for the procedure, left his 
post unexpectedly. Any technical problems associated with this procedure (new for this 
particular laboratory) were thus dealt with by non lipid-specialist laboratory staff. This 
remains a limitation of this part of the study. 
Subjects and methods 5-72 
5.8.7. Very low density lipoprotein (VLDL) triglyceride and cholesterol 
Two ml plasma was transferred to an Ultra-Clear tube. The tube was then filled to within 
2 cm of the top by gently overlaying the sample with d1.006 g/ml KBr solution, which was 
made as described above. The tubes were balanced and placed into accurate positions on 
the rotor, and then spun at 18,000 rpm for 20 minutes at 4°C. The supernatant, which 
forms the chylomicron fraction, was then removed. The tubes were topped up again with 
the density solution up to 2 cm below the top, and capped. They were weighed and paired 
within 1 gram of their weight, ready to be spun. The centrifuge tubes were placed in the 
rotor and spun for 18 hours at 32,000 rpm at 4°C (overnight). The next morning the 
ultracentrifuge was stopped and the vacuum turned off. The centrifuge tubes were 
carefully removed and placed in order (tubes 1-44). 
Each centrifuge tube was carefully uncapped and the upper 2.0 ml containing VLDL 
harvested into a 2.0 ml volumetric flask, draining off the supernatant at the level of the 
meniscus. A set of 2.5 ml tubes numbered 1-44 were used to transfer the product. For 
VLDL-cholesterol measurement the HDL cholesterol assay was used [see 5.8.4]. For 
VLDL-triglyceride measurement the triglyceride assay was used as described above 
[section 5.8.5]. 
5.8.8. Non-esterified fatty acids (NEFA) 
Non-esterified fatty acid (NEFA) concentrations were measured on serum (from visit one, 
on frozen samples) and EDTA plasma (from fat tolerance visit, on fresh plasma, within 48 
hours of collection), using kits supplied by Alpha Laboratories (Wako NEFA-C, 
994-75409). The assay was performed using a Cobas Mira discrete analyser (Roche, 
Switzerland) and was based on the acylation of coenzyme A by NEFA in the presence of 
acyl-CoA synthetase. The acyl-CoA produced is oxidised by added acyl-CoA oxidase with 
the generation of hydrogen peroxide. Hydrogen peroxide, in the presence of peroxidase, 
permits the oxidative condensation of 3-methyl-N-ethyl-(3-hydroxyethyl)-aniline with 
4-aminoantipyrine to form a purple coloured adduct which can be measured 
colorimetrically at 550nm. The assay was standardised against the manufacturer's 
provided standard. Due to the lability of NEFA, there are no commercially available 
Quality Control materials that provide target ranges. At the Wynn Division of Metabolic 
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Medicine, internal quality control is monitored using three commercially available 
materials (Lyphocheck) and two internally prepared serum pools. Also, due to the lability 
of NEFA, there are no external quality assurance schemes for NEFA. The between assay 
coefficient of variation at the lab is <7% and the within assay coefficients of variation 
(n=10) are as follows: 
Fasting pool, mean concentration 1.0 mEq/1 <1% 
Suppressed pool, mean concentration 0.2 mEq/1 <5% 
5.9. Data entry and statistical analyses 
Fox-Pro and File Maker-Pro databases were used for double data entry. These data were 
converted into the statistical package STATA (version-5, STATACORP, Texas, USA) 
format using DBMSCOPY software programme. Some of the laboratory data was 
supplied in Microsoft Excel. This was read directly into STATA. 
A programme was written in STATA to derive the insulin sensitivity index (ISI). For this 
the slope of the rate of fall of log glucose over 3 to 15 minutes during the short insulin 
tolerance test was multiplied by -100 giving the ISI in % min-' (see section 1.5.4). The 
graph of the relation between fall in log glucose with time is shown in Figure 2. 
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Figure 2: Graph to show the rate of fall of In glucose with time in Europeans and 
South Asians following a bolus of i. v. insulin in the short insulin tolerance test 
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Data were "cleaned" and any discrepancies resolved by checking against "hard-copy" 
records. The distribution of each continuous variable was examined for normality, and 
those that were skewed were log (natural) transformed to ensure normality. Tests of 
significance for ethnic differences in variables were based on unpaired students' t-tests (and 
standard errors) of mean values, and on geometric mean and 95 % confidence intervals for 
log transformed variables. For categorical variables tests of significance for differences 
between groups were based on the x2 statistic. Pearson's product moment correlation 
coefficients were used to explore the univariate association between continuous variables. 
Multiple linear regression analyses were performed to examine the joint effect of more 
than one variable on the dependent variables. To facilitate comparison of strength of 
association between different explanatory variables contributing to insulin sensitivity, 
continuous variables were divided by their standard deviations. For each of these variables 
the standardised regression coefficient is the coefficient associated with increase of the 
variable by one standard deviation. 
For testing the significance of the difference in slopes (ß) between groups tests of 
interaction were used. 
5.10. Justification for the choice of methods used in this study 
In this section I have described the rationale for why particular methods were chosen in 
this study. The discussion focuses on the methods used for measuring (A) insulin 
sensitivity, (B) postprandial lipids and (C) percent body fat. 
5.10.1. Measurement of insulin sensitivity 
In the current study one of the primary objectives [section 4.2] was to compare 
insulin 
sensitivity in South Asians and Europeans, and to study its relationship specifically with 
obesity. Thus we wanted to measure insulin sensitivity accurately. 
A full discussion of 
the choice of methods available to do this has been given in section 
1.5. 
Practical, logistic and ethical considerations led to the short insulin tolerance test (SITT) 
being used as the method of choice for measuring insulin sensitivity 
in this study. This 
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choice was based on the fact that we needed to perform the test on a large number of 
people (n=120), and we wanted the test to be valid, reliable, safe and acceptable. The 
SITT fulfils all these criteria as shown in section 1.5.4. This choice of method enabled the 
participant to give up a maximum of one hour of their time in the morning, and continue 
with the rest of the day's activities unchanged (e. g. go to work). This was particularly 
important in this study, where we were already asking the participants to take time off 
work for the multiple visits involved. The SITT was also chosen because the registrant 
was able to perform up to four - six of these tests in a morning with minimal help (which 
often entailed only time keeping). 
5.10.2. Measurement of postprandial lipids 
The methods available to measure lipids in the postprandial state all require the 
administration, orally or intravenously, of a fat containing meal (amount of fat varies 
according to the meal chosen), before and after which blood lipids are measured - fat 
tolerance test. Patsch's test meal 171,220 has been used extensively before to test the 
difference between cases and controls of coronary artery disease. They have specifically 
suggested that a single postprandial sample taken at around 6 to 9 hours1 ' 142 may be just as 
discriminatory as the area under the curve of a full fat tolerance test with hourly blood 
samples. This was an important consideration in our choice of method, due to the multiple 
visits involved, to keep high compliance. We thus chose to measure a single postprandial 
sample at 8 hours after the test meal. In some participants who consented (n=35), a 
second sample was also taken at 6 hours postprandially. 
5.10.3. Measurement of total percent body fat 
A number of different methods are available for quantifying total body fat. These include 
underwater weighing and densitometry, deuterium dilution, 40K counting, bio-electrical 
impedance analysis (BIA), and DEXA scan. The use of BIA as a fast, cheap and efficient 
field method has been validated 223,224 in people of European descent, but not in South 
Asians. Recommendations for the use of BIA for estimating adiposity have been made by, 
and reviewed by Houtkooper and colleagues225. We measured percent fat by DEXA scan 
as the standard, against which we wanted to validate the use of BIA in South Asians. 
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CHAPTER 6: Relation between obesity, body fat 
distribution, insulin sensitivity and 
postprandial lipids 
6.1. Presentation of Results 
6.1.1. Baseline characteristics 
135 people (70 European and 65 South Asian) were eligible to proceed with the study (with 
fasting triglyceride < 3.5 mmol/1 and non-diabetic on OGTT). 
Table 3 summarises the distribution of baseline characteristics among Europeans and South 
Asians. The mean age of participants was 46.9 (range: 40.2-56.4, sd: 4.7) years. The 
mean age was similar across all sex and ethnic groups. Prevalence of ever-smoking was 
much lower in South Asians compared with Europeans. There was no significant ethnic 
difference in blood pressure. A higher number of South Asians were in manual 
occupations [48 % of Europeans and 71 % of South Asians reported manual occupations] 
though the difference was only significant among women. Levels of physical activity were 
low in both groups, and especially so in South Asian women. 
There was no significant ethnic difference in the reported family history of ischaemic heart 
disease (48% in Europeans, 52% in South Asians), hypertension (18% in Europeans, 22% 
in South Asians), or stroke (21 % in Europeans and South Asians). There was a trend 
towards higher prevalence of family history of diabetes in South Asians (20.6%) compared 
with Europeans (10.6%; p=0.116). 73.5 % of European women, and 77.4 
% of South 
Asian women were pre-menopausal. Only 4% of Europeans but 48% of South Asians 
described themselves as vegetarian (p < 0.001). 
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Table 3: Distribution of baseline characteristics in Europeans and South Asians 
Men Women 
European S. Asian P European S. Asian p 
n 32 33 38 32 
Age (years) 47.3 ± 0.8 46.6 ± 0.9 NS 47.7 ± 0.8 45.7 ± 0.7 0.081 
% Ever smoker 62.5 21.2 0.001 60.5 0 <0.001 
% in manual 
occupation 
57.1 71.0 NS 40.6 72.0 0.018 
Mean 'activity' 
score (1-5) 
2.28_0.16 + 1.97_0.17 NS 2.31±0.15 1.75±0.17 0.016 
Mean walking 
score (1-3) 
1.94 ± 0.13 1.54 ± 0.12 0.030 1.53 ± 0.09 1.47 ± 0.12 NS 
% active in sport 25.0 21.2 NS 39.5 9.4 0.004 
Mean TV-hours 
score (1-3) 
2.19±0.13 1.57±0.13 0.001 1.97±0.14 1.37±0.13 0.003 
Mean systolic 
BP (mmHg) 
124.1 ± 2.8 126.8 ± 2.7 NS 112.2 ± 2.4 112.9 ± 3.2 NS 
Mean diastolic 
BP (mmHg) 
81.2 ± 2.0 84.9 ± 2.0 NS 72.5 ± 1.4 76.4 ± 1.8 0.095 
Values are mean and SEM, except when percentages are given. Details of physical activity 
measures and smoking are given in sections 5.6.1 and 5.6.2 respectively 
6.1.2. Differences in fat distribution 
Although mean BMI, waist girth and WHR were similar between the ethnic groups of both 
sexes, South Asian women had greater total percent fat than European women (Table 4). 
The range of BMI for the whole group was from 17 to 34.3 kg/m2. Mean VFA was 
generally higher in South Asians compared with Europeans, but in men this did not reach 
statistical significance. South Asian women had significantly greater VFA than European 
women [P=0.36, se=0.10, p=0.001, adjusted R2 =25%]. This ethnic difference in 
women persisted after adjustment for SFA and percent fat [ß=0.21, se=0.10, p-0.047, 
adjusted R'=42%]. However when further adjustment was also made for TFA, the ethnic 
difference in VFA was abolished [ß=0.003, se=0.04, p=0.928, adjusted R2=93%]. As 
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expected, women of both ethnic groups had more total fat than men, but a lower degree of 
central obesity than men (lower waist girth, WHR, and VFA; p<0.001 for sex difference 
in each central obesity measure in both ethnic groups). 
The correlations of VFA measured by CT scan with both waist girth and WHR were high 
(p<0.0001) in all groups (except p=0.003 for association between WHR and VFA in 
European women) as follows. Correlation coefficients (r) between VFA and waist girth: 
0.81 and 0.70 in European men and women, and 0.70 and 0.80 in South Asian men and 
women respectively; Correlation coefficients (r) between VFA and WHR: 0.72 and 0.51 
in European men and women, and 0.69 and 0.71 in South Asian men and women 
respectively. 
Table 4: Distribution of anthropometric variables in men and women of European 
and South Asian descent. 
Men Women 
European S. Asian P European S. Asian p 
n 32 33 38 32 
BMI (kg/m2) 25.8 (0.7) 25.9 (0.5) NS 25.2 (0.6) 25.8 (0.6) NS 
Waist girth (cm) 87.6 (1.9) 88.8 (1.6) NS 77.1 (1.6) 79.3 (1.5) NS 
Waist hip ratio 0.90 (0.01) 0.92 (0.01) NS 0.79 (0.01) 0.80 (0.01) NS 
%fat(DEXA) 22.9(1.3) 25.7(1.2) NS 35.0(1.2) 39.8(1.0) 0.003 
fat (BIA) 21.9 (0.7) 23.3 (0.5) NS 33.6 (0.9) 37.2 (0.9) 0.007 
Visceral fat 
area* (cm2) 
111.5 
[91 - 137] 
126.1 
[108- 148] 
NS 65.8 
[57- 76] 
86.4 
[73- 102] 
0.019 
Subcutaneous 
fat area (cm2) 
193.6 (15.8) 230.1 (16.2) 0.112 263.4 (19.5) 284.2 (15.8) NS 
Total fat area 
(cm2) 
323.2 (25.9) 366.4 (21.8) NS 334.7 (22.5) 379.5 (21.1) NS 
*: geometric means of (backtransformed) log(natural) variables and 95% confidence intervals; 
otherwise means and SEM are given 
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6.1.3. Differences in glucose, insulin and insulin sensitivity index 
The pattern of glucose and insulin concentrations was consistent with greater insulin 
resistance in South Asians (Table 5). Fasting insulin and 2h glucose levels were 
significantly higher among South Asians and there was a much exaggerated post-glucose 
insulin response in South Asians compared with Europeans. Three South Asian men and 5 
South Asian women had glucose intolerance (2h glucose > 7.8 but less than 11.1 mmol/1), 
while all Europeans were normoglycaemic. Mean ISI was higher among Europeans than 
South Asians [(mean and SEM 3.5 ± 0.2 and 2.9 ± 0.6 %/min. respectively, p=0.010), 
and (ß = -0.71,95 % Cl -1.18 to -0.25, p=0.003 for South Asians versus Europeans in age 
and sex adjusted regression analysis)]. 
Table 5: Mean level of glucose, insulin and insulin sensitivity index by sex and ethnic 
group 
Men Women 
European S. Asian p European S. Asian p 
n 32 33 38 32 
Fasting glucose 
(mmol/1) 
5.3 ± 0.1 5.4 ± 0.1 NS 4.9 ± 0.1 5.1 ± 0.1 0.106 
2 hr glucose 
(mmol/1) 
4.9±0.2 5.7±0.3 0.010 4.8±0.2 6.2±0.3 <0.001 
Fasting insulin* 
(µu/ml) 
4.9 
[4.0-6.1] 
8.7 
[6.9- 11.1] 
0.001 4.6 
[4.0-5.3] 
6.1 
[4.9-7.6] 
0.037 
2 hr insulin* 
(µu/ml) 
10.5 
[7.4 - 14.8] 
42.2 
[27.4- 65.1] 
<0.001 17.2 
[13.8- 21.6] 
34.8 
[25.8- 47.0] 
<0.001 
Insulin (%o/min) 
sensitivity index 
3.3 ± 0.3 
(n = 29) 
2.4±0.2 
(n = 27) 
0.024 3.7±0.2 
(n = 28) 
3.2 ± 0.2 
(n = 30) 
NS 
*: geometric means of (backtransformed) log(natural) variables and 95% confidence intervals; 
otherwise mean and SEM are given 
When the sexes were analysed separately, this difference was significant only among men 
(Table 5). When the analysis was restricted to those with normal glucose tolerance during 
the OGTT the findings were unchanged. Among South Asians, women had higher ISI and 
lower fasting insulin and fasting glucose than men [p=0.009, p=0.036 and p=0.019 
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respectively]. Among Europeans, fasting glucose was lower in women than men 
(p < 0.001), but there was no significant sex difference in 2h glucose, insulin or ISI. 
The strength of association between ISI and other markers of insulin sensitivity was 
generally greater in South Asians compared with Europeans (Table 6). 
Table 6: Correlation coefficients for relation between ISI and glucose and insulin 
levels 
Europeans South Asians 
r p r p 
Fasting glucose (mmol/I) -0.21 NS -0.40 0.002 
2h glucose (mmol/I) -0.18 NS -0.35 0.008 
Fasting insulin* (µu/ml) -0.37 0.005 -0.51 <0.001 
2h insulin* (µu/ml) -0.37 0.005 -0.45 <0.001 
*: log (natural transformed) 
6.1.4. Differences in lipids including postprandial triglyceride levels 
These results are summarised in Table 7 and Table 8. There was no significant ethnic 
difference in the fasting levels of total cholesterol or HDL-cholesterol, though the latter 
was significantly higher in South Asian women than men. Fasting triglyceride level was 
higher in South Asian men than European men, but not significantly so (Table 7). The 
8-hour postprandial triglyceride level was higher in South Asian men than European men, 
with a 61 % increase over the fasting level among South Asian men. In women there was 
no ethnic difference in the postprandial triglyceride level. At 8 hours women of both 
ethnic groups had a more favourable postprandial lipid profile (with lower triglyceride 
level) than men. The validity of the data for the proportion of triglyceride concentration at 
8 hours in the chylomicron and non-chylomicron plasma fractions is uncertain, as there is 
an unusually high amount in the chylomicron fraction. It is possible that there were 
technical problems with the preparation of the plasma fractions in the 
laboratory as 
referred to in section 6.3.4. 
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At 6 hours postprandially there was a very exaggerated triglyceride response among South 
Asian men, even though the numbers of subjects studied at this time were small (Table 7). 
For both fasting and 2h NEFA level during the OGTT, and fasting NEFA level during the 
fat tolerance test, South Asian women tended to have higher NEFA levels than European 
women. There was no ethnic difference in levels of VLDL-triglyceride or 
VLDL-cholesterol but there was a significant sex difference in both ethnic groups, with 
lower levels in women compared with men. 
Table 7: Mean fasting and postprandial triglyceride levels, and fasting total and HDL- 
cholesterol in South Asian and European men and women 
Men Women 
Lipids: 
(mmol/I) European S. Asian p European S. Asian p p1 p2 
n 28 28 29 28 
Fasting 5.65 ± 0.24 5.40 ± 0.17 NS 5.24 ± 0.16 5.15 ± 0.17 NS NS NS 
Choi* 
Fasting 1.39 1.26 NS 1.56 1.51 NS 0.106 0.004 
HDL-Choi [1.25- 1.55] [1.16- 1.38] [1.43- 1.71] [1.40- 1.62] 
Fasting TG 1.58 1.72 NS 1.24 1.27 NS 0.056 0.036 
[1.30- 1.92] [1.45- 2.04] [1.06- 1.44] [1.02- 1.58] 
8h TG 1.97 2.51 NS 1.45 1.39 NS 0.060 0.003 
[1.56-2.48] [1.96-3.21] [1.17- 1.79] [1.06- 1.83] 
8h Chylo 1.34 1.75 0.137 0.97 0.92 NS 0.059 0.002 
TG [1.05- 1.71] [1.36- 2.25] [0.79- 1.20] [0.70- 1.24] 
8h Non- 0.62 0.75 NS 0.47 0.48 0.098 0.074 0.016 
chylo TG [0.51- 0.76] [0.59- 0.95] [0.38- 0.59] [0.36- 0.63] 
6h TG 3.27 5.71 0.057: 2.58 3.17 NS NS 0.103 
(n=8) (n=7) (n=8) (n=12) 
[2.15- 4.96] : [4.27- 7.62] [ 1.73- 3.85] 
11] [ 1.97- 5. 
Geometric means and 95% CI are given, except for total cholesterol 
(*) where arithmetic mean 
and SEM is given; exact p values are given for p<0.150 
p: p value for ethnic differences amongst men and amongst women 
pl :p value for sex differences in Europeans; p2: p value 
for sex differences in S. Asians 
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Table 8: Mean fasting and postprandial lipids (NEFA, VLDL-TG and VLDL- 
cholesterol) in South Asian and European men and women. 
Men Women 
Lipids: 
(mmol/I) European S. Asian P European S. Asian p p1 p2 
n 28 28 29 28 
Fasting 0.29 0.34 NS 0.33 0.40 0.098 NS 0.100 
NEFA- [0.25- 0.34] [0.28- 0.40] [0.27- 0.40] [0.35- 0.47] 
OGTT 
2h NEFA - 0.07 0.06 1 NS 0.03 0.04 0.065 0.002 1 0.131 
OGTT [0.04- 0.10] [0.04- 0.09] [0.02- 0.04] [0.03- 0.05] 
Fasting 0.36 0.34 NS 0.35 0.45 0.042 NS 0.048 
NEFA - [0.29- 0.45] [0.27- 0.42] [0.30- 0.41] [0.38- 0.54] 
FTT 
8h 0.77 0.89 NS 0.81 0.89 NS NS NS 
NEFA - [0.68- 0.88] [0.75- 1.05] [0.71- 0.92] [0.80- 0.98] 
FTT 
Fasting 0.49 0.56 NS 0.37 0.36 NS 0.085 0.025 
VLDL-TG [0.38- 0.62] [0.44- 0.70] [0.30- 0.45] [0.27- 0.48] 
8h 0.43 0.52 NS 0.28 0.23 NS 0.032 0.001 
VLDL-TG [0.33- 0.57] [0.40- 0.69] [0.20- 0.37] [0.16- 0.33] 
Fasting 0.35 0.38 0.106 0.27 0.24 NS 0.106 0.016 
VLDL-Choi [0.27- 0.44] [0.31- 0.47] [0.22- 0.34] [0.18- 0.32] 
8h 0.28 0.30 NS 0.17 0.12 NS 0.039 : 0.001 
VLDL-Choi [0.22- 0.37] [0.22- 0.40] [0.12- 0.24] [0.08- 0.18] 
All values are geometric means and 95% Cl. exact p values are given for p<0.150 
p: p value for ethnic differences amongst men and amongst women 
p1: p value for sex differences in Europeans 
p2: p value for sex differences in S. Asians 
The marked sex difference in postprandial triglyceride in South Asians (with 
lower level in 
women vs. men) persisted when adjusted for age and percent 
fat [standardised ß=-0.84, 
se=0.31, p= 0.008] or age and SFA [ß=-0.76, se =0.39, p= 
0.061]. But the sex 
difference in 8h triglyceride level was abolished when VFA was accounted for ß =0.09, 
se=0.38, p=0.813]. The pattern was 
identical in Europeans, i. e., adjusting for age, 
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percent fat or SFA did not account for the lower 8h triglyceride level in women, but 
adjusting for VFA abolished this difference. When also taking the effect of fasting 
triglyceride into account, in South Asians the same pattern as above was true, but in 
Europeans the sex difference in 8h triglyceride level was no longer significant after 
adjusting for age and fasting triglyceride. 
6.1.5. Relation between obesity and metabolic variables (glucose, insulin, ISI 
and triglyceride concentration) 
Table 9 and Table 10 show the correlations of generalised obesity (BMI and percent fat) 
and abdominal obesity with ISI, insulin, glucose and triglyceride levels in men and women. 
Table 9: Pearson's product moment correlation coefficients of obesity measures with 
metabolic variables in European and South Asian men 
7 BMI % Fat WHR W girth VFA SFA TFA 
European men 
Fasting glucose 0.29 0.27 0.41a 0.33 a 0.05 0.32 0.23 
2h glucose 0.16 0.17 0.10 0.10 0.17 0.15 0.14 
Fasting insulin 0.42 a 0.45 a 0.29 0.45 a 0.32 0.57 c 0.51 b 
2h insulin 0.07 0.28 0.01 0.02 0.19 0.16 0.15 
IS) -0.38 a -0.56 
b 
-0.28 -0.43 a -0.50 
b 
-0.48 a -0.49 
b 
Fasting TG 0.35 0.40 a 0.40 a 0.34 0.63 c 0.35 0.51 b 
8h TG 0.38a 0.48b 0.31 0.32 0.60c 0.46a 0.55b 
S. Asian men 
Fasting glucose 0.11 -0.12 0.18 0.01 0.19 -0.13 0.01 
2h glucose 0.08 0.06 0.49 
b 0.13 0.44 a -0.14 0.08 
Fasting insulin 0.59 ° 0.38 0.57 b 0.62 c 0.61 ° 0.36 0.54b 
2h insulin 0.54b 0.47a 0.66c 0.60c 0.61° 0.39a 0.53b 
ISI -0.41 a -0.29 -0.55 
b 
-0.47 a -0.34 -0.29 -0.37 a 
Fasting TG 0.33 0.10 0.52 b 0.49 
b 0.32 0.23 0.27 
8h TG 0.53 a 0.45 a 0.69' 0.61 c 0.49 0.46 0.51 
b 
a p<0.05, b p<0.01, ° p<0.001, insulin, triglyceride (TG) and visceral 
fat area (VFA) have been 
log (natural) transformed. W girth: Waist girth. 
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Table 10: Pearson's product moment correlation coefficients of obesity measures 
with metabolic variables in European and South Asian women 
BMI % Fat WHR W girth VFA SFA TFA 
European women 
Fasting glucose 0.46 b 0.46 b 0.24 0.40 a 0.53 b 0.40 a 0.48 b 
2h glucose 0.33 a 0.18 0.55c 0.44b 0.22 0.15 0.18 
Fasting insulin 0.61 b 0.55 b 0.44 a 0.640 0.65 ` 0.50 b 0.58 c 
2h insulin 0.22 0.22 0.45 b 0.27 0.28 0.15 0.20 
ISI 0.01 0.03 -0.11 -0.11 -0.37 a 0.05 -0.04 
Fasting TG 0.19 0.07 0.55 b 0.39 a 0.37 a 0.13 0.20 
8h TG 0.19 0.01 0.70 c 0.47b 0.44 a 0.08 0.17 
S . Asian women 
Fasting glucose 0.31 0.17 0.39 a 0.38 a 0.42 a 0.01 0.14 
2h glucose 0.13 -0.01 0.45 
b 0.29 0.35 -0.09 0.04 
Fasting insulin 0.30 0.09 0.33 0.35 a 0.38 a 0.06 0.16 
2h insulin 0.19 0.06 0.18 0.16 0.27 0.06 0.11 
ISI -0.38 a -0.21 -0.19 -0.30 -0.35 -0.02 -0.13 
Fasting TG 0.32 0.10 0.58 ` 0.49 b 0.56 b 0.16 0.34 
8h TG 0.13 -0.06 0.42 a 0.26 0.40 a -0.03 0.13 
a p<0.05, b p<0.01, ° p<0.001; Insulin, triglyceride (TG) and visceral fat area (VFA) have been 
log (natural) transformed. W girth: waist girth 
ISI and insulin levels were associated with all measures of obesity, and particularly with 
central obesity. The main departure from this pattern was that ISI in European women was 
not significantly associated with most measures of obesity (except with VFA). In men 
there was a striking ethnic difference in the strength of the association between insulin 
concentration and measures of central obesity: in South Asian men these correlation 
coefficients were generally larger than in European men. There was a strong correlation 
of measures of central obesity (VFA, waist girth and WHR) with fasting and 8h 
triglyceride level in all 4 sex/ethnic groups. In men, but not women, generalised obesity, 
TFA and SFA were also associated with 8h triglyceride level. The correlations between 
VFA and percent fat were stronger in men (r=0.79 in Europeans and 0.68 in South 
Asians) than in women (r=0.48 in Europeans and 0.59 in South Asians). 
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6.1.6. Ethnic difference in the relation between insulin sensitivity and 
obesity 
6.1.6.1. Insulin sensitivity index as the dependent variable 
6.1.6.1.1. ISI and BMI 
The relationship between ISI and BMI in all participants (n =114) of the two ethnic groups 
is shown in Figure 3. 
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Figure 3: Relationship between insulin sensitivity index and BMI in Europeans and 
South Asians 
The regression line for this association was steeper in South Asians [ß=-0.15, p=0.003] 
than in Europeans [P= -0.08, p=0.093], but the slopes were not significantly 
different 
from each other [p for interaction between ethnicity and BMI =0.334] . The slope of the 
regression line for the association between ISI and BMI, adjusted for age and sex was 
-0.07 (se=0.05, p= 0.1 50) in Europeans and -0.14 
(se=0.05, p=0.003) in South Asians 
[also not significantly different; p for interaction =0.285]. There was no interaction 
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between sex and BMI, thus the results have been presented for the whole group of 
participants. 
6.1.6.1.2. ISI and percent fat 
There was a significant interaction between sex and percent fat [p==0.020], thus analyses 
were performed separately for men and women. Among men there was a significant 
association between percent fat and ISI in Europeans [ß = -0.11, p=0.003] but not in South 
Asians [ß=-0.05, p=0.145], and the slopes of the regression lines were not significantly 
different [p for interaction =0.201]. In women there was no significant association 
between percent fat and ISI. 
6.1.6.1.3. ISI and central obesity 
The relationship between ISI and VFA in all participants of the two ethnic groups is shown 
in Figure 4. 
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Figure 4: Relationship between insulin sensitivity index and visceral fat area in 
Europeans and South Asians 
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Although the association between ISI and VFA was strong in each group, the slopes of the 
regression lines were not significantly different in Europeans [ß=-1.21, p<0.001] and 
South Asians [ß=-1.05, p=0.001], with p for interaction =0.706. The results were 
similar in analyses adjusted for age and sex, and there was no interaction between sex and 
VFA [p for interaction =0.476]. The results were in the same direction when either waist 
girth or WHR ratio were used as markers of central obesity. 
6.1.6.2. Fasting insulin level as the dependent variable 
6.1.6.2.1. Fasting insulin and BMI 
In regression analyses adjusted for age and sex, the association between fasting insulin and 
BMI was strong in both Europeans [P=0.06, p<0.001] and South Asians [P=0.09, 
p<0.001], but there was no significant ethnic difference [p for interaction ==0.376]. 
There was no interaction between sex and BMI [p=0.407]. Figure 5 shows graphically 
the relation between fasting insulin and BMI in European and South Asian participants. 
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Figure 5: Relationship between fasting insulin and BMI in Europeans and South 
Asians 
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6.1.6.2.2. Fasting insulin and percent fat 
There was no evidence of interaction [p=0.267] between sex and percent fat, so analyses 
are presented for the whole group combined. In regression analysis of the whole group 
adjusted for age and sex the association between percent fat and fasting insulin was 
stronger in Europeans [P=0.03, p<0.0011 than in South Asians [P=0.03, p=0.041], with 
borderline interaction between ethnicity and percent fat [p=0.1071. The crude association 
between fasting insulin and percent fat was significant in Europeans [D=0.02, p-0.015] 
but not in South Asians [ß= -0.006, p=0.532], and is shown in Figure 6. 
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Figure 6: Relationship between fasting insulin and percent fat in Europeans and 
South Asians 
6.1.6.2.3. Fasting insulin and central obesity 
The relationship between fasting insulin and VFA in all participants of the two ethnic 
groups is shown in Figure 7. The association between fasting insulin and VFA was strong 
in each group, with a significantly steeper slope [p for interaction =0.060] 
in South Asians 
[R=0.73, p<0.0011 than in Europeans [ß=0.37, p=0.001]. When the analysis was 
repeated with additionally adjusting for age and sex [no interaction 
between sex and VFA, 
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p=0.730], the slopes of the regression lines were significantly different at the 5% level [p 
for interaction =0.045]. 
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Figure 7: Relationship between fasting insulin and visceral fat area in Europeans and 
South Asians 
The results were in the same direction when either waist girth (Figure 8) or WHR 
(Figure 
9) were used as markers of central obesity. 
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6.1.6.3.2h insulin level as the dependent variable 
6.1.6.3.1.2h insulin and BMI 
In contrast to the lack of ethnic difference in association between BMI and fasting insulin, 
there was a significant ethnic difference in the association between BMI and 2h insulin. 
The slope of this association in the whole group was much steeper [p for 
interaction =0.047] in South Asians [ß=0.12, p=0.006] than in Europeans [ß=0.02, 
p=0.553]; Figure 10. In analyses further adjusted for age and sex the results were 
unchanged. There was no evidence for a sex/BMI interaction [p-=0.364]. 
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Figure 10: Relationship between 2h-insulin and BMI in Europeans and South Asians 
6.1.6.3.2.2h insulin and percent fat 
There was an interaction [p=0.052] between sex and percent fat, so analyses were 
performed separately for men and women. There was no significant association between 
2h insulin and percent fat except in South Asian men [P=0.09, p=0.019]. 
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6.1.6.3.3.2h insulin and central obesity 
The relationship between 2h insulin and VFA in all participants is shown in Figure 11. 
There was no association between 2h insulin and VFA in Europeans [P=0.04, p=0.8391, 
but there was a strong association in South Asians [ß=0.93, p=0.001]; p for 
interaction =0.007. The results were unchanged when age and sex were added to the 
models [p for sex/VFA interaction =0.300]. The results were in the same direction (and 
same order of magnitude) when either waist girth or WHR were used as markers of central 
obesity (Figure 12 and Figure 13 respectively). 
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Figure 11: Relationship between 2h-insulin and visceral fat area in Europeans and 
South Asians 
Body fat, insulin sensitivity & postprandial lipids 
6-94 
- Europeans 0 
South Asians °- 
6QQQ 
QQ 
oCh cl 
8Qo 
Q D4Q°°° 13 °Q 
=L 13 0 
EZ 
°° Oll o o63°° o°Q 
. CD Noo° öoo° °ö° 
o oob a8Q 
0 Q0 
N2 o 
Co00 
J oo 
0 ° go 
° 
co 0 
Q° 
0 
60.0 80.0 100.0 
Waist girth (cm) 
Figure 12: Relationship between 2h-insulin and waist girth in Europeans and South 
Asians 
Europeans o 
South Asians Q 
6 
: 
c, 
c 
J 
QQQ 
QQ 
e Qo QQ 
QQ 
00 
08° 
Qoo Qo 
°® 0o QQ oQo 
oQ °So 
00 0 00° QQ0 
O 
``9 o 
Cl QQ0 
o o° 
oo ®o 0 oo00 
Q 
00 
° 
00 0°0o 
0 
Q 000 
Q0 
120.0 
0 
6 81 1.2 
Waist/hip ratio 
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South Asians 
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6.1.7. Relation between insulin sensitivity, visceral obesity, lipids and ethnic 
origin 
There was a significant strong relationship of ISI and VFA in both ethnic groups [in 
regression analyses adjusted for sex and age: standardised P= -0.64, se=0.18, p=0.001, 
adjusted R2=21% in Europeans; ß=-0.43, se =0.17, p=0.015, adjusted R2=20% in South 
Asians]. In the whole group (in analyses adjusted for age, ethnicity and sex) there 
persisted a significant relation between ISI and VFA after adjustment for % fat and SFA 
[ß=-0.45, se=0.17, p=0.009, adjusted R2=25%]. However, this relationship was 
eliminated after additional adjustment for triglyceride level (fasting and 8h) [P=0.02, 
se = 0.19, p=0.911, adjusted R2 = 34 % ]. The results for the effect of VFA on ISI in each 
ethnic group separately with and without adjustment for overall obesity and triglyceride 
level, are shown in Table 11. 
Table 11: Multiple linear regression with insulin sensitivity as dependent variable and 
visceral fat area as independent variable, adjusted for age, sex, obesity and lipids, in 
Europeans and South Asians. 
Europeans S. Asians 
independent variables ß s. e. p R2 % ß s. e. p % R2 
VFA, age, sex -0.64 0.18 0.001 20.6 -0.43 0.17 0.015 19.8 
VFA, age, sex, % fat -0.53 0.26 0.046 19.6 -0.40 0.22 0.076 18.0 
VFA age, sex, % fat, SFA -0.51 0.26 0.054 21.6 -0.41 0.22 0.076 17.7 
VFA, age, sex, % fat, 
SFA, Oh TG 
-0.11 0.33 0.743 22.4 0.002 0.25 0.993 28.9 
VFA, age, sex, % fat, 
SFA, 8h TG 
0.09 0.32 0.767 28.0 -0.04 0.23 0.854 32.5 
VFA, age, sex, % fat, 
SFA, Oh TG, 8h TG 
0.03 0.33 0.914 27.3 0.003 0.24 0.989 31.5 
log (natural) transformed values of VFA and TG were used. VFA= visceral fat area, TG= 
triglyceride, ß= standardised ß, R2 = adjusted R2 value. The standardised beta (ß) is the slope 
of the relationship of ISI on VFA, with the continuous variables standardised to unit standard 
deviation (see methods section 5.9). 
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In analyses adjusted for age and ethnicity, there was a significant association between SFA 
and ISI in men [ß=- 0.55, se =0.18, p= 0.004] but not women [ß=0.04, se=0.16, 
p=0.786]; p value for sex/SFA interaction =0.014. In men, when additional adjustment 
was made for VFA, the significance of association with SFA was lost [ß=-0.28, se=0.22, 
p=0.210]. Thus the association between ISI and VFA was independent of SFA, but the 
converse was not the case. 
The results were similar when fasting or 2h insulin were chosen as the marker of insulin 
resistance for the whole group. That is, there was a significant association between fasting 
insulin and VFA, and 2h insulin and VFA that was independent of % fat and SFA. This 
association was eliminated after additionally adjusting for triglyceride level (fasting or 8h). 
6.1.8. The ethnic difference in insulin sensitivity 
In standardised regression analyses adjusted for age and sex ISI was 0.71 %/min lower in 
South Asians than in Europeans (Table 12). The contribution of obesity and triglyceride 
level to the ethnic difference in ISI was examined, and is summarised in Table 12. 
Adjustment for total adiposity (measured by BMI or percent fat), body fat distribution or 
triglyceride level did not account for more than one-third of the ethnic difference in ISI. 
In a multivariate model with adjustment for age, sex, percent fat, VFA, as well as fasting 
and 8h triglyceride only 42% of the ethnic difference in ISI was accounted for [P== -0.41, 
se=0.22, p==0.066, adjusted R2 =33%]. With additional adjustment for variables 
measuring level of physical activity, none of the reported results were significantly altered, 
and measures of physical activity were not significant in the model. Adding smoking 
status was also not significant in the model. However addition of social class (manual vs. 
non-manual occupation) was significant in the model, and increased the ethnic difference in 
ISI [ß=-0.63, se=0.24, p=0.009]. Among women adjustment for menopausal status did 
not alter the model. 
With fasting or 2h insulin as dependent variable the results were similar; none of the 
measured variables accounted for more than half the ethnic difference. 
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Table 12: Effect of measures of obesity and body fat distribution on age and sex 
adjusted association between insulin sensitivity index and ethnicity. 
variables adjusted for: s. e. p 2% 
age, sex - 0.71 0.24 0.003 11.1 
age, sex, BMI - 0.71 0.23 0.002 16.8 
age, sex, %fat - 0.49 0.24 0.045 16.0 
age, sex, waist girth - 0.66 0.22 0.004 19.8 
age, sex, waist-hip ratio -0.62 0.23 0.008 15.7 
age, sex, visceral fat area* - 0.52 0.23 0.024 24.5 
age, sex, subcutaneous fat area - 0.66 0.24 0.007 14.6 
age, sex, visceral/subcutaneous fat area ratio* - 0.69 0.24 0.004 14.1 
age, sex, total fat area - 0.61 0.23 0.010 18.0 
age, sex, fasting triglyceride* - 0.59 0.22 0.009 23.5 
age, sex, 8h postprandial triglyceride* 
L- 1 - 
0.57 1 0.21 0.008 29.4 1 
Independent variable of primary interest: ethnic group coded as ethnicity: 2=South Asian, 
1=European; n=114. Dependent variable: insulin sensitivity index. *: log (natural) transformed 
variables; all obesity and metabolic variables are standardised continuous variables. 
standardised ß, R2 = adjusted R2 value. 
6.1.9. Relation between postprandial triglyceride concentration and insulin 
resistance 
Univariate associations of postprandial triglyceride level and features associated with the 
insulin resistance syndrome are presented in Table 13. This shows that postprandial 
triglyceride level was associated with features of the metabolic syndrome in all 4 sex/ethnic 
groups. To assess whether there was an independent association of postprandial 
triglyceride with insulin resistance, multivariate analyses were performed for the entire 
group (adjusted for age, sex and ethnic group) with and without adjustment for fasting 
triglyceride level. The results are presented in Table 14 and show that by and large 
postprandial triglyceride concentration had an independent association with features of the 
insulin resistance syndrome. 
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Table 13: Pearson's product moment correlation coefficients (r) for the relation 
between 8h triglyceride level and metabolic and obesity features of the insulin 
resistance syndrome 
Men Women 
European S. Asian European S. Asian 
ISI (%/min) -0.29 -0.64b -0.42d -0.45d 
Fasting insulin* (µu/ml) 0.454 0.64b 0.51° 0.62k 
2h insulin* (µu/ml) 0.31 0.75a 0.61b 0.424 
Fasting glucose (mmol/I) -0.05 -0.04 0.09 0.47d 
2h glucose (mmol/I) 0.35e 0.36d 0.22 0.41" 
HDL-cholesteroi* (mmol/I) -0.44d -0.76a -0.53` -0.32' 
Fasting NEFA* (mmol/I) 0.11 0.03 0.07 0.49` 
8h NEFA* (mmol/I) 0.35e 0.38d 0.19 0.66b 
Fasting VLDL-TG* (mmol/I) 0.78a 0.616 0.73a 0.80a 
8h VLDL-TG* (mmol/I) 0.87a 0.80a 0.90a 0.93a 
Fasting VLDL-Choi* (mmol/I) 0.71a 0.60b 0.72a 0.77a 
8h VLDL-Chol* (mmol/I) 0.73' 0.66a 0.85a 0.87a 
Fasting triglyceride* (mmol/I) 0.77a 0.76a 0.81a 0.91a 
VFA* (cm2) 0.60b 0.49` 0.44d 0.40d 
SFA (cm2) 0.46d 0.46d 0.08 -0.03 
Waist girth (cm) 0.32e 0.61b 0.47 c 0.26 
Waist-hip ratio 0.30 0.69k 0.70a 0.424 
BMI (kg/m2) 0.38d 0.53` 0.19 0.13 
Percent fat (%) d 0.47 d 0.45 0.01 -0.06 
*These variables were log (natural) transformed; a=p<0.0001; b=p<0.001; c=p<0.01; d=p<0.05; 
e=p<O. 1 
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Table 14: Multivariate analyses for the relation between 8h triglyceride level 
(dependent variable) and features of the insulin resistance syndrome, adjusted for 
sex, ethnicity, and age, with and without adjustment for fasting triglyceride level 
independent variables: 
age sex ethnic group + 
No adjustment for fasting TG Adjustment for fasting TG 
, , 
se p %R2 se p % R2 
ISI (%/min) -0.31 0.06 <0.001 25.9 -0.12 0.04 0.004 70.3 
Fasting insulin* (µu/ml) 0.37 0.05 <0.001 36.2 0.16 0.04 <0.001 71.8 
2h insulin* (µu/ml) 0.37 0.06 <0.001 31.4 0.18 0.04 <0.001 72.9 
2h glucose (mmol/I) 0.24 0.06 <0.001 18.4 0.10 0.04 0.010 71.6 
HDL-Chol* (mmol/I) -0.35 0.06 <0.001 31.8 -0.16 0.04 <0.001 74.1 
Oh NEFA* (mmol/I) 0.11 0.06 0.086 10.4 -0.06 0.04 0.092 70.6 
8h NEFA* (mmol/I) 0.25 0.06 <0.001 21.5 0.10 0.04 0.005 71.9 
Oh VLDL-TG* (mmol/I) 0.50 0.04 <0.001 58.3 0.03 0.08 0.709 69.8 
8h VLDL-TG* (mmol/I) 0.61 0.03 <0.001 78.8 0.43 0.05 <0.001 81.7 
Oh VLDL-Chol* (mmol/I) 0.47 0.05 <0.001 53.5 0.05 0.06 0.458 70.0 
8h VLDL-Chol* (mmol/1) 0.55 0.04 <0.001 64.8 0.26 0.05 <0.001 74.8 
Visceral fat area* (cm2) 0.36 0.06 <0.001 28.4 0.07 0.05 0.118 70.8 
SFA (cm2) 0.16 0.07 0.018 12.3 0.04 0.04 0.304 70.4 
Waist girth (cm) 0.31 0.07 <0.001 22.4 0.05 0.05 0.266 70.2 
WHIR 0.47 0.08 <0.001 31.0 0.11 0.06 0.073 70.7 
BMI 0.20 0.06 0.003 15.5 0.04 0.04 0.355 70.1 
Percent fat (%) 0.20 0.09 0.029 11.2 0.07 0.05 0.189 68.8 
*= log (natural) transformed values of these variables were used; R2 : Adjusted R2 values; ß= 
standardised beta coefficient. (see methods section 5.9) 
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6.2. Summary of results 
The results in this chapter can be summarised as follows: 
1. South Asians compared with Europeans tended to have 
0 Higher levels of overall obesity (greater percent fat), and central obesity 
(greater VFA), especially so in women. 
" Greater prevalence of insulin resistance (higher glucose and insulin levels and 
lower ISI) 
0 Higher levels of postprandial triglyceride in men (significant at 6h, but not at 
8h) 
2. All measures of insulin sensitivity (ISI, fasting insulin and 2h insulin) were strongly 
related with obesity in all groups, especially central obesity. In particular there was a 
strong association between VFA and ISI that was independent of SFA and percent fat. 
There was also a strong association between SFA and ISI, but this association was 
eliminated when adjustment was made for VFA. 
3. The strong association between ISI and VFA persisted when adjusted for overall 
obesity (percent fat), but was eliminated when adjustment was made for triglyceride 
level (fasting or 8h). 
4. The slopes of the regression lines for the association between ISI and BMI, and 
between ISI and VFA were not significantly different between Europeans and South 
Asians. However, the slopes of the regression lines for the association between fasting 
insulin and VFA (as well as waist girth and WHR), and between 2h insulin and BMI, 
and 2h insulin and VFA (as well as waist girth and WHR) were significantly different 
in Europeans and South Asians, with the latter group having steeper slopes. 
5. Less than half the ethnic difference in insulin sensitivity (ISI, or insulin level) was 
accounted for by obesity, body fat distribution and triglyceride level. 
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6. Postprandial triglyceride level was a correlate of the metabolic syndrome, and this 
association was independent of the fasting triglyceride level in both Europeans and 
South Asians. 
6.3. Discussion of results 
While it has been suggested that in South Asians central obesity is related to the high 
prevalence of insulin resistance, diabetes and CHD29, no one has used direct measures to 
study the relationship between central obesity and insulin resistance in South Asians and 
Europeans. The results from this study are the first to address this issue using direct 
measures. 
We found overall higher levels of total obesity (percent fat), central obesity (VFA), 
postprandial triglyceride level and insulin resistance (lower ISI and higher insulin level) in 
South Asians than Europeans who were frequency matched for BMI. The level of obesity 
was significantly different in women but not men; there was a trend towards higher 
postprandial triglyceride concentration in men (significant at 6h in a small number, but not 
at 8h in the whole group) but not women; the greater insulin resistance in South Asians 
was significant among men for ISI, but both for ISI and insulin level among women. We 
have shown that postprandial triglyceride level has a strong relation with both central 
obesity and insulin sensitivity, and statistically accounts for the association between them. 
We also report that the ethnic difference in insulin sensitivity is not accounted for by 
central obesity. 
6.3.1. Ethnic differences in obesity 
We have found that South Asians had higher overall obesity (total percent body fat) than 
Europeans at any given level of BMI. Among the sexes separately, this was significantly 
so in women but not men, though the trend in men was also in the same direction. This is 
a novel finding as there are no previous studies of South Asian - European ethnic 
comparison that have quantified percent body fat measured accurately by DEXA scan. 
However some previous studies have attempted to quantify percent body fat by measuring 
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sum of total skinfolds. Thus studies so far that have quantified obesity only by BMI will 
have not fully accounted for ethnic differences in body composition. 
The greater level of percent fat in South Asians compared with Europeans could be due to 
genetic differences, environmental and life-style factors and lower levels of exercise, or a 
combination of these. In this study reported levels of physical activity were low in both 
groups, and even lower in South Asians than Europeans. The only exception to this was 
that South Asians reported significantly lower number of hours spent watching television 
than Europeans. This could be because of cultural differences in the way that periods of 
physical inactivity are spent. It is possible that South Asians spend more time socialising 
for example than watching television. There might also be differences in the way exercise 
is taken; for example it is noteworthy that none of the South Asian women rode a bicycle. 
There are many limitations due to cultural/ethnic factors in assessing levels of physical 
activity from self-report. The most objective way to quantify physical fitness would have 
been to measure maximal aerobic power (V02-max). However, this was not possible in 
the current study because the study protocol already involved multiple tests on multiple 
visits, and it was not feasible to fit in any more formal tests. 
It is also noteworthy that although there were no ethnic differences in mean waist girth or 
WHR, mean VFA measured by CT scan was higher in South Asians than in Europeans, 
although this difference was statistically significant only in women. We have previously 
reported that in comparison with European men and women, South Asian men and women 
have higher levels of central obesity, (as measured by WHR, sagittal abdominal diameter 
or trunk skinfolds), than Europeans29. The failure to detect a significant ethnic difference 
in VFA in men in this and another smaller study comparing South Asians and 
Europeans226, may be a chance result, as differences in abdominal obesity have consistently 
been detected in larger surveys using anthropometry. 
6.3.2. Ethnic difference in insulin sensitivity 
Higher average levels of insulin resistance in South Asians compared with Europeans have 
been demonstrated in epidemiological studies measuring fasting and post-load insulin 
levels. In a steady-state study using the insulin suppression test227, the ethnic difference in 
insulin resistance (measured by the steady-state plasma glucose level) between weight- 
matched South Asians and Europeans was of comparable size to that typically observed 
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when patients with NIDDM are compared with weight-matched controls. As a measure of 
insulin-stimulated glucose uptake, the short insulin tolerance test has been validated against 
the euglycaemic clamp with correlation coefficients of 0.81 to 0.86100-10'. The higher 
insulin sensitivity in women compared with men of similar BMI in the present study is in 
keeping with a previous study228 which measured ISI by the frequently sampled intravenous 
glucose tolerance test. The ethnic difference in ISI in the current study was statistically 
significant among men but not women. However insulin levels (fasting and 2h) were 
markedly higher in South Asians than in Europeans in both men and women, as previously 
observed in a larger epidemiological study in this population29. 
This suggests that the defect in insulin-mediated glucose disposal in South Asians may be 
more evident after a glucose load than in the fasting state. Furthermore, although the short 
insulin tolerance test has been validated against the euglycaemic clamp, it has never 
specifically been validated in South Asians. It is likely to be valid in South Asians as one 
group has successfully employed it in a study of an ethnic comparison of prevalence of 
insulin resistance in non-diabetic relatives of patients with diabetes53. Nonetheless, specific 
validation in South Asians should be undertaken before it is used in further studies of 
ethnic comparison. 
6.3.3. Ethnic differences in relation between insulin sensitivity and obesity 
ISI and insulin levels were correlated with VFA in each ethnic group and in the whole 
group, and this relationship was independent of percent body fat. This contrasts with a 
smaller study in India229 in which there was no significant relation of insulin level to CT- 
scan-measured abdominal fat areas in South Asians. 
Also, the significant association between ISI and VFA was independent of SFA, but the 
converse was not the case. This finding is directly in contrast with a study by Goodpaster 
et aff, where SFA was the strongest correlate of insulin sensitivity (measured by the 
glucose clamp technique), independently of VFA. The primary importance of visceral 
adipose tissue versus subcutaneous abdominal obesity has also been challenged by 
others231'232 One reason for the difference in our results could be that Goodpaster et al's 
study was based on a smaller number of subjects (n=54), who were recruited by public 
advertisement. 
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We report that the ethnic difference in insulin sensitivity as measured by the short insulin 
tolerance test cannot be accounted for by central obesity based on 3 lines of evidence in 
this study - (A) the ethnic difference in ISI did not disappear with the addition of VFA in 
regression analysis; (B) the slopes of the regression lines for the association between ISI 
and VFA or ISI and BMI were not significantly different - i. e. the reduction in ISI with 
increasing BMI or VFA did not differ significantly between the ethnic groups; and (C) the 
results did not fit a sex pattern: in men there was a large ethnic difference in ISI but not in 
VFA, whereas in women there was no significant difference in ISI but a large ethnic 
difference in VFA. 
If accumulation of visceral fat accounts for the greater susceptibility of South Asians to 
insulin resistance, in comparison with Europeans, we would predict that (i) adjusting for 
direct measures of visceral fat would account for the ethnic difference in insulin resistance, 
and (ii) the slope of the relationship between insulin resistance and percent body fat would 
be steeper in South Asians than in Europeans because in the leanest individuals visceral fat 
stores are low in both ethnic groups. Neither of these two predictions was confirmed. 
South Asians had lower insulin sensitivity (ISI) than Europeans at all levels of overall 
adiposity, even when lean. Central obesity did not account statistically for the ethnic 
difference in insulin sensitivity. Our finding that the ethnic difference in insulin sensitivity 
was statistically significant only in men, while the ethnic difference in VFA was 
statistically significant only in women is not consistent with the hypothesis that central 
obesity has a primary role in the ethnic difference in insulin sensitivity. 
However, when insulin level was used as the measure of insulin sensitivity there was an 
interaction between ethnicity and VFA. This suggests that lean individuals of either ethnic 
group had low insulin levels, but as visceral obesity increased, South Asians had 
significantly higher insulin levels than Europeans. This was shown clearly by the crossing 
over or diverging of the regression lines (in Europeans and South Asians) in the graphs of 
the relationship between insulin concentration and measures of central obesity (figures 7- 
9 and 11 - 13) as well as by the differences in the correlation coefficients of the relation 
between insulin concentration and measures of central obesity (especially in men; Table 9). 
This difference in finding with insulin concentration versus ISI as the outcome measure 
could be due to reasons discussed before in section 6.3.2, and has also been further 
addressed in chapter 10 (section 10.3.6.1). The finding of greater increases among South 
Asians in insulin concentration with increasing levels of central adiposity is of potential 
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public health importance. This finding suggests that that in South Asians, even more so 
than in Europeans, efforts to control central adiposity should form the focus of efforts to 
reduce insulin resistance (as indexed by insulin concentration), and hence CHD. This 
subject is further discussed in section 10.5. 
Even though central (visceral) obesity did not account for the ethnic difference in insulin 
sensitivity in this study, nonetheless it was strongly and independently associated with 
insulin sensitivity in each ethnic group. The mechanism by which accumulation of fat in 
visceral depots is associated with insulin resistance is not fully understood. It is postulated 
that greater lipolytic activity of centrally located adipocytes contributes to portal venous 
elevations of NEFA, because omental fat cells in vitro are resistant to insulin-mediated 
suppression of lipolysis233. Elevated NEFA decrease hepatic insulin extraction 13' and 
promote synthesis of apolipoprotein B lipoproteins46,95,95,235,235 Thus NEFA derived from 
visceral fat might selectively potentiate peripheral hyperinsulinaemia and dyslipidaemia236 
Recent evidence suggests that resistance to insulin-mediated glucose uptake is strongly 
related to the level of triglyceride stores in muscle cells208'209 Triglyceride levels in muscle 
are likely to depend upon plasma triglyceride levels, which in turn are highly correlated 
with central adiposity. 
6.3.4. The role of postprandial triglyceride in the relation between insulin 
sensitivity and obesity 
Triglyceride levels at 8h after a fat load in this study were strongly correlated with 
measures of central adiposity including waist/hip ratio and VFA. This relationship is what 
we would expect to observe: the accumulation of fat in intra-abdominal depots could lead 
to a sustained production of VLDL and an impaired clearance of triglyceride-rich 
lipoproteins in the postprandial period147,23' 8h triglyceride was also strongly associated 
with insulin sensitivity, and accounted statistically for the association between central 
adiposity and insulin sensitivity. 
Both at 8h and in a smaller number at 6h, there was a higher postprandial triglyceride 
level 
in South Asian men versus European men, but there was no significant ethnic difference 
between women. This is probably because most of the women in this study were 
premenopausal, and as such are probably relatively "protected" 
from an adverse lipaemic 
response. In both ethnic groups the sex difference 
in 8h triglyceride level persisted when 
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adjusted for age, percent fat or SFA, but was abolished when adjusted for the sex 
difference in VFA. This suggests that the higher level of visceral fat in men compared 
with women is related to their more adverse postprandial lipaemic response. This 
argument is supported by the finding that when this sex difference in body fat distribution 
is taken into account, no sex difference in lipaemic response remains. This has been 
shown before for sex differences in fasting triglyceride level238, but never before to our 
knowledge, for sex differences in postprandial triglyceride. 
We have shown that postprandial triglyceride level was, independently of fasting 
triglyceride level, associated with the metabolic syndrome or the insulin resistance 
syndrome. Thus we propose that postprandial triglyceride forms part of the cluster of 
CHD risk factors associated with the metabolic syndrome in both Europeans and South 
Asians. This is a new finding in South Asians, not previously reported. Although in 
people of European descent it has been suggested previously that elevated postprandial 
triglyceride level is part of the cluster of features that form the metabolic 
syndrome 144,146,147, it is still not widely accepted, and it remains controversial whether this 
association is independent of fasting triglyceride level. Some groups have failed altogether 
to find an association between insulin resistance (or insulin level) and postprandial 
trig lyceride133,145 In a recent study in men, Couillard et a1147 showed that visceral obesity 
is associated with an impaired postprandial triglyceride clearance, and that visceral obesity 
may contribute to fasting and postprandial hypertriglyceridaemia by altering NEFA 
metabolism in the postprandial state. They reported that features of the insulin resistance 
syndrome were all significant correlates of an impaired postprandial TGRL clearance. 
However, in the current study even after adjusting for central obesity and triglyceride level 
(fasting and 8h), there remained a significant ethnic difference in insulin sensitivity. For 
this epidemiological study, rather than undertake a full fat tolerance test with hourly blood 
samples, we took a single post-load sample at 8h, plus a 6h measurement in a sub-sample. 
This was based on previous studies showing that a single measurement at 8h correlates 
with the extent of coronary disease at angiography13' . 
As the ethnic differences in 
postprandial triglyceride level were greater at 6h than at 8h, it is possible that we have 
underestimated the ethnic difference in postprandial triglyceride level by relying on a 
single measurement at 8h in most participants. If so, then it is possible that we have also 
underestimated the extent to which differences in postprandial triglyceride levels could 
account for the ethnic difference in insulin sensitivity. From the limited information that 
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we have, it looks as if there may be ethnic differences in postprandial triglyceride earlier in 
the fat tolerance test that are not detectable at 8 h, at least not with total triglyceride. 
There may have been subtle differences in fractions of the postprandial response that were 
possibly not evident in the measurement of total triglyceride level alone. We wanted to 
measure apoB-48 and apoB-100, as well as plasma retinyl palmitate in chylomicron and 
non-chylomicron plasma fractions to see whether there were ethnic differences in the 
exogenous (dietary; apoB-48 and retinyl palmitate) and/or endogenous (hepatic derived; 
apoB-100) levels of triglyceride. However, although samples were collected, due to 
technical problems and lack of a laboratory that was able to measure these for us on a 
collaborative basis, we were unable to do so. This remains a limitation of this part of the 
study. As a compromise we did measure triglyceride level in the chylomicron and non- 
chylomicron fractions of the plasma at 8 hours, but found there to be no ethnic difference 
in these. However the validity of the data obtained for triglyceride concentration in the 
two fractions is open to question, as there were technical problems associated with the 
preparation in the laboratory. 
In conclusion, our results suggest that the greater resistance to insulin-mediated glucose 
uptake in South Asians compared with Europeans cannot be fully accounted for by 
differences in body fat pattern, or in plasma triglyceride levels. In both ethnic groups the 
relationships of insulin sensitivity to visceral fat were eliminated by adjusting for 
postprandial triglyceride level, suggesting that an underlying alteration of lipid metabolism 
may be responsible for the relationship between these variables. Ethnic differences in 
plasma lipids appear to be larger in the postprandial state than in the fasting state, and this 
may be relevant to the excess risk of CHD in South Asians compared with other groups. 
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CHAPTER 7: The relation between insulin sensitivity, 
body fat pattern and i ntramyocel Iu lar lipid 
content 
7.1. Presentation of results 
7.1.1. Basic characteristics and general associations of IMCL 
Mean (± SEM) IMCL content (measured with creatine as the internal standard) was higher 
in South Asians than in Europeans [72.1 ± 7.5 vs. 53.6 ± 4.9 mmol/kg dry weight 
respectively, p=0.046]. The clinical and metabolic measurements of the participants, and 
their correlation with IMCL are summarised in Table 15. 
South Asian men had significantly higher percent body fat and insulin resistance than 
European men. In Europeans IMCL was positively correlated with indices of generalised 
obesity and central obesity (Table 15), and inversely correlated with ISI (Figure 14). In 
South Asians IMCL was not significantly correlated with any measured variable. 
European men smoked more and had a higher mean walking score than South Asians, 
though both groups took little exercise. The distribution of ISI by BMI in the two groups 
is shown in Figure 15. 
One possible reason for the lack of association of IMCL with the measured obesity and 
metabolic variables among South Asian men could be because of one South Asian "outlier", 
who had very low IMCL and low ISI (figure 14). Thus the analysis was repeated with the 
exclusion of this outlier. This did not make any difference to the observed associations. In 
particular the slope (beta coefficient) of the ISI/IMCL association in South Asian men was 
+0.05 (p = 0.891) with all men, and -0.08 (p = 0.875) with the outlier excluded. 
The 
correlation coefficient (r) for this association changed from +0.03 (p = 
0.891) to -0.04 (p = 
0.875) with the exclusion of the outlier. 
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Table 15: Mean values of clinical and metabolic variables and Pearson's correlation 
coefficients (r) with intramyocellular lipid in men by ethnic group 
European (n =20) South Asian (n =20) pb 
Mean* r pa Mean* r pa 
Age (years) 47.8 ± 1.0 0.45 0.048 46.3 ± 1.1 0.01 NS NS 
BMI (kg/m2) 26.4 ± 0.8 0.72 <0.001 26.3 ± 0.6 0.25 NS NS 
% body fat 22.5 ± 1.7 0.49 0.028 26.8 + 1.3 0.31 NS 0.052 
WHR 0.91 ± 0.01 0.74 <0.001 0.92 + 0.01 0.25 NS NS 
Visceral fat area* (cm2) 113.5 
[87- 148] 
0.62 0.004 137.2 
[115 - 164] 
0.14 NS NS 
Fasting glucose (mmol/I) 5.3 t 0.1 0.10 NS 5.4 0.1 -0.20 NS NS 
2h glucose (mmol/l) 4.9 ± 0.2 -0.12 NS 5.9 0.4 -0.08 NS 0.022 
Fasting insulin* (µU /ml) 4.9 
[3.7 - 6.5] 
0.37 NS 9.7 
[7.2 - 13.1] 
-0.17 NS 0.003 
2h insulin* (µU/ml) 10.3 
[6.9 - 15.6] 
0.15 NS 51.4 
[31.6- 83.7] 
-0.09 NS <0.001 
ISI (%/min) 3.4 ± 0.3 -0.53 0.016 2.4 + 0.2 0.03 NS 0.013 
Fasting triglyceride* 
(mmol/I) 
1.46 
[1.2 - 1.8] 
0.13 NS ' 1.60 
[1.3 - 2.0] 
-0.08 NS NS 
Fasting NEFA* (mmol/I) 0.29 
[0.24 - 0.37] 
0.04 NS 0.34 
[0.28-0.41] 
-0.19 NS NS 
2h NEFA* (mmol/l) 0.06 
[0.04-0.10] 
0.01 NS 0.05 
[0.04-0.08] 
0.03 NS NS 
Physical activity (1-5) 2.2 + 0.2 -0.33 NS 2.0 ± 0.2 -0.15 NS NS 
Walking score (1-4) 3.0 ± 0.1 -0.08 NS 2.2 ± 0.2 0.04 NS 0.009 
Active in sport (%) 25 0.02 NS 25 -0.03 NS NS 
Ever smoker (%) 55 0.37 NS 10 -0.12 NS 0.002 
Arithmetic means and SEM are given except where the variable has been log transformed (*), 
where geometric means and 95% CIs are shown. a: significance level associated with r; 
b: p 
value for ethnic difference in mean values; Exact p values are quoted for p<O. 10. Ever smoker 
= past or current smoker 
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Figure 14: Relationship between insulin sensitivity index and intramyocellular lipid 
content in 40 European and South Asian men 
Europeans o- 
South Asians Q- 
60 
00 
°. o 
4 
o 
r-. .ý 
Cl) 
c2 
N 
c 
Z3 
U) 
0 
Figure 15: Relationship between insulin sensitivity index and BMI in 40 European 
and South Asian men 
Body fat, insulin sensitivity & IMCL 
7-111 
20.0 25.0 30.0 J5. u 
Body mass index (kg/m2) 
When water was used as the internal standard instead of creatine, the results were similar 
but associations of IMCL content with ethnic origin, obesity, insulin sensitivity and lipids 
were generally weaker. 
7.1.2. Relation between IMCL, insulin sensitivity, obesity, and lipids 
The relation of ISI to obesity, plasma lipids and IMCL was examined in each ethnic group 
separately. All analyses were adjusted for age, and standardised regression coefficients are 
presented (Table 16). The strongest (age adjusted) associations of ISI in Europeans were 
with: generalised obesity [percent fat and BMI], central obesity [VFA, WHR and waist 
girth], and IMCL. There was no significant association of ISI with plasma lipids among 
Europeans. Among South Asians ISI was significantly associated with plasma fasting and 
8h triglyceride, and central obesity measured anthropometrically (WHR and waist girth). 
However ISI in South Asians was not significantly associated with VFA, IMCL, BMI or 
percent fat. These results were unchanged when the analyses were repeated with the 
exclusion of one South Asian "outlier" (figure 14). 
Table 16: Age adjusted univariate regressions of insulin sensitivity index on 
measures of obesity, plasma lipids and IMCL content in men by ethnic group 
European men South Asian men 
ß se p value se p value 
VFA* (cm2) -0.79 0.25 0.005 -0.41 0.25 0.128 
WHR -1.01 0.44 0.034 -0.74 
0.30 0.025 
Waist girth (cm) -1.09 0.28 0.001 -0.41 0.20 
0.063 
BMI (kg/m2) -1.03 0.25 0.001 -0.43 0.22 
0.066 
percent fat -1.52 0.33 <0.001 -0.04 
0.32 NS 
Fasting TG* (mmol/I) 0.22 0.29 NS -0.72 0.17 <0.001 
8h TG* (mmol/I) -0,12 0.32 NS -0.67 
0.17 0.001 
Fasting NEFA* (mmol/I) -0.21 0.32 NS -0.16 
0.24 NS 
2h NEFA* (mmol/I) -0.13 0.26 NS -0.13 
0.25 NS 
IMCL* (mmol/kg dry wt) -0.80 0.39 0.058 0.02 
0.17 NS 
*: log (natural) transformed values of these variables were used; TG = triglyceride; 
Standardised 
regression coefficient: ß 
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Analyses with fasting and 2h insulin as the dependent variables showed a similar pattern 
with strong associations with central obesity (WHR, waist girth and VFA), triglyceride 
level (Oh and 8h), and additionally BMI in South Asians. In Europeans the most 
significant association was with percent fat, but not with central obesity. 
In multiple regression analyses we examined whether the association between insulin 
sensitivity and central obesity, seen in both European and South Asian men, persisted when 
adjusted for IMCL. In age-adjusted analyses in Europeans the significant association 
between ISI and VFA, and ISI and percent fat persisted even after adjustment for IMCL, 
in contrast to the association between ISI and WHR which was made non-significant when 
adjusted for IMCL (Table 17, model A). Among South Asian men the association between 
ISI and WHR remained significant when adjusted for IMCL. Among European men the 
significant association between IMCL and WHR, and IMCL and VFA persisted even after 
adjusting for fasting plasma triglyceride (Table 17, model B). The results with 8h 
triglyceride in the models were identical. 
The significant relationship between ISI and IMCL in Europeans was independent of 
fasting and 2h glucose, insulin and NEFA, and plasma triglyceride. However, this 
association was no longer statistically significant when adjustment was made for 
generalised obesity [percent fat: ß= -0.40, p=0.199; BMI: ß= 0.03, p=0.941] or for 
central obesity [VFA: 3= -0.29, p=0.493; WHR: ß= -0.37, p=0.494]. 
There were fewer smokers among South Asians (Table 15). Adjusting for smoking did not 
make a difference to the relations between insulin sensitivity, central obesity and IMCL. 
The level of physical activity reported were low in both groups, and adjusting for it did not 
alter the reported results. 
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Table 17: Effect of (A) adjusting for IMCL on association between insulin sensitivity 
(ISI) and obesity, and of (B) adjusting for plasma triglyceride on association between 
IMCL and obesity, in men by ethnic group 
European South Asian 
ßa se p pa se p 
(A) insulin sensitivity index as dependent variable 
Slope of relationship with WHR 
age, whr -1.01 0.44 0.034 -0.74 0.30 0.025 
age, whr, IMCL* -0.72 0.61 0.256 -0.80 0.32 0.022 
Slope of relationship with VFA 
age, VFA* -0.79 0.25 0.005 -0.41 0.25 0.128 
age, VFA*, IMCL* -0.68 0.29 0.035 -0.42 0.26 0.129 
Slope of relationship with percent body fat 
age, %fat -1.52 0.33 <0.001 -0.04 0.19 0.909 
age, %fat, IMCL* -1.38 0.34 0.001 -0.06 0.34 0.873 
(B) IMCL as dependent variable 
Slope of relationship with WHR 
age, whr 0.38 0.10 0.001 0.25 0.23 0.299 
age, whr, plasma fasting TG* 0.36 0.11 0.006 0.32 0.26 0.242 
Slope of relationship with VFA 
age, VFA* 0.19 0.07 0.019 0.11 0.18 0.543 
age, VFA*, plasma fasting TG* 0.23 0.10 0.043 0.09 0.19 0.636 
Slope of relationship with percent body fat 
age, %fat 0.18 0.13 0.174 0.28 0.20 0.188 
age, %fat, plasma fasting TG* 0.11 0.14 0.441 0.17 0.24 0.484 
aß= standardised regression coefficient; *: log (natural transformed) values used; TG = 
triglyceride 
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7.2. Summary of results 
1. South Asian men compared with European men had higher mean percent fat and lower 
insulin sensitivity. 
2. Mean intramyocellular lipid content was higher in South Asian men than in European 
men. 
3. In Europeans IMCL was strongly correlated with percent fat, WHR, visceral fat and 
insulin sensitivity. In South Asians IMCL was not significantly related to insulin 
sensitivity or obesity, and the strongest associations of insulin sensitivity were with 
plasma triglyceride (fasting and 8h) and WHR. 
4. In Europeans the relation between IMCL and ISI was independent of plasma glucose, 
insulin or lipid levels, but not independent of generalised or central obesity. 
7.3. Discussion of results 
Our findings in Europeans are consistent with the hypothesis that IMCL content modulates 
insulin sensitivity. We found, like others208, that the relation in Europeans between ISI and 
IMCL was independent of fasting and 2h glucose, insulin and NEFA, and triglyceride 
level. However, in contrast to other studies where insulin sensitivity was correlated with 
IMCL independently of BMI in Europeans208 and independently of BMI, percent fat or 
waist/thigh ratio in Pima Indians202, we found that the relation between ISI and IMCL was 
not independent of obesity and was not stronger than the relation between ISI and 
obesity209. This was the case whether we used creatine or water as the internal standard in 
'H-NMR. The reason for these differences is unclear, but it is unlikely to be related to 
data acquisition given that others used similar localisation techniques and have reported 
similar reproducibility208'209 Likely possibilities may relate to differences in the population 
sample, and the larger sample size of our study. 
Although in South Asian men IMCL content was higher than in Europeans, IMCL was not 
significantly related to ISI or indices of obesity. The strongest associations of ISI were with 
WHR and plasma triglyceride (fasting and 8h) in South Asians. These results are not 
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easily reconciled with the simple hypothesis that elevated IMCL content mediates the 
associations of central obesity and raised triglyceride with insulin resistance in South 
Asians. Phillips et a? °° have shown that IMCL measured in biopsy specimens of 
gastrocnemius muscle was inversely associated with glycogen synthase (an insulin 
regulated enzyme that is rate limiting for insulin action in muscle), but not with insulin 
sensitivity measured by the short insulin tolerance test. However in our study we found an 
association between IMCL and ISI in Europeans but not in South Asians. Other 
physiological mechanisms may mediate impairment of insulin sensitivity in South Asians. 
For instance increased lipolysis of IMCL stores (modulated by hormone-sensitive lipase) or 
increased supply of triglyceride from plasma could cause insulin resistance. The strong 
correlation between plasma triglyceride and ISI observed in South Asians in this study is 
consistent with this. This may also account for our failure to detect the usual association 
of insulin resistance with obesity in South Asians in this small sample. 
We would expect to see a close relationship between central obesity and IMCL content 
because VLDL triglyceride is likely to be one of the main sources of triglyceride in 
muscle, and the main substrate for hepatic VLDL triglyceride production is NEFA derived 
from lipolysis of fat stores drained by the portal veina6, as, 235 Because lipolysis of lipid 
stores in skeletal muscle is not easily suppressed by insulin, the NEFA derived from 
triglyceride stores would compete with glucose for oxidative metabolism and reduce 
insulin-mediated glucose uptake via the glucose fatty-acid cycle. 
In summary, we found a negative correlation between IMCL and insulin sensitivity in 
Europeans but not in South Asians. To establish definitively whether insulin resistance 
depends upon muscle cell triglyceride stores will require experimental studies of the effects 
of dietary and pharmacological interventions that alter muscle triglyceride stores on 
insulin-mediated glucose uptake. This could open up possibilities for developing new 
measures to prevent and control insulin resistance and NIDDM. 
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CHAPTER 8: Validation and reproducibility of 
bio-electrical impedance analysis to 
measure percent body fat 
8.1. Presentation of results 
8.1.1. Validation of the use of bio-electrical impedance (BIA) 
The correlation coefficients of the relation between percent fat measured by DEXA scan 
and percent fat measured by BIA in each of the 4 sex and ethnic groups were as follows 
(Table 18) : 
Table 18: Product moment correlation coefficients (r) between %fat by DEXA and 
BIA 
n r p value 
South Asian men 26 0.77 <0.0001 
South Asian women 30 0.85 <0.0001 
European men 31 0.86 <0.0001 
European women 31 0.81 <0.0001 
The relationship between BIA and DEXA measurements of percent fat in European and 
South Asian men and women is shown in Figure 16 and Figure 17 respectively. 
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Figure 16: Relationship between measurement of %fat by DEXA and bio-electrical 
impedance analysis in European and South Asian men 
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Figure 17: Relationship between measurement of %fat by DEXA and bio-electrical 
impedance analysis in European and South Asian women 
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The agreement between the two methods (DEXA and BIA) of measuring percent fat was 
calculated using the method of Bland and Altman239. The results of this calculation which 
yielded the lower and upper limits of agreement between the two methods are shown in 
Table 19. 
Table 19: Agreement between the DEXA and BIA measures of %fat 
Group N Mean of 
differences 
sd of 
differences 
Agreement: 
lower limit 
Agreement: 
upper limit 
All South Asians 56 2.43 2.99 -3.56 8.42 
All Europeans 62 1.57 3.12 -4.67 7.81 
S. Asian men 26 1.90 3.18 -4.47 8.26 
S. Asian women 30 2.89 2.82 -2.75 8.53 
European men 31 0.86 2.98 -5.11 6.82 
European women 31 2.28 3.25 -4.23 8.79 
8.1.2. Reproducibility of BIA 
Additionally in 87 people we were also able to repeat the BIA measurement of percent fat 
during the visit for DEXA scan. There was very strong correlation between percent fat 
measured at the two separate visits (Table 20). 
Table 20: Product moment correlation coefficients (r) between %fat at two separate 
visits (measured by BIA) 
n r p value 
South Asian men 22 0.91 <0.0001 
South Asian women 21 0.98 <0.0001 
European men 23 0.96 <0.0001 
European women 21 0.73 0.0002 
The strong correlation between the two visits for BIA-percent fat measurement in 
European and South Asian men and women is shown in Figure 18 and Figure 19 
respectively. 
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impedance analysis in European and South Asian men 
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Figure 19: Relationship between two repeat measurements of %fat by bio-electrical 
impedance analysis in European and South Asian women 
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To assess the reproducibility of percent fat measurement by BIA, the coefficient of 
variation for between-visits was calculated for each group, using the method of Bland24o 
The coefficients of variation for two repeat measurements of percent fat by BIA in 87 
subjects were as follows: 5.0% in South Asian men, 2.0% in South Asian women, 3.9% in 
European men and 8.0% in European women. The repeatability coefficients as defined by 
the British Standards Institution 240,241 were 3.3 and 2.0 in South Asian men and women 
respectively, and 2.5 and 7.2 in European men and women respectively. The reliability 
coefficient represents the 2x sd (of differences), the value below which the difference 
between two measurements will lie with a probability of 0.9524' . 
8.2. Summary of results 
We have shown that BIA is a valid and reliable (reproducible) method for measuring 
percent body fat in both South Asians and Europeans. We have validated the use of BIA 
against DEXA scan. 
8.3. Discussion of results 
BIA is now an accepted method for measuring percent body fat. Although single 
frequency BIA has been validated against DEXA for use in people of European 
descent ...... 5, its validity against DEXA scans in South Asians has never previously been 
established. 
Since the design and conduct of the current study, one group from India has published 
results for the validation of BIA against hydrodensitometry242. They found that BIA 
estimates of percent fat were higher than those from hydrodensitometry, which they argued 
could be attributable to the use of inappropriate regression equations derived from studies 
in people of European descent. They developed their own predictive equation for the 
derivation of fat-free mass, using the variables of height2/impedance and fat free mass by 
under-water weighing. The use of this equation in BIA gave good agreement between BIA 
and hydrodensitometry method. We were unable to do this as the company that 
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manufactures the Bodystat impedance meters was unwilling to release the components of 
the equations it uses in computing the final formula for percent body fat or for impedance. 
Single frequency bio-electrical impedance analysis can be used as an epidemiological 
"tool" to measure percent fat in studies of South Asians. It offers a cheap, quick and 
acceptable method to measure percent fat, which can be performed at the bedside. 
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CHAPTER 9: Relation of inflammation with risk for CHD 
During the course of this study evidence started to emerge for a possible link between 
markers of inflammation (C-reactive protein level) and CHD. Opportunistically a 
collaboration also became possible (Appendix) which enabled measurement of C-reactive 
protein (CRP) on frozen plasma from this study. Spare aliquots of plasma that were kept 
frozen at -70°C from the visit for fat tolerance test (n=113) were used for this 
measurement. The background and rationale to this measurement is explained below. 
9.1. The evidence for a link between inflammation and CHD 
C-reactive protein (CRP) is an acute phase reactant which is a measurable marker of 
inflammation in the body. There is a growing body of evidence that low grade chronic 
inflammation may be associated with the development of cardiovascular disease241-246 A 
summary of published studies examining the association between CRP and cardiovascular 
disease has recently been given by Lagrand et a1122. Mild elevations of CRP concentrations 
even when within the clinically 'normal' range are predictive of future cardiovascular 
events. This association holds true for individuals with multiple risk factors247, those with 
stable or unstable angina245, and in men with favourable coronary risk factor profiles243 
More recent data also link plasma CRP concentrations to the risk of developing peripheral 
arterial disease248. New evidence published from the ARIC study (Atherosclerosis Risk in 
Communities) has also linked inflammation to the development of diabetes mellitus, in a 
population free of diabetes at baseline 249 
Whether inflammation also contributes to this increased CHD risk in South Asians is not 
known as no studies comparing CRP concentrations in South Asians and other groups have 
been published. The only inflammatory marker to have been studied in an ethnic 
comparison so far is plasma fibrinogen, which has been found to be no higher in South 
Asians than in Europeans28'33. It is certainly plausible that inflammatory markers such as 
CRP might be elevated in South Asians compared with Europeans, given the greater 
degree of total fat mass in South Asians, and the suggested link between obesity and CRP 
level. The latter is thought to occur through increased production of CRP by hepatocytes 
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in response to elevated interleukin-6 cytokine, which in turn is elevated through increased 
production of TNF-alpha250, which is overproduced by adipocytes2s' 
Thus we measured CRP levels with the following aims: to test (i) whether CRP 
concentrations were elevated in South Asians compared with Europeans, (ii) whether CRP 
was associated with insulin sensitivity measured directly by the short insulin test, and 
indirectly by insulin level, and (iii) whether there was an association between CRP level 
and body fat distribution and lipid levels (fasting and postprandial) in the two ethnic 
groups. 
9.2. Measurement of plasma CRP 
C-reactive protein was measured using a sensitive double antibody sandwich ELISA with 
rabbit antihuman C-reactive protein and peroxidase conjugated rabbit anti-human 
C-reactive protein. The assay was linear up to 5mg/l and logarithmic thereafter. The 
interassay and intra-assay coefficients of variation were less than 10% across the range of 
measured results252. 
9.3. Presentation of results 
Among women median CRP level was higher among South Asians [1.35 mg/1, 
(interquartile range 0.72,3.04)] vs. Europeans [0.70 mg/1, (0.41,1.70)], p=0.050. This 
was despite the absence of any smokers among South Asian women. Although the median 
CRP level was about 15% higher in South Asian men [1.07 mg/1, (0.76,1.50)] compared 
with European men [0.92 mg/1, (0.34,1.61)], this was not statistically significantly 
different. This is reflective of the lack of power to examine sub-group differences in this 
study with relatively small numbers. Only 3 people had CRP level greater than 10 mg/1, 
the cut point used in clinical practice to identify inflammation. There was a trend towards 
a significant ethnic difference in the CRP level in analysis adjusted for age, sex and 
smoking [ß=0.45, se=0.25, p=0.076]. 
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The age, sex and smoking adjusted standardised regression coefficients for the relation 
between CRP level and its determinants are shown in Table 21. CRP concentrations were 
generally more strongly associated with central obesity in South Asians but with both 
overall obesity and central obesity in Europeans. Social class was not significantly 
associated with CRP in either ethnic group in this study. 
Table 21: Determinants of C reactive protein concentration among Europeans and 
South Asians. 
Europeans South Asians 
ß se p se p 
Age (years)a 0.35 0.18 0.053 0.21 0.12 0.087 
BMI (kg/m2) 0.49 0.17 0.005 0.26 0.13 0.058 
Percent fat 0.55 0.24 0.026 0.34 0.20 0.096 
Waist/hip ratio 0.37 0.26 NS 0.60 0.15 <0.001 
Waist girth (cm) 0.49 0.21 0.027 0.44 0.13 0.002 
Visceral fat area* (cm2) 0.51 0.20 0.013 0.41 0.14 0.004 
Exact p values are given for p<=0.1; *: log (In) transformed. a : adjusted only for sex & smoking 
Age, sex and smoking adjusted standardised regression coefficients are given for log (natural) 
C reactive protein as the dependent variable (per one standard deviation increase in 
explanatory variable). 
The association of CHD risk factors with CRP concentration as the independent variable is 
shown in Table 22. In multiple regression analyses adjusted for age, sex and smoking, 
CRP level was significantly associated with insulin (Oh and 2h) and triglyceride (Oh and 
8h) in both ethnic groups, and also with HDL-cholesterol (negative) and Oh glucose in 
Europeans, but not with ISI in either group. After additionally adjusting for percent fat, 
there remained an independent association of CRP level with fasting glucose and 
insulin 
and HDL-cholesterol in Europeans, and with triglyceride level in South Asians. 
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Table 22: Relationship between cardiovascular risk factors and CRP among 
Europeans and South Asians 
Europeans South Asians 
Dependent variable ß se p ß se p 
ISI (%/min) a -0.11 0.14 NS -0.07 0.18 NS 
b -0.04 0.15 NS 0.00 0.18 NS 
Fasting insulin* (µu/ml) a 0.14 0.05 0.005 0.12 0.10 NS 
b 0.11 0.05 0.023 0.07 0.10 NS 
2h insulin* (µu/ml) a 0.13 0.09 NS 0.33 0.15 0.029 
b 0.09 0.09 NS 0.26 0.14 0.085 
Fasting glucose (mmol/I) a 0.10 0.04 0.018 0.03 0.08 NS 
b 0.09 0.04 0.017 0.02 0.09 NS 
2h glucose (mmol/1) a 0.11 0.11 NS 0.38 0.25 NS 
b 0.10 0.11 NS 0.31 0.25 NS 
Fasting triglyceride* (mmol/I) a 0.07 0.05 NS 0.19 0.08 0.025 
b 0.05 0.05 NS 0.16 0.08 0.054 
8h triglyceride* (mmol/i) a 0.12 0.06 0.056 0.23 0.11 0.035 
b 0.11 0.07 NS = 0.19 0.11 0.098 
Total cholesterol (mmol/l) a 0.10 0.11 NS 0.15 0.14 NS 
b 0.13 0.12 NS 0.17 0.14 NS 
HDL-cholesterol* (mmol/I) a -0.07 0.03 0.013 0.01 0.03 NS 
b -0.06 0.03 0.044 0.02 0.04 NS 
log (natural) CRP as the independent variable with each measured cardiovascular risk factor as 
the dependent variable in turn. a= adjusted for age, sex and smoking; b= adjusted for age, 
sex, smoking and percent fat; *= log (natural) transformed values of these variables were used. 
To account for potential residual confounding when adjusting for the effect of smoking we 
repeated the analyses among ever-smokers and never-smokers separately. In analyses 
adjusted for age and sex, among ever-smokers (n=41) there was no significant ethnic 
difference in CRP level [P=0.06, se=0.55, p=0.913]. In similar analyses among never- 
smokers (n=72) South Asians had higher CRP levels than Europeans 
[1 for ethnic 
difference 0.60, se=0.28, p=0.039]. With additional adjustment for triglyceride 
level (0 
and 8h) and BMI the ethnic difference persisted [P=0.62, se=0.26, p=0.021]. 
The 
ethnic difference was no longer statistically significant when 
further adjustment was made 
for percent fat [ß=0.44, se=0.27, p=0.115] or for VFA 
[ß=0.42, se=0.27, p=0.121]. 
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9.4. Discussion of results 
In this study healthy South Asian women and all never-smokers (men and women 
combined) had higher CRP levels than Europeans. Among never-smokers the higher CRP 
levels in South Asians vs. Europeans persisted after adjusting for age, sex, BMI and 
triglyceride level. 
It is interesting that we found a significant ethnic difference in CRP level among never- 
smokers but not in ever-smokers. Our finding is at variance with that of one group who 
reported that the association between CRP level and increased risk for CHD death in men 
was limited to smokers24', and that lifetime smoking exposure affects the association of 
CRP level to cardiovascular disease risk factors253. However, our finding is in agreement 
with recent results from (i) IRAS (Insulin Resistance Atherosclerosis Study) where in 1560 
participants there was no significant relationship between smoking status and CRP level254, 
and (ii) the Honolulu Heart Program cohort, where baseline CRP level was significantly 
related to the incidence of thromboembolic stroke in Japanese American non-diabetic never 
smokers, but not in current or past smokers255. We speculate that our finding of a 
significant ethnic difference in CRP level in never smokers is probably because most 
(89%) of the South Asians in this study were never smokers, but also raises the possibility 
that it is among the healthy non-smokers that the ethnic difference in inflammatory burden 
is most extreme. A high proportion of South Asians at high risk for CHD are non- 
smokers. 
The raised CRP concentrations in both South Asians and Europeans were strongly 
associated with obesity (including central obesity), raised insulin levels and raised 
triglyceride concentration, and additionally with raised glucose levels and low HDL- 
cholesterol in Europeans, suggesting an association of CRP level with features of the 
metabolic syndrome. However, in both groups there was no direct association between 
CRP and insulin sensitivity index measured directly. As CRP levels are related to 
insulin 
levels and to obesity, it is surprising that they are not also related to 
insulin sensitivity 
index measured by the short insulin tolerance test in the current study. 
The reasons for 
differences between ISI and insulin level have been discussed in section 10.3.6.1. 
The association of metabolic disturbances with raised C-reactive protein could reflect a 
higher inflammatory burden associated with increased atherosclerosis, or direct metabolic 
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effects on synthesis of C-reactive protein256. There is biological plausibility for direct 
metabolic effects on inflammation and acute phase response. It has been shown that 
adipocytes from obese humans overproduce tumour necrosis factor-alpha (TNF-alpha) 
mRNA and protein25' , and TNF-alpha 
is a potent inducer of interleukin-6 (IL-6) production 
by various cells250, which in turn causes inflammation. 
A previous study has shown a correlation between plasma fasting triglyceride concentration 
and CRP leve1257. We have found an association between both fasting as well as 8h 
triglyceride and CRP level in this study, suggesting a link between inflammation and 
postprandial fat clearance. This may be a direct effect of cytokines (IL-6 or TNF-alpha) 
on the activity of lipoprotein lipase218'259 (the endothelial enzyme responsible for catabolism 
of triglyceride-rich lipoproteins), or alternatively may reflect the association of both factors 
with insulin resistance. CRP levels are correlated with PAI-1 levels260, which are also 
strongly related to central obesity, insulin resistance and lipid disturbances. It has been 
shown that PAI-1 synthesis in vitro is stimulated by raised NEFA levels26 . If this applies 
to CRP also, raised (intracellular or extracellular) NEFA levels could underlie the 
associations of CRP with triglyceride, insulin and central obesity. The association of CRP 
level with plasma lipids persisted in each of the two ethnic groups after adjustment for 
percent body fat, but the ethnic difference in CRP level was no longer significant when 
adjustment was made for percent body fat or for VFA. This may suggest that a higher fat 
mass level, in association with greater visceral fat, is directly responsible for an increased 
inflammatory burden in South Asians. 
CRP level is correlated with the extent of coronary disease in patients undergoing 
angiography and predicts the progression of coronary atherosclerosis262. It is not 
known 
whether inflammation (indexed by raised CRP level) promotes atherogenesis, or whether 
atheroma itself causes raised CRP levels. But, whatever the mechanism, 
if our 
observations are confirmed then there may be implications 
for preventive strategies. 
Ridker et al 243 demonstrated that the efficacy of aspirin in reducing the 
incidence of 
myocardial infarction appears to be directly related to the level of 
CRP. If elevated levels 
of CRP account for some of the excess risk of CHD 
in South Asians compared with other 
groups in prospective studies, a possible next step might 
be to evaluate the efficacy of 
aspirin therapy in reducing the high CHD risk in this group. 
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CHAPTER 10: Overall discussion 
10.1. Main findings of the study 
This study has shown ethnic differences between South Asians and Europeans in body fat 
distribution, insulin sensitivity, intramyocellular lipid content, lipid metabolism and 
inflammation, and the inter-relationships between them. Many of the findings have been 
shown for the first time in South Asians. The main findings from different parts of the 
study, in relation to the hypotheses we had on an a priori basis, can be summarised as 
following: 
" South Asians had more total body fat than Europeans at a given level of BMI 
(significantly so in women in this study); and at a given level of body fat, the 
distribution of this fat was located more centrally in South Asians than in Europeans. 
In addition the use of bio-electrical impedance analysis as a field method for 
quantifying total percent body fat in South Asians was validated against DEXA scan 
measurement, and its reproducibility established. This provides a basis for using this 
quick, safe and cheap method in future studies. There are also implications for public 
health - criteria for "ideal weight" that are based on weight-for-height in European 
populations may be inappropriate for South Asian populations where for any given 
BMI average percent body fat is higher than in Europeans. 
" As the level of central obesity increased, levels of insulin resistance (as measured by 
insulin concentration) increased more steeply in South Asians than in Europeans. Thus 
we found that the slopes of the regression lines for the association between fasting or 
2h insulin and central obesity were significantly steeper in South Asians than in 
Europeans. This is in keeping with our original hypothesis that the tendency to insulin 
resistance in South Asians increases at higher levels of central adiposity. Thus 
lean 
individuals of either ethnic group are insulin sensitive, but as central obesity increases 
South Asians become more insulin resistant than Europeans. However the slopes of 
the regression lines for the association between insulin sensitivity (as measured 
by the 
short insulin tolerance test) and obesity (both generalised and central obesity) were not 
Overall discussion 10-130 
significantly different between Europeans and South Asians. This points to differences 
in the two methods of measuring insulin resistance, and is discussed further below 
(section 10.3.6.1). 
" The hypothesis was not confirmed that visceral obesity would account for the lower 
insulin sensitivity in South Asians compared with Europeans. Visceral obesity had a 
strong and independent association with insulin sensitivity in both Europeans and South 
Asians, but it failed to explain the ethnic difference in insulin sensitivity. We found 
that the proportion of the ethnic difference in insulin sensitivity index that was 
accounted for by adjusting for visceral fat area alone was 27%, adjusting for visceral 
fat area as well as percent body fat was 34%, and adjusting for obesity (visceral fat 
area and percent fat) as well as fasting and postprandial triglyceride concentration was 
42%. No more than 40 % of the ethnic difference in each of fasting and 2h insulin was 
accounted for by central obesity or obesity plus triglyceride concentration. We 
suggested that lipid disturbances (in the fasting or postprandial state) may be the 
primary defect underlying the higher insulin resistance in this group. 
0 The hypothesis that South Asians would have higher postprandial triglyceride 
concentration than Europeans was not substantiated at the single postprandial time 
point of 8h at which triglyceride level was measured in this study. We did however 
establish that an elevated postprandial triglyceride level is associated with component 
features of the insulin resistance syndrome in all groups. 
" South Asian men had greater intramyocellular lipid content than European men. In 
Europeans there was a strong association between insulin sensitivity, central obesity 
and intramyocellular lipid content, but not in South Asians. Thus the findings in 
Europeans were consistent with the hypothesis that the relation between insulin- 
mediated glucose uptake and central obesity is mediated through triglyceride stores in 
skeletal muscle. However this was not demonstrated in South Asians. As this 
technique is new and has never been validated in South Asians, there remain 
uncertainties about its use in South Asians. 
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10.2. New hypotheses 
C-reactive protein concentration was found to be higher in South Asians than Europeans, 
particularly in women and all non-smokers, and it was associated with features of the 
insulin resistance syndrome and with central obesity and percent fat, as well as triglyceride 
concentration in both the fasting and postprandial state. From this we hypothesise that 
inflammation may mediate the greater insulin resistance seen in South Asians, and also 
may mediate the relation between insulin resistance and CHD in South Asians. This 
hypothesis would need to be tested in further studies. 
Other hypotheses relate to measurement issues. 
Firstly we hypothesise that measurement of insulin concentration is more effective in 
studying ethnic differences in insulin resistance than the use of the short insulin tolerance 
test as used in this study. We have found that measurement of insulin resistance by the 
fasting and 2h insulin concentration showed much greater ethnic differences than 
measurement of insulin sensitivity by the short insulin tolerance test. Additionally with 
insulin concentration as the dependent variable the slopes of the relationship with central 
obesity were significantly steeper in South Asians than in Europeans, but this was not the 
case when the insulin sensitivity index was the dependent variable. This subject is 
discussed in greater detail below (section 10.3.6.1). 
Secondly we hypothesise that in epidemiological studies, including those of a metabolic 
nature, use of anthropometric measures to quantify central obesity is adequate, and no 
added advantage is gained by measuring visceral fat area directly by CT scan. This is 
based on the following. In this small study of subjects frequency matched on BMI we 
found no ethnic difference in the waist/hip ratio or waist circumference in either men or in 
women, but visceral fat area was higher among South Asians compared with 
Europeans, 
and significantly so in women. However we found that there was high correlation between 
both waist/hip ratio and waist girth with visceral fat area (see section 6.1.2 
for results). 
We also found that whatever associations were found for CT-derived visceral 
fat area with 
variables of interest such as insulin resistance (insulin sensitivity 
index or insulin 
concentration), intramyocellular lipid content, triglyceride concentration or 
C-reactive 
protein concentration, were also of similar magnitude and 
direction for anthropometrically 
derived measures of central obesity (waist girth or waist/hip ratio). 
Thus the use of a 
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relatively expensive method such as a CT scan, which also includes a small but measurable 
degree of radiation exposure is not justified on the basis of this study. 
Although hypotheses have been generated and some a priori hypotheses have been 
substantiated or rejected by this study, they need to be seen in the light of the many 
limitations of the study. These limitations relate particularly to methodological issues 
including the study design itself, the methods employed in the study and the lack of pilot 
studies, and these are discussed below. 
10.3. Methodological issues 
10.3.1. Study design 
A cross-sectional design was chosen as we wanted to generate hypotheses about the 
relation between obesity, body fat pattern, insulin sensitivity, postprandial lipids and 
intramyocellular lipid in relation to ethnicity in a preliminary study. This is the first study 
to examine these relationships in detail. We chose to study an age group of people (40 to 
55 years) who were young enough to have not developed chronic illnesses such as diabetes 
and coronary heart disease. To avoid the influence of exogenous oestrogens on insulin 
resistance and lipid metabolism in women, we only included women who were not taking 
any hormonal preparations. The majority of the women included were premenopausal 
(section 6.1.1) . 
This study suffers with the usual limitations of cross-sectional studies. One of these is that 
the status of an individual with respect to the presence or absence of both exposure and 
disease is assessed at the same point in time. Thus it is difficult to distinguish the causal 
pathways, and to know the temporal sequence of events (such as which is the "chicken" 
and which is the "egg" in a sequence of events). However, associations can still be 
defined, and particularly if the associations are strong and independent of other effects, 
interpretation can be made based on biological plausibility. Thus given the current results 
(chapter 6) it is possible to say in this study that the findings are consistent with the idea 
that primary defect in South Asians is something to do with lipid metabolism. 
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A cross sectional study provides information about the frequency and characteristics of a 
disease by furnishing a "snapshot" of the health experience of the study population at a 
specified time. This is a limitation in that what may be the situation at one time point 
might be different at another time point. However, as our aim was to compare the ethnic 
differences in characteristics such as response to a fat meal and to a bolus of insulin 
injection, this is a valid study design. Case control studies also suffer from the same draw- 
backs. Prospective studies in the metabolic field are difficult to design and perform 
because of the dynamic nature of the metabolic variables, and are often not feasible. 
We have found ethnic differences in obesity, body fat pattern, insulin sensitivity, lipid 
levels and intramyocellular lipid content in this cross-sectional study. Although it is 
difficult to tease out the temporal sequence of events, hypotheses can be generated, which 
can be tested in future, better designed studies. Some suggestions for these are given in 
chapter 11. 
10.3.2. Subject recruitment 
The selection of participants in this study was through inviting randomly eligible healthy 
people registered with general practitioners. A total of 1638 invitations were sent out and 
351 people responded (22%). Of these, 210 were eligible for participating, thus 
representing 13% of those invited. We actually only invited 143 of those eligible, because 
mainly of frequency matching on BMI, and because a larger number were not needed 
according to our sample size calculations. Thus 9% of the original invitees attended for 
the first screening visit. A response rate of 22% and a participation rate of 9% is very 
small, but is understandable given the very involved and invasive nature of a study with 
multiple visits, which was clearly explained in detail as part of the original invitation. 
Most studies of a metabolic nature often recruit volunteers through advertisements in the 
media because of the expected low response rate from healthy subjects registered with 
family practitioners. We chose not to do that to make an attempt to draw our study sample 
from randomly eligible people who represented a cross-section of the population residing 
in the geographical area of the study. 
We might speculate that the motivation for participating in the study might have been 
because of family history of diabetes or CHD. We did find a high prevalence of 
family 
history for CHD that was not different in the two groups. We also found a high 
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prevalence of family history for diabetes mellitus, nearly twice as high in South Asians 
than in Europeans (though this did not reach statistical significance). Although not 
formally recorded, it was indicated to the registrant by some participants that their 
motivation to participate was that they might get a "full check up" and might get advice for 
healthy living, and find out if "anything was wrong with them". Some also said they just 
wanted to help with medical research because it is "very worthwhile". 
We do not have detailed information available about the non-responders, except that they 
were healthy according to their doctor's records. To assess seriously if there were 
differences between the participants and non participants, one could send out 
questionnaires asking about family history, for example, or for reasons for participating or 
not. However it was not felt necessary to do that in the current metabolic study. Response 
rate could have been increased by following up the first invitation letter with a second one, 
or with a phone call or a visit. However, given the invasive and involved nature of the 
study, it was not considered ethical to "pressurise" people to take part. Selecting 
participants in this manner, particularly for a metabolic study, does not invalidate the 
findings, but may limit their generalisability. Since our aim was to compare the results for 
the two ethnic groups, this is particularly the case. 
Three of the four general practices whose lists were used for the initial mailshots had 
previously been involved in research studies in collaboration with the London School of 
Hygiene and Tropical Medicine. These practices may be above average in Southall and 
Greenford with respect to the services they offer patients and their organisational 
efficiency. This may in turn be reflected in the readiness of the responders to participate 
in such a study. Again, these factors do not undermine the validity of the results but may 
affect their generalisability. 
10.3.3. Adverse events 
The main adverse event was that of a chemical phlebitis following the injection of 50% 
dextrose solution to terminate the SITT as mentioned in section 5.5.4. The precaution of 
giving the injection slowly and of using plenty of saline flush, combined with raising the 
arm after the flush minimised such incidents in anyone who complained of an "aching" or 
"burning" sensation in the receiving arm. 
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10.3.4. Drop-outs 
Of the 143 people who were screened there were 11 not eligible to proceed and 12 people 
withdrew, leaving a total of 120 people who proceeded with the rest of the study (see 
section 5.5.6). Among those who withdrew the reasons given were mainly practical ones 
(section 5.5.6) except for 2 people who felt the tests were too invasive. This actually left 
us with our target number of 120 people for the study. Because of the multiple visits 
involved and the implication for taking time off work, not all 120 people could complete 
all the stages of the study. A summary of the number of people completing each of the 
stages of the study is given in section 5.5.6.1. For a study of this nature the compliance 
with attendance was actually quite good and acceptable. 
10.3.5. Time lag between visits 
We tried to get participants through all stages of the study in batches, so there was a 
minimal time delay between visits. So rather than complete the screening stage for all 
participants, before starting on other visits and so on, we took a batch of people through 
the first stage, on to the next and so on, while a new batch of people was starting on the 
first stage. For many participants this meant attending for the second visit within 3 to 4 
weeks of the screening visit, on to the 3`d visit within another 4 weeks and so on. The 
clinical data collection was completed within a total of 8 months for all participants, for all 
stages of the study, except for the sub study involving NMR-spectroscopy in 40 men. This 
was completed within 15 months from starting. 
The time lag between different stages of the study may introduce behavioural changes for 
instance which might affect the results of the study. For example some participants might 
increase the amount of exercise taken regularly, or improve their diet. Or changes may 
occur with the passing of time involuntarily. We did not measure any of these factors. In 
a study of this nature it was impossible to complete the many stages of the study any 
sooner than already accomplished. 
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10.3.6. Experimental measures 
A description of the reasons for choice of the particular tests that were used in this study 
has already been given in section 5.10. However based on the results of the study, certain 
points arise regarding the choice of methods. 
10.3.6.1. Measurement of insulin resistance 
The method employed for obtaining a direct measure of insulin sensitivity in this study was 
the short insulin tolerance test. However it was apparent that measurement of fasting and 
2h insulin concentration showed much larger ethnic differences, with elevated levels 
among South Asians relative to Europeans, than did measurement of the insulin sensitivity 
index. We also found that the ethnic differences in insulin level were present among both 
men and women, while those for ISI were only significant in men. 
Furthermore the data failed to show a significant ethnic difference in the slope of the 
relationship between ISI (as measured by the short insulin tolerance test) and measures of 
central obesity. There was, however, a significant ethnic difference in the slope of the 
relationship between both fasting and 2h insulin as the dependent variable, with measures 
of central obesity as the independent variables. 
This raises two issues. The first relates to the fact that ISI and insulin level are measuring 
two different things. In the short insulin test we measure the glucose disposal rate in 
response to a bolus of insulin, while in the measurement of 2h insulin level we measure the 
body's response to an oral glucose load. The SITT gives an overall assessment of whole 
body sensitivity to insulin, but does not allow direct quantitative measurement of insulin 
mediated glucose metabolism. The SITT also does not distinguish between hepatic and 
peripheral insulin sensitivity. It is possible that the SITT measures mainly the effect of 
suppression of hepatic glucose production following a bolus of exogenous insulin. 
The second issue relates to the fact that there is a possibility that the defect in 
insulin- 
mediated glucose disposal in South Asians may be more evident after a glucose 
load than 
in the fasting state. It has been observed that ethnic differences in the 2h 
insulin level are 
much greater than the differences in fasting insulin. This could 
be extrapolated to imply 
that the insulin resistance in South Asians is a specific defect 
in the delayed response to 
insulin. It would be of interest to perform studies of an ethnic comparison of 
the time- 
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course relation of insulin concentration to glucose uptake. It is possible that such a relation 
might be shifted to the right in South Asians. 
Furthermore the use of the short insulin tolerance test has never previously been validated 
specifically in South Asians. A pilot study validating the SITT against the "gold standard" 
of an euglycaemic clamp would have added to this study, but was not undertaken due 
mainly to the following reasons: time constraints, the fact that the SITT had been used in a 
study of an ethnic comparison of first degree relatives of Europeans and South Asians with 
diabetes53, the fact that this was an already invasive study and further tests were not 
feasible and also because the ISI calculated from the SITT allows relative ranking of 
individuals with respect to insulin sensitivity, which was our main aim in this study. 
This study did not find any advantage of the short insulin tolerance test over the 
measurement of insulin resistance by a fasting and post-challenge insulin concentration in 
studying the relationship of insulin resistance with obesity, metabolic measures and ethnic 
origin. 
10.3.6.2. Fat tolerance test and postprandial triglyceride 
As discussed in section 6.3.4, for this epidemiological study, rather than undertake a full 
fat tolerance test with hourly blood samples, we took a single post-load sample at 8h, plus 
a 6h measurement in 35 people. It is possible that we have underestimated the ethnic 
difference in postprandial triglyceride level by relying on a single measurement at 8h in 
most participants. If so, then it is possible that we have also underestimated the extent to 
which differences in postprandial triglyceride levels could account for the ethnic difference 
in insulin sensitivity. 
With hindsight, a more detailed fat tolerance test, with measurements at perhaps 4,6 and 8 
hours would have allowed a much more comprehensive assessment of the role of 
postprandial triglyceride, as the area under the triglyceride curve could possibly give more 
information than just a single measurement. If the finding of Patsch263 in an European 
population suggesting that a single time point at 6 or 8 hours was as 
discriminatory 
between cases of CHD and controls is to be extrapolated to a South Asian population, and 
a study of an ethnic comparison, as in this study, a pilot study should 
have been 
undertaken first. This would have helped to determine the optimal time point(s) 
for 
measurement of total triglyceride concentration in the 
fat tolerance test which would have 
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discriminated between Europeans and South Asians. In this study we found that there was 
a significant ethnic difference in the 6h triglyceride concentration in those men who had it 
measured, but by 8 hours postprandially the triglyceride concentration was returning 
towards fasting values and was no longer significantly different between ethnic groups. A 
pilot study of triglyceride concentrations at different time points of a full (unmodified) fat 
tolerance test in each of the four ethnic and sex groups would have enabled us to avoid the 
problem we experienced of having missed the optimal time point for maximal ethnic 
differences. This should be considered before future fat tolerance test studies are 
undertaken. 
We only measured total postprandial triglyceride level. It would have been more 
informative to have the measurement of apoB-48 and apoB-100, as well as retinyl palmitate 
in chylomicron and non-chylomicron plasma fractions, as discussed in section 6.3.4. 
Future studies should attempt to undertake these more detailed measurements. 
10.4. Discussion of results 
The results have been specifically discussed in sections 6.3,7.3,8.3 and 9.4. 
10.5. Relevance of the findings of this study to overall strategies to 
reduce CH D risk in South Asians 
We have found an adverse risk factor profile of factors associated with CHD risk in South 
Asians compared with Europeans in this study. These risk factors included: (i) greater 
levels of obesity, generalised and central, in South Asians as shown by the greater amount 
of total percent fat and visceral fat in South Asians; (ii) higher degree of insulin resistance 
in South Asians as shown by the lower insulin sensitivity index in South Asians (significant 
in men only), and higher levels of fasting and 2h insulin in South Asian men and women; 
(iii) a steeper rise in insulin concentration in South Asians (than in Europeans) with 
increasing levels of central adiposity, and (iv) a trend towards higher postprandial 
triglyceride level in South Asian men (significant at 6h, but not at 8h postprandially). 
Overall discussion 
10-139 
In this study there was no collection of detailed information on diet, and assessment of 
physical activity was limited, and based on self-report in response to a questionnaire. This 
showed that levels of physical activity were low in both groups, but even lower in South 
Asians, and especially so among South Asian women. Attempts to reduce the absolute risk 
for CHD include lifestyle interventions such as modifications to diet and physical activity, 
as well as therapeutic interventions such as to lower lipids. The relevance of these 
strategies to South Asians is discussed in the following sections. 
10.5.1. Physical activity 
The increased obesity in South Asians may be due to genetic reasons, or to lifestyle and 
environmental factors including lack of exercise. But whatever the reason, prevention of 
diabetes and CHD in South Asians may require control of obesity and regular exercise to 
be maintained throughout life. 
10.5.1.1. Effect of physical activity on risk for diabetes and CHD 
The effect of physical activity on the development of diabetes in people with impaired 
glucose tolerance (with 50 % from minorities including people of Asian origin) is being 
tested in the United States as part of a multicentre (27 centres) randomised controlled trial, 
the Diabetes Prevention Program (DPP)264.3000 participants are being randomised to 
either a standard advice package and placebo (as control group), or an intensive lifestyle 
intervention comprising weight-loss diet and exercise or to metformin. There was to be an 
additional treatment group, with troglitazone, a thiazolidinedione recently licensed for use 
in insulin resistant states in the U. S. However this has now been discontinued because of 
the hepato-toxicity of the drug. The main outcome measure during follow-up is the 
development of NIDDM. This study will yield important information on the relative 
effectiveness of the three interventions. 
The Southall Intervention Study [Gail Davey, manuscript submitted to Medicine and 
Science in Sports and Exercise] is the first to demonstrate a significant increase in insulin 
sensitivity in the twenty-four hours following exercise in South Asians (and Europeans). 
The results of this study suggested that exercise may increase insulin sensitivity, 
independent of its effect on body weight or lipid profile 
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promotion material has moved from encouraging vigorous exercise for twenty minutes 
three times per week265 to advocating daily or more than daily activity of lower intensity266 
These changes reflect the trend towards increasing energy expenditure rather than fitness in 
interventions against coronary heart disease. The Southall Intervention Study adds support 
to this pattern of increased frequency of activity for improving insulin resistance. Lehman 
et a1267 conducted a trial of exercise training over 3 months in 16 patients with NIDDM, 
with 13 NIDDM patients as controls. They found that in those who took regular physical 
exercise there was a significant amelioration of cardiovascular risk profile; in particular 
total percent fat, WHR and triglycerides decreased, while HDL-cholesterol levels 
increased independently of changes in body weight and glycaemic control. 
10.5.1.2. Effect of physical activity on abdominal obesity 
That exercise training can be beneficial in South Asians is highlighted by the fact that the 
effect of training is to reduce both percent body fat as well as visceral fat. Despres et a1268 
have shown that when aerobic exercise is used to induce weight loss, men generally lose 
more fat than women. In men the loss of adipose tissue is more central. Although 
resistance to fat loss is noted in women, those with a "male" distribution of adipose tissue 
greatly benefit from aerobic exercise training. They showed further that obese 
premenopausal women who participated in an exercise training programme lost a greater 
amount of fat (measured by CT) from the abdominal area than from the mid-thigh area 269 
Another group showed that of 60-70 year old men and women who participated in a 9-12 
month exercise programme, men lost more weight than women, but in both groups the 
largest absolute and relative changes occurred in the truncal area, indicating a preferential 
loss of fat from the central regions of the body270. This preferential loss of visceral adipose 
tissue with exercise in women has also been shown by others 271 . 
However one group showed that decrease in subcutaneous fat mass, but not visceral fat 
mass was proportional to the amount of aerobic exercise training in women272. They 
argued that the change in visceral fat mass appears to be related to a deficit in caloric 
balance either by dietary restriction (decrease in caloric intake) or by increased caloric 
expenditure. Ross273 reviewed the studies of effects of diet and exercise induced weight 
loss on visceral adipose tissue in men and women. He concluded that for every kg of diet- 
induced weight loss, the corresponding reduction in visceral fat was about 3-4 cm2, and 
that there appears to be a resistance to visceral fat area reduction in obese women but not 
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in men. He suggested that data on the separate effects of diet and exercise induced weight 
loss on visceral fat from well controlled studies are required to advance current knowledge 
with respect to the effects of diet and exercise on the adipose tissue depot that conveys the 
greatest health risk. Such studies are not only needed for the general population, but also 
for people from the Indian sub-continent, whose risk for visceral obesity, insulin 
resistance, diabetes and CHD remains high. 
10.5.1.3. Effect of physical activity on postprandial lipids 
It is now known that exercise can also have a beneficial effect on postprandial lipaemia. 
Zhang et a! 274 studied 21 recreationally trained men and found that exercising before a fat 
meal, at 60 % of maximal 02 consumption for 1 hour, had a beneficial effect on 
postprandial triglyceride response and HDL metabolism. Another group275 studied 
postprandial triglyceride and apoB-100 level in 54 men and women who were sedentary, 
recreational exercisers or endurance trained. They found that both recreational and 
competitive aerobic training were associated with a lower triglyceride response and 
apoB-100 level after a fatty meal. Further, Hardman et aP76 have studied changes in 
postprandial lipaemia in endurance trained people during a short interruption to training. 
They found that postprandial lipaemia increased with detraining, and concluded that 
frequent exercise is needed to maintain a low level of postprandial lipaemia and 
insulinaemia in trained individuals. 
Thus there is evidence that physical activity is beneficial both for increasing insulin 
sensitivity, and for reducing a postprandial lipaemic response. Although there are 
numerous such studies in Europeans, further such studies need to be performed in South 
Asians. However, it seems plausible that physical activity will be equally, if not more, 
beneficial in South Asians. 
10.5.1.4. Public health implications of physical activity 
But how can this public health message about the necessity and beneficial effect of exercise 
be highlighted to the public, especially the South Asian population in the U. K.? 
In the 
United Kingdom, the Health Education Authority are currently encouraging exercise 
among people in a national campaign called "Active for 
Life". The second phase of the 
campaign over 1997-98, had as its target people over the age of 
50 years and people from 
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black or minority backgrounds. The Health Education Authority has made use of national 
and local media to promote regular moderate physical activity. It has also undertaken 
training for general practitioners and community nurses, and offered support including 
small grants to health professionals. The message being conveyed encourages modest but 
frequent physical activity such as cycling, dancing, walking and gardening. These have 
been put across as activities that do not require special preparation or facilities, but can 
contribute to health if pursued frequently. Another part of the campaign involves general 
practitioners in "exercise prescription" (free or at reduced rates) schemes in conjunction 
with local leisure centres. However, the aims of the campaign are broad: improving health 
by increasing physical activity, which makes evaluation difficult. While one could 
evaluate whether activity has increased by using, for instance, actometers, no such 
evaluation efforts have been made. Thus what proportion of South Asians, particularly 
women have taken the "message on-board" is currently unknown. 
10.5.2. Diet 
In the current study there were more vegetarians among South Asians than among 
Europeans. Detailed information on diet was not collected in this study. However we 
have information about diet in this group of people from a previous, larger study, the 
Southall Study36. Recording of 7-day weighed dietary intakes in 173 South Asian and 
European men showed that overall the South Asian diet was more favourable: in South 
Asian men (compared with European men) mean energy intake was lower, carbohydrate 
intake was higher, polyunsaturated fat intake was higher, and dietary fibre intake was 
higher. Elevated serum 2h-insulin concentrations were positively associated with 
carbohydrate intake, but not with saturated fatty acid intake. The authors concluded that 
the high coronary risk in South Asians is not explained by any unfavourable characteristic 
of South Asian diets. 
Leaf27'278 has estimated that the average diet of our ancestors consisted of fat as about 20% 
of total food energy, with 7 to 8% saturated fat, and a n-6 to n-3 fatty acid ratio of about 
4 
to 3. However, since the Industrial Revolution the saturated fat content has risen 
dramatically, and the n-6 to n-3 fatty acid ratio has changed to about 15 to 
1. He argues 
that n-3 class of polyunsaturated fatty acids (PUFA) are 
beneficial for coronary 
protection 2", 2'9. The Diet and Reinfarction trial (DART) was the 
first large trial to report 
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that advice (among 2033 men) to eat oily fish rich in n-3 PUFA was associated with a 29% 
reduction in total mortality in the first two years after myocardial infarction280. 
It has been suggested that low intake of polyunsaturated fatty acids of the n-3 series (alpha 
linolenic acid) may contribute to the high coronary risk in South Asians281-283. This may be 
one factor in causing high rates of CHD in Gujarati Hindus, but cannot account for the 
high risk in Bengalis12 whose diet is high in n-3 fatty acids from fish284. Also, some groups 
from South Asia already have low average plasma cholesterol and low saturated fat intake, 
but still have very high CHD mortality, such as among Gujarati Hindu women living in 
North-West London3s, zgs 
10.5.2.1. Effects of dietary change on plasma lipids 
Previous dietary advice consisted of lowering total fat intake by low fat diets. However 
such low fat diets were achieved by having a higher proportion of carbohydrates. 
Carbohydrates, however, not only decreased LDL-cholesterol, but also lowered 
HDL-cholesterol286.287. First suggested in the 1970's38, it is now well accepted that 
HDL-cholesterol is cardioprotective. Thus recommendations to decrease fat and increase 
carbohydrate intake have come under scrutiny288. In a recent commentary Katan287 
discusses the evidence for whether there are "good and bad carbohydrates for 
HDL-cholesterol", based mainly on a recent report by Frost and colleagues289 suggesting 
that the glycaemic index of the diet is a stronger predictor than dietary fat intake, of serum 
HDL-cholesterol concentration. Katan concludes that as yet the effects of low-glycaemic 
index foods on blood lipids remain unproven287. 
10.5.2.2. Effects of diet on CHD risk 
It is known that lowering saturated fat intake by substituting it with polyunsaturated fatty 
acids of the n-6 series (linoleic acid; such as in vegetable oils) has adverse effects or fails 
to improve clinical prognosis. It is only when n-6 fatty acids are decreased and n-3 fatty 
acids are increased that there is clinical benefit and risk reduction for CHD. 
Ravnskov290 has reviewed the existing literature on the influence of diet on cardiovascular 
disease. He examined the results of all available ecological, cross-sectional, case-control, 
cohort and intervention studies (including randomised trials) of the effect of fat reduction 
alone on cardiovascular disease. He reported that the findings from these numerous 
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studies including studies in different ethnic groups yielded inconsistent and contradictory 
results. He thus concluded that the hypothesis that dietary saturated fatty acids are harmful 
while polyunsaturated fatty acids are protective for CHD is questionable. However he 
presents one extreme view. Most epidemiological evidence now points in favour of 
advocating a "Mediterranean" diet, high in n-3 polyunsaturated fatty acids, mono- 
unsaturates, fibre, fish and fresh vegetables. 
The results of the recent Lyon Diet Heart Study provide support for a cardio-protective 
role of the Mediterranean type diet27'291. An initial report of this randomised secondary 
prevention trial292 at 27 months of follow up had shown a striking 70% reduction in 
all-cause mortality due to a reduction in CHD mortality and non-fatal CHD sequelae. 
Thus the trial was terminated by the Ethics committee at 27 months rather than the planned 
5 years. Recently published results of the final 4 year follow up of this cohort further 
show that the initial remarkably beneficial effects of the experimental dietary programme 
persisted compared with the control group consuming the usual Western type diet. The 
heartening thing about this diet, versus low fat diets, seems to be that there was continued 
good adherence to the experimental diet for up to 4 years, despite the fact that the study 
was officially terminated at a mean follow up of 27 months. The Mediterranean type diet 
consisted of about 30% total fat, with only 8% saturated fat. Participants were instructed 
to consume more bread, root and green vegetables, more fish and less meat, fruit at least 
once daily, canola-based margarine (made from rapeseed oil, and rich in n-3 PUFA) and 
olive oil as a fat source. The authors concluded that a cardio-protective diet should be part 
of a comprehensive programme to reduce CHD morbidity and mortality. 
If these results can be confirmed by others, there are implications for preventive strategies. 
It has been argued whether 18: 3[n-3] PUFA (alpha linolenic acid) derived from vegetable 
oils such as soya oil and rapeseed oil could have similar cardio-protective effects as 
93 20: 5[n-3] PUFA (eicosapentaenoic acid) derived from oily fish2. It would be useful to 
test specifically in secondary prevention trials the effect of substituting oils containing 
18: 3[n-3] PUFA for other sources of dietary fat. The rationale for this is that it is easier to 
substitute vegetable oils rich in 18: 3[n-3] PUFA for other sources of 
dietary fat than to 
increase consumption of oily fish on a mass scale. 
Based on the currently available evidence no specific recommendations regarding 
the South 
Asian diet can be made. However, it would do well for all people, 
South Asian or 
European to reduce their total daily fat intake. It also stands to reason 
that a 
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Mediterranean type diet would be beneficial to both Europeans and South Asians. The 
Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy29' 
recommended that the average intake of saturated fatty acids should be reduced to 10% of 
total energy. Based on the Keys equation295 it has been estimated by McKeigue and 
Sevak27 that among South Asians achieving the above goal could reduce the average 
cholesterol to about 5.0 mrnol/l. Some would extrapolate this to predict that in so doing 
effective control of CHD as a leading cause of death could be achieved. 
10.5.3. Lipid abnormalities 
10.5.3.1. Underlying defect might be related to lipid metabolism 
It is intriguing that while there was a trend towards higher postprandial triglyceride level 
coupled with a higher intramyocellular lipid content in South Asian men, yet postprandial 
triglyceride failed to account for the lower insulin sensitivity, and the intramyocellular lipid 
content was not related to insulin sensitivity in South Asians in this study. However 
postprandial triglyceride was strongly related to the insulin resistance syndrome, and 
together with body fat distribution, accounted for almost 50% of the ethnic difference in 
insulin sensitivity. 
This raises the possibility that there is some basic derangement in lipid metabolism or 
storage in South Asians, which with better measurement technique(s) could yield more 
detailed information. For instance, we have only been able to measure the level of 
triglyceride in this study in plasma and in skeletal muscle. It would be informative to be 
able to measure the flux of lipids between different body compartments such as plasma and 
muscle. It would also be informative and of interest to measure the fate of triglyceride 
after a fat load; thus studies of intramyocellular lipid by NMR spectroscopy before and 
after a fat load would be helpful. Techniques for study of uptake of NEFA in cells are 
becoming available296. Such techniques as positron emission tomography (PET) can be 
used to measure the uptake of NEFA into muscle cells. Using this technique a recent 
study296 showed that subjects with impaired glucose tolerance (compared with 
normoglycaemic controls) had similar myocardial but lowered femoral muscle 
NEFA 
uptake. Such studies performed in South Asians would be valuable to try and tease out 
the 
mechanisms involved in their high rates of insulin resistance. 
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The suggestion that disturbances of lipid metabolism might be primary in the development 
of insulin resistance and diabetes mellitus is not new. Randle et a1182 proposed a glucose- 
fatty acid cycle in 1963. The pros and cons of this cycle have been discussed in section 
3.1.1. McGarry raised this possibility in his classical paper in 1992297 entitled "What if 
Minkowski had been ageusic? An alternative angle on diabetes". Boden155 has reviewed 
the evidence for a central role of NEFA in the pathogenesis of insulin resistance and 
Type II diabetes. 
Genetic studies in rat models are also beginning to support this hypothesis. Aitman et al298 
reported earlier this year that Cd36 (Fat) is an insulin resistance gene causing defective 
fatty acid and glucose metabolism in the spontaneously hypertensive rat. Cd36 has been 
identified as a fatty acid receptor/transporter. Aitman et al found that the protein product 
of Cd36 is absent in the rat adipocyte plasma membrane, while overexpression of Cd36 in 
transgenic mice reduces blood triglycerides and fatty acids. This suggests that a deficiency 
of Cd36 (i. e. a defect in a fatty acid transport gene) underlies insulin resistance, defective 
fatty acid metabolism and hypertriglyceridaemia in the rat model. By extrapolation, Cd36 
may play an important part in the pathogenesis of human insulin resistance syndromes. 
However, since the publication of Aitman's report, there has been a further report (in July 
1999) by a Japanese group299 showing that the Cd36 mutation is absent in the original 
spontaneously hypertensive rat strains, maintained since their development in Japan. This 
throws into question the aetiological relevance of the Cd36 mutation to insulin resistance in 
this rat model. However, further study of this rat line, as well as others and studies of the 
human genome project should shed further light into the genetic origins of insulin 
resistance. 
10.5.3.2. Management of lipid abnormalities 
Evidence from several large randomised clinical trials has shown coronary benefit of 
reducing LDL cholesterol, and evidence is also emerging for a beneficial effect of 
lowering elevated triglyceride levels. Among South Asians the predominant lipid 
disturbances are related to the insulin resistance syndrome and include high triglyceride 
level and low HDL-cholesterol, as well as increased concentrations of small 
dense LDL 
particles. When these lipid abnormalities occur together the atherogenic 
lipoprotein 
phenotype (ALP) is said to exist. The role of lipid lowering 
drugs specifically in South 
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Asians has not been evaluated. It is not known whether we should target lowering of 
triglycerides and the ALP, or LDL cholesterol. 
10.5.3.3. Lowering plasma triglyceride levels 
The data available so far suggest that treatment to lower plasma triglyceride levels may 
reduce cardiovascular events. In the Helsinki Heart Study (HHS) treatment with the 
fibrate gemfibrozil produced a 34% reduction in incident coronary events with a 35% 
reduction in plasma triglyceride levels, a 9% increase in HDL-cholesterol levels and an 
11% reduction in plasma LDL concentration 300. However the beneficial effect of 
gemfibrozil was mostly confined to overweight subjects (with BMI greater than 26 kg/m2). 
This may not be directly relevant to those South Asians who have the lipid abnormalities 
despite average/below average BMI. The formal published results of the Bezafibrate 
Infarction Prevention (BIP) secondary prevention trial are still awaited, in which subjects 
with CHD were randomised to either bezafibrate or placebo. However a preliminary 
report was presented at the European Society of Cardiology meeting in Vienna in 1998. 
This showed a non-significant 9% reduction in CHD (combined endpoint of nonfatal 
myocardial infarction, fatal myocardial infarction, or sudden death). Total mortality was 
also unaffected by bezafibrate, and only a small sub-group with high baseline plasma 
triglyceride levels profited from treatment. 
Results of a large scale trial to address the issue of these lipid abnormalities in the 
secondary prevention of CHD have just been published (August 1999). The Veterans 
Affairs HDL-cholesterol Intervention Trial (VA-HIT) Study301 of 2531 men with previous 
CHD, with HDL-cholesterol levels of 1.0 mmol/1 or less and LDL cholesterol levels of 3.6 
mmol/1 or less showed, at one year, a relative risk reduction of 22% (95% CI 7 to 35%) 
for CHD (non-fatal myocardial infarction or coronary death) in those treated with a fibrate 
(gemfibrozil) compared with those on placebo. The effect of treatment with gemfibrozil 
was to increase HDL-cholesterol (6%), lower the mean triglyceride level (31 %) and lower 
the total cholesterol level (4 %). LDL cholesterol levels did not differ between the 
treatment groups. It was concluded that the rate of coronary events is reduced by raising 
HDL-cholesterol levels and lowering triglyceride levels, without lowering LDL cholesterol 
levels. This may be of relevance to South Asians. If these findings apply to South Asians, 
they may also benefit from reversing of these lipid abnormalities. Trials of 
fibrates in 
South Asians would merit consideration. 
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It is too early to say as yet whether those South Asians (or Europeans) who have normal 
fasting triglyceride levels but elevated postprandial triglyceride levels will benefit from 
drug therapy targeted at lowering of postprandial triglyceride levels. Further more detailed 
studies are needed to first establish whether this is the case in South Asians, and then 
randomised trials will need to be conducted to gather the evidence for any beneficial effect 
on CHD risk. 
10.5.3.4. Lipid lowering with statins 
10.5.3.4.1. Evidence for coronary benefit of statin therapy 
Statins are hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that form 
an important group of lipid-lowering drugs for prevention of CHD. Compelling evidence 
for their role in cardioprotection has been shown in large trials of secondary prevention 
such as the Scandinavian Simvastatin Survival Study (4S)302, the Cholesterol and Recurrent 
Events Trial (CARE)303 and the Long-term Intervention with Pravastatin in Ischaemic 
Disease (LIPID) study304. These studies showed reduction in relative risk for CHD of 
34%, 24% and 24% respectively. Evidence for a cardioprotective role has also come from 
trials of primary prevention such as the West of Scotland Coronary Prevention Study 
(WOSCOPS)305 and the Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS)306 study in the United States. These studies showed a relative risk 
reduction of CHD of 31 % and 37 % respectively. The initial reports of these trials have 
largely been in people with average to high lipid levels and with no history of diabetes. 
However, little information has been available on the role of statins in people with diabetes 
or glucose intolerance until recently. 
The role of pravastatin has been investigated in a subgroup analysis of patients with 
diabetes and glucose intolerance with average cholesterol levels in the CARE trial (of 
secondary prevention in myocardial infarction survivors)307. The trial included 586 
patients with clinical diagnosis of diabetes, and 342 patients from 3553 non-diabetic 
patients had impaired fasting glucose at entry. The analysis showed that patients with 
diabetes and impaired fasting glucose were at high risk of recurrent coronary events that 
could be substantially reduced by pravastatin therapy (in the diabetic group: absolute risk 
reduction of 8.1%, and relative risk reduction of 25%; in the impaired fasting glucose 
group: 50% reduced recurrence rates for non-fatal MI in treatment group). Similar results 
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were reported from a subgroup analysis of 202 diabetic patients and 4242 non-diabetic 
patients in the 4S study308. The authors concluded that cholesterol lowering with 
simvastatin improves the prognosis of diabetic patients with CHD. They argued that the 
absolute clinical benefit achieved may be greater in diabetic than in non-diabetic patients 
with CHD because diabetic patients have a higher absolute risk of recurrent CHD events. 
It is also been shown by Haffner et al3o9in a7 year follow-up study of 2432 subjects that 
diabetic patients without prior myocardial infarction had as high a risk of myocardial 
infarction (20.2 %) as non-diabetic patients with previous myocardial infarction (18.8%). 
They argued that CHD risk factors in diabetic subjects should be treated as aggressively as 
in non-diabetic patients with a prior history of CHD. Since much of the risk for 
macrovascular disease (such as CHD) is associated with impaired glucose tolerance, before 
the onset of clinically detectable diabetes, it can be extrapolated that people with impaired 
glucose tolerance will have risk for CHD of similar proportions. This is important in the 
context of the high prevalence of insulin resistance and glucose intolerance, as well as 
diabetes, in people of South Asian descent. 
10.5.3.4.2. Relation between baseline cholesterol level and benefit from statin therapy 
Evidence is now accumulating that statins are beneficial regardless of the baseline 
cholesterol level. Results of the CARE study3o3 showed benefit of statins in those with 
average cholesterol levels (total cholesterol below 6.2 mmol/l and LDL cholesterol 
between 3 to 4.5 mmol/1). A further analysis of results from CARE trial showed that the 
LDL concentration achieved during follow-up was a significant predictor of the coronary 
event rate down to an LDL concentration of 3.2 mmol/1310 However, the extent of LDL 
reduction (absolute or percentage reduction) had no significant relationship to coronary 
events. Results of the LIPID study304 also showed benefit of statins in subjects with a 
broad range of initial cholesterol levels (total cholesterol of 4 to 7 mmol/1). Benefit of 
statin therapy was also shown by MacMahon et a131 in the LIPID Carotid Atherosclerosis 
Sub-study of the LIPID trial among 522 patients with a history of ischaemic heart disease. 
Thickening of the carotid arteries increased in those given placebo, but decreased in those 
given pravastatin. The statin prevented substantial carotid wall thickening in patients with 
cholesterol levels that were high or average as well as below average (4 to 7 mmol/1). 
These studies suggest that there might be benefit in lowering cholesterol even in 
normocholesterolaemic individuals at high risk for CHD 
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argued before by Byrne and Wild312. It is not clear what the cellular mechanisms are for 
the beneficial effects of cholesterol lowering, especially in people with average or below 
average cholesterol levels. It seems likely that plaque stabilisation or improvement in 
endothelial function will play a part. Further studies will help to clarify this. 
10.5.3.4.3. Non lipid lowering effects of statins 
In fact evidence is now emerging that statins may also exert their effect independently of 
their lipid-lowering effects. Ridker et a1313 have shown this recently in a trial of secondary 
prevention of 472 survivors of myocardial infarction. They found that C-reactive protein 
concentrations (CRP -a marker for inflammation) fell by a mean of 17% in patients 
receiving pravastatin but rose by 4% in those treated with standard therapy plus placebo. 
The changes in CRP did not correlate with changes in lipid values, so for example, CRP 
values rose in patients who lowered their LDL-cholesterol by diet and exercise. 
10.5.3.4.4. Should statins be used in South Asians? 
South Asians have higher prevalence of insulin resistance and diabetes associated with high 
risk for CHD in the face of cholesterol levels in the normal or below normal range. Thus 
a case can be made for consideration of statin therapy in the prevention (primary and 
secondary) of CHD in South Asians. This is based on the evidence available for coronary 
benefit of statin therapy in those with glucose intolerance and diabetes, coupled with the 
evidence that statins are beneficial regardless of initial cholesterol levels. 
At present risk for CHD is commonly calculated as a probability (%) of developing CHD 
(non-fatal myocardial infarction or coronary death) over 10 years; that is, the number of 
people per 100 expected to have a major CHD event in the next 10 years. This calculation 
is based on the risk equation from the Framingham study. However, this equation has not 
been validated for use in ethnic minorities. For example, raised serum triglycerides or 
evidence of impaired glucose tolerance or insulin resistance are not currently part of the 
risk calculation. 
To test if there is specific coronary benefit in South Asians one possibility 
is to consider 
trials of statins in South Asians with evidence of insulin resistance. 
The selection of a 
group of people suitable for randomisation would have to be carefully performed as 
there 
will be some in whom it will be unethical not to treat with a statin, while 
there will also be 
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those in whom it will be unreasonable to treat with statins. For example it may not be 
ethical to perform a trial of secondary prevention, where perhaps everyone with a previous 
myocardial infarction should be on a statin, but it may be ethical to perform a trial of 
primary prevention. 
Of course there will be cost implications for use of statins in primary prevention in South 
Asians. In general as the CHD risk profile becomes less favourable the cost-effectiveness 
increases. Thus the number of subjects who would need to be treated in order to prevent 
an adverse event decreases dramatically. However, specific studies of cost-effectiveness 
will need to performed. 
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CHAPTER 11: Conclusions and suggestions for further 
research 
From the results of this study we can conclude as follows: South Asians have more total 
body fat than Europeans at a given level of BMI, and it is more centrally distributed, 
especially in the women in this study. South Asians have lower insulin sensitivity than 
Europeans, especially so in men. Insulin concentration rises significantly more steeply in 
South Asians compared with Europeans as the level of central obesity increases. There is 
a trend towards a higher postprandial triglyceride response in South Asian men, and 
elevated postprandial triglyceride level is associated with component features of the insulin 
resistance syndrome in all groups. South Asian men also have greater intramyocellular 
lipid content than European men. In Europeans there is a strong association between 
insulin sensitivity, central obesity and intramyocellular lipid content, but not in South 
Asians. Although visceral obesity has a strong and independent association with insulin 
sensitivity in both Europeans and South Asians, it fails to account for the lower insulin 
sensitivity in South Asians compared with Europeans. Lastly, there is a trend towards 
higher CRP concentrations in South Asians, and CRP concentration is associated with 
features of the insulin resistance syndrome. 
We have suggested that postprandial lipid metabolism may be important in South Asians, 
and that lipid disturbances (in the fasting or postprandial state) may be the primary defect 
underlying the higher insulin resistance in this group. However it has not been possible in 
this study to determine what specific lipid disturbance may be more important in South 
Asians. The possible defects in lipid metabolism in South Asians could include one or 
more of the following: (i) increased VLDL-triglyceride production or failure to shut down 
postprandial triglyceride production, (ii) reduced triglyceride clearance, or (iii) increased 
triglyceride storage in skeletal muscle. 
Although we have learnt in more detail about the relationships between body 
fat 
distribution, insulin sensitivity and lipid disturbances (in plasma as well as in skeletal 
muscle) from this cross-sectional study, there remain large gaps in our understanding of 
the reasons for the excess risk for CHD and diabetes in South Asians. 
Some specific 
suggestions for further research arising from the current study are as 
follows. 
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11.1. Further research relating to measurements 
Several novel techniques, not previously used in South Asians, were employed in this 
study. Their strengths and weaknesses have been discussed before, but specific 
recommendations are summarised below. 
Specific validation of the short insulin tolerance test (SITT) against the euglycaemic insulin 
clamp should be performed in South Asians. While the validity and reproducibility of the 
SITT have been established in European subjects, South Asians have not been included in 
such studies. It is possible that in South Asians measurement of insulin concentration 
following an oral glucose load is a more valid measurement to use than the SITT. Until 
this specific validation has been performed the use of the SITT is not recommended in 
studies of South Asians as it is not clear that ethnic differences in insulin resistance are 
"captured" by the SITT. 
Pilot studies should be performed with the full (unmodified) fat tolerance test to determine 
the optimal time point(s) for measurement of total triglyceride concentration that would 
discriminate best between Europeans and South Asians. To determine which component of 
lipid metabolism is specifically defective more detailed studies than measuring total 
triglyceride concentration should also be performed. This includes measuring exogenous 
(dietary derived; apoB-48) and endogenous (hepatic derived, apoB-100) triglyceride 
concentration in different plasma fractions (plasma chylomicron and non-chylomicron 
fractions). Measurement of a single 8h postprandial total triglyceride concentration proved 
to be inadequate in this study, and is not recommended for future studies. 
Reproducibility and validity of nuclear magnetic resonance spectroscopy to measure IMCL 
content should also be performed specifically in South Asians. To date all such studies 
have been limited to European descent populations. The results of the current study 
showing higher IMCL content in South Asian men, but failure to find any association 
between IMCL and insulin resistance or obesity measures raise questions about the use of 
the technique in this ethnic group. 
Measurement of central obesity by anthropometric measures of waist/hip ratio or waist 
girth was adequate. No additional benefit was found in measuring visceral fat area directly 
by CT scan for studying the associations between central obesity and various metabolic 
measurements. This study has validated bio-electrical impedance analysis against DEXA 
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scan as a method for measuring total percent body fat in South Asians. We recommend 
that future studies should include measurement of percent body fat, measured by this non- 
invasive technique. 
11.2. Further experimental studies 
Suggestions for specific experimental studies that build on the research findings from the 
current study are as follows. 
Measuring plasma triglyceride concentration alone yields limited information. Studies of 
triglyceride flux (in the fasting state and postprandially) between plasma and the muscle 
compartment will add to our understanding of ethnic differences in synthesis and clearance 
of lipids. The availability of a non-invasive method, the nuclear magnetic resonance 
spectroscopy, has now opened up the possibility for performing such studies. Examples of 
such studies include examining what happens when one manipulates intramyocellular lipid 
stores by short-term experimental interventions such as running a marathon or consuming a 
fatty-meal. Studies can also be designed to measure changes in muscle triglyceride content 
before and after administration of drugs that modulate (increase or decrease) plasma 
triglyceride concentration. Such changes should also be measured before and after 
administration of drugs that modulate insulin sensitivity. It would be of interest to study 
whether insulin sensitising drugs affect insulin resistance at the level of skeletal muscle, 
and whether there are any ethnic differences in such effects. 
11.3. Suggestions for other studies to take forward the current 
area of research 
11.3.1. The use of electron beam computerised tomography (EBCT) 
In the past there has been almost exclusive focus on clinical cardiovascular events as an 
outcome in epidemiological studies. As such we have little information on the 
distribution 
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and determinants of early atheromatous change in the coronary arteries. The advent of 
EBCT, a rapid, non-invasive method of detecting and quantifying calcification in the 
coronary arteries, provides us for the first time with a research tool that can define early 
(pre-symptomatic) atheromatous change in the coronary arteries. This opens up exciting 
possibilities in the current area of research. Specific suggestions for studies using EBCT 
are as follows. 
To study postprandial lipid metabolism in both ethnic groups in subjects with and without 
evidence of coronary calcification on EBCT. This will help to determine whether 
postprandial triglyceride concentration is associated with the presence of coronary 
calcification, and whether ethnic origin is associated with calcified coronary atheroma. To 
date there is scant information on the relative importance of early atheroma development 
and later stages such as arterial occlusion in the pathogenesis of cardiovascular events. It 
is of scientific interest to find out whether elevated postprandial triglyceride concentration 
relates only to late stages of atheroma formation manifested by arterial occlusion, or 
whether it is also associated with early calcification (and atheroma) development. 
A further separate suggestion is for a case-control study of the association, in South Asians 
and Europeans, between CRP concentration and coronary calcification on EBCT. CRP 
concentration would be measured in those with and without evidence of coronary 
calcification. This would help to clarify whether inflammatory markers such as CRP 
concentration are elevated in association with development of coronary calcification, or 
predate its development. This would be an important contribution as it is not known 
whether inflammation is a phenomenon arising as a result of development of 
atherosclerosis, or is causal in the development of atherosclerosis. 
11.3.2. Prospective studies 
Our finding of a trend towards elevated C-reactive protein concentration in South Asians 
should be confirmed in larger studies. The ideal setting for this would be a prospective 
study of stored sera from the Southall Study29, where records were flagged at the 
ONS 
(Office of National Statistics) and mortality data are available from death certificates 
for 
each person enrolled in that study in 1988-1990. Association between 
baseline CRP 
concentration and CHD mortality at 10 years of follow-up can be studied prospectively. 
If 
Conclusions 
11-156 
such an association is found in South Asians it will provide, in a strong research design, 
the first such data in this group. 
Another separate suggestion relates to the use of the stored sera in a prospective study 
design. While the stored sera were thawed for analysis of CRP concentration, it would be 
opportune to measure antibodies to Chlamydia pneumoniae and Helicobacter pylori in the 
stored sera, to test if the excess CHD incidence in South Asians can be accounted for by an 
ethnic difference in the prevalence of chronic infections (section 1.6). Additionally the 
extent to which Lp(a) could account for the ethnic differences in CHD mortality has not 
been examined. Lp(a) should also be measured on the frozen sera. At the same time there 
would be the opportunity to measure serum homocysteine, raised levels of which have 
been shown to be associated with increased cardiovascular disease risk. 
11.3.3. Randomised clinical trials 
If in larger, prospective studies, elevated levels of CRP are confirmed in South Asians, and 
an association is found with CHD mortality as has been reported in European populations, 
and if elevated levels of C-reactive protein are shown to account for some of the excess 
risk of CHD in South Asians compared with other groups, a recommended next step would 
be to evaluate the efficacy of aspirin therapy in reducing the high CHD risk in South 
Asians. The hypothesis would be that aspirin therapy would reduce CHD mortality 
through reductions in CRP concentrations. 
A case for possible randomised trials of fibrate therapy or statin therapy, or both, in South 
Asians has already been discussed in sections 10.5.3.3 and 10.5.3.4.4. 
11.3.4. Studies of the vascular endothelium 
The present study has raised the possibility that there is a trend towards higher postprandial 
lipid concentration in South Asians (which would have been better measured with a more 
detailed fat tolerance test as discussed before). New evidence is emerging in studies of 
people of European descent that postprandial lipaemia can affect endothelial 
function (as 
discussed in section 2.3.1.1). One recent study314 of 44 men showed that endothelial 
function was impaired in healthy South Asians compared with Europeans, and the 
defect 
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was not accounted for by measured coronary risk factors. However, they only measured 
fasting triglyceride level (which was not significantly different in the two groups). Non- 
invasive techniques such as brachial artery ultrasound can be easily undertaken in South 
Asians to assess the effects on the vascular endothelium of postprandial lipaemia. 
The reasons for the excess risk of diabetes and CHD in South Asians are still not 
understood. From the results of this study, in general we have demonstrated that insulin 
resistance is closely related to plasma lipid levels, but not simply to excess of central 
obesity or excess of intramyocellular lipid stores. To understand this further we need 
focused studies of lipid metabolism and its effects on insulin resistance and atheroma. 
There are very few research groups addressing the issue in South Asians of metabolic and 
physiological disturbances associated with insulin resistance, diabetes and CHD. The 
results from the current study, albeit with its limitations, as well as the suggestions made 
for further research, should help us to understand this more clearly. 
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APPENDIX: FUNDING, SITES, COLLABORATORS, 
PERSONNEL 
Many departments and people enabled this study to be performed and completed. Those 
who collaborated or helped were as follows: 
Funding for this study came from the Wellcome Trust, as part of a clinical training fellowship 
in Clinical Epidemiology for the registrant, Nita Forouhi. 
Supervision was provided by Dr Paul McKeigue. The idea for the study was originally 
conceived by him. He was available for discussion regarding any problems. He also read 
the first draft of the dissertation and gave his comments for improvement. 
This study was performed in the department of cardiology at Ealing Hospital, Uxbridge Road, 
Southall, Middx, UB1 3HWI, and was facilitated by Dr Jaspal Kooner. He also kindly 
arranged for Miss Mary Rowley, research nurse, to assist up to two mornings a week with 
clinical data collection. CT scans were kindly performed with the agreement of Dr Bill 
Svennson at Ealing Hospital. Mr Paul Eathorne and Mr Tim Rabbitte performed all the 
scans. 
DEXA scans were performed by Mr Uday Bhonsle at the Medical Physics Department of the 
Northwick Park Hospital, Watford Road, Harrow, Middlesex. He provided the final percent 
fat data to the registrant. 
Magnetic resonance spectroscopy was undertaken at the Robert Steiner MRiI Unit, 
Hammersmith Hospital, Du Cane Road, London, with the collaboration of Dr Jimmy Bell. 
Louise Thomas, Gabby Jenkinson and S Mierisova performed the scans and analysed the 
computer output for the scans. 
The laboratory analyses were undertaken at the Wynn Division of Medicine, Wellington 
Road, London, NW1. The lab work was mainly performed by Mandeep Sidhu, Melik 
Worthington and Tony Proudler under the supervision of Dr Ian Godsland and Dr David 
Crook. The chylomicron separation protocol was developed by Dr David Crook. 
The analysis of C-reactive protein was very kindly performed by Dr. Naveed Sattar of the 
department of Pathological Biochemistry at the Glasgow Royal Infirmary. 
The following general practioners assisted with subject recruitment. Dr Chatrath and Dr 
Choudhury, Drs Thomas, Gill and Patel, Drs Jenkins and Heavey, and Dr Irene Ross. 
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Dr Saiqa Mullick attended during clinical data sessions. She helped with clinical data 
collection. 
Mrs Jan Bibi Mazar, research assistant, helped with data entry and in booking appointments 
for the study participants. Mrs Sheelagh Kerr set up the FoxPro database for data entry. 
Mrs Christine Brandon-Jones gave advice regarding preparing small labels for subject 
identification, and helped with teaching the registrant how to use the File Maker Pro 
database. 
Mr Stephen Sharp, medical statistics unit at the London School of Hygiene & Tropical 
Medicine, helped with writing a programme to calculate the insulin sensitivity index, and with 
generating the graphs for the mean glucose values against time. Mr Ian White, also of the 
same unit, helped with the original sample size calculations for the study. 
Dr Janendrappa, a visiting clinical fellow from Bangalore, India, attended some clinical 
sessions during his short stay in London. During these he helped with preparing sample 
collection tubes. 
Lucozade for the study was donated by Smith Kline Beecham. 
The responsibility for the study rested with the registrant. She attended every single clinical 
session and did all the data collection personally. She also prepared the fat meal for the fat 
tolerance test. All the insulin tolerance tests were personally performed by her. She 
managed all the day to day running of the project, from grant proposal stage, through to 
completion of the study. The ordering of equipment and managing of the budget, secretarial 
work and all management and administrative issues were dealt with by her. 
The registrant 
performed all the statistical analyses and wrote the papers for publication. 
This dissertation 
has been written by the registrant. 
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